https://flcube.com/chinese-pharmacopoeia-commission-approves-draft-for-chp-2025-edition/2024-11-29T15:28:06+08:00https://flcube.com/akeso-biopharma-initiates-phase-ia-ib-study-for-tigit-mab-ak127-in-solid-tumors-combination-therapy/2024-11-29T14:50:53+08:00https://flcube.com/acrobiosystems-partners-with-obio-technology-to-advance-cell-and-gene-therapy/2024-11-29T14:46:08+08:00https://flcube.com/lucence-and-innovent-biologics-partner-to-enhance-access-to-cholangiocarcinoma-treatment-in-hong-kong/2024-11-29T14:20:22+08:00https://flcube.com/beijing-balance-medicals-transcatheter-valve-system-enters-chinas-innovative-device-review/2024-11-29T14:17:18+08:00https://flcube.com/eli-lillys-tirzepatide-demonstrates-up-to-26-6-weight-loss-in-phase-iii-obesity-studies/2024-11-29T14:14:23+08:00https://flcube.com/cde-issues-guiding-principles-for-natural-history-research-in-rare-disease-drug-development/2024-11-29T14:12:21+08:00https://flcube.com/sino-biopharmaceutical-receives-nmpa-approval-for-biosimilar-herceptin-for-her2-cancers/2024-11-29T14:10:35+08:00https://flcube.com/cde-launches-technical-guidelines-to-emphasize-patient-centered-drug-clinical-trials/2024-11-29T14:06:16+08:00https://flcube.com/eli-lillys-donanemab-shows-significant-slowdown-in-alzheimers-disease-progression-in-phase-iii-study/2024-11-29T14:04:15+08:00https://flcube.com/jiangsu-simcere-pharmaceutical-receives-nmpa-approval-for-atopic-dermatitis-drug-sim0278/2024-11-29T14:00:52+08:00https://flcube.com/epimab-biotherapeutics-licenses-bispecific-antibody-platform-to-almirall/2024-11-29T13:38:29+08:00https://flcube.com/pingshan-district-and-fosun-pharma-ink-strategic-deal-to-boost-biomedical-industry/2024-11-29T13:34:27+08:00https://flcube.com/sanreno-therapeutics-partners-with-wuxi-sta-for-comprehensive-rd-and-manufacturing-services/2024-11-29T13:28:41+08:00https://flcube.com/chongqing-zhifei-biological-partners-with-pt-bio-farma-for-global-tuberculosis-vaccine-development/2024-11-29T13:19:49+08:00https://flcube.com/brl-medicine-inc-receives-ind-approval-for-cd19-targeted-car-t-therapy-brl-301-from-cde/2024-11-29T13:14:02+08:00https://flcube.com/bristol-myers-squibb-q2-2023-results-miss-estimates-full-year-guidance-revised-downward/2024-11-29T13:11:05+08:00https://flcube.com/pfizer-announces-leadership-shake-up-with-focus-on-oncology-rd/2024-11-29T13:08:48+08:00https://flcube.com/roche-groups-h1-2023-financial-report-pharmaceuticals-grow-while-diagnostics-dip/2024-11-29T12:29:53+08:00https://flcube.com/akeso-biopharma-reports-first-positive-earnings-in-h1-2023-financial-results/2024-11-29T12:21:00+08:00https://flcube.com/microport-medbots-skywalker-orthopedic-surgery-robot-gains-tga-approval-in-australia/2024-11-29T12:18:02+08:00https://flcube.com/cde-releases-draft-guidelines-for-clinical-pharmacology-research-of-chemical-modified-drugs/2024-11-29T12:14:46+08:00https://flcube.com/baidu-health-partners-with-gsk-for-shingles-disease-education-programs-in-china/2024-11-29T12:11:28+08:00https://flcube.com/transcenta-holdings-gets-cde-approval-for-phase-ii-study-of-tst002-for-bone-density/2024-11-29T12:08:58+08:00https://flcube.com/zelgen-biopharmaceuticals-zg006-earns-nmpa-approval-for-clinical-trials-in-solid-tumors/2024-11-29T12:06:34+08:00https://flcube.com/mabwell-secures-licensing-deal-with-moroccos-sothema-for-biosimilar-humira/2024-11-29T12:03:23+08:00https://flcube.com/shanghai-benemaes-benaglutide-approved-by-nmpa-for-adult-weight-management-in-china/2024-11-29T11:58:00+08:00https://flcube.com/nanjing-leads-biolabs-lbl-034-secures-clinical-trial-approvals-from-nmpa-and-fda/2024-11-29T11:29:03+08:00https://flcube.com/sanofi-to-boost-chc-unit-with-full-acquisition-of-us-health-brand-qunol/2024-11-29T11:26:37+08:00https://flcube.com/astrazenecas-alexion-secures-gene-therapy-portfolio-in-deal-with-pfizer/2024-11-29T11:17:11+08:00https://flcube.com/astrazenecas-h1-2023-financials-show-4-yoy-revenue-growth-oncology-and-ri-drive-sales/2024-11-29T11:11:00+08:00https://flcube.com/sanofi-reports-3-3-yoy-sales-growth-in-q2-2023-driven-by-vaccines-and-dupixent/2024-11-29T11:07:52+08:00https://flcube.com/huadong-medicine-receives-nmpa-approval-for-phase-i-clinical-trial-of-dr10624-for-weight-management/2024-11-29T11:05:27+08:00https://flcube.com/nmpa-seeks-public-input-on-strengthening-supervision-of-medical-device-contract-manufacturing/2024-11-29T10:53:52+08:00https://flcube.com/chinas-nhc-launches-trial-specifications-for-clinical-decision-support-systems-in-hospitals/2024-11-29T10:50:47+08:00https://flcube.com/yingli-pharmas-yl-17231-receives-nmpa-approval-for-clinical-trials-in-advanced-solid-tumors/2024-11-29T10:48:11+08:00https://flcube.com/nhsa-issues-2023-guidelines-enhancing-basic-medical-insurance-and-major-illness-coverage/2024-11-29T10:42:24+08:00https://flcube.com/takeda-reports-3-7-yoy-revenue-growth-in-q1-2023-fiscal-year-with-priority-products-driving-sales/2024-11-29T02:17:09+08:00https://flcube.com/gsks-jemperli-receives-fda-approval-for-first-line-treatment-of-advanced-endometrial-cancer/2024-11-29T02:11:49+08:00https://flcube.com/viatris-inc-secures-fda-nod-for-generic-symbicort-equivalent-breyna/2024-11-29T02:09:43+08:00https://flcube.com/mindray-bio-medical-electronics-to-acquire-majority-stake-in-diasys-diagnostic-systems/2024-11-29T02:06:39+08:00https://flcube.com/enchannel-secures-rmb-200-million-in-series-a-funding-to-advance-electrophysiology-solutions/2024-11-29T02:04:01+08:00https://flcube.com/sinovation-secures-over-rmb-100-million-in-series-d-financing-for-neurosurgery-innovations/2024-11-29T01:57:38+08:00https://flcube.com/peijia-medical-commences-clinical-study-for-taurus-trio-tavr-system-with-first-patient-enrollment/2024-11-29T01:50:37+08:00https://flcube.com/remegens-novel-bispecific-antibody-rc148-receives-clinical-trial-approval/2024-11-29T01:48:30+08:00https://flcube.com/jacobio-pharmas-glecirasib-enters-breakthrough-therapy-review-for-pancreatic-cancer-treatment/2024-11-29T01:41:06+08:00https://flcube.com/jiangsu-aideas-acc008-demonstrates-non-inferior-efficacy-to-genvoya-in-phase-iii-hiv-study/2024-11-29T01:39:03+08:00https://flcube.com/everest-medicines-completes-enrollment-for-nefecons-phase-iii-extension-study-in-china/2024-11-29T01:36:47+08:00https://flcube.com/wuxi-apptec-reports-6-28-revenue-growth-and-23-67-net-profit-increase-in-h1-2023/2024-11-29T01:34:13+08:00https://flcube.com/hutchmed-ltd-reports-164-revenue-growth-and-clinical-updates-for-h1-2023/2024-11-29T01:30:40+08:00https://flcube.com/shanghai-hsa-unveils-measures-to-boost-access-to-innovative-drugs-and-devices/2024-11-29T01:25:44+08:00https://flcube.com/sinopharm-partners-with-harbin-institute-of-technology-to-boost-biomedical-industry-innovation/2024-11-29T01:16:17+08:00https://flcube.com/nk-celltech-and-rongcan-biotech-partner-to-advance-mrna-nk-cell-therapy-and-lnp-delivery-system/2024-11-29T01:12:46+08:00https://flcube.com/abbisko-therapeutics-initiates-phase-ii-clinical-trial-for-pimicotinib-in-tendon-sheath-giant-cell-tumor/2024-11-29T01:07:25+08:00https://flcube.com/astellas-pharmas-zolbetuximab-bla-accepted-by-chinas-cde-for-gastric-cancer-treatment/2024-11-29T00:51:37+08:00https://flcube.com/shanghai-junshi-biosciences-partners-with-zein-biotechnology-for-pcsk9-mab-commercialization-in-china/2024-11-29T00:48:55+08:00https://flcube.com/suzhou-jiecheng-medical-secures-fda-bdd-for-transvascular-aortic-valve-treatment/2024-11-29T00:40:54+08:00https://flcube.com/biogen-inc-to-acquire-reata-pharmaceuticals-in-7-3-billion-deal/2024-11-29T00:03:02+08:00https://flcube.com/pfizer-inc-reports-q2-2023-revenues-signals-shift-beyond-covid-19-products/2024-11-28T23:59:30+08:00https://flcube.com/eqrx-inc-to-be-acquired-by-revolution-medicines-in-all-stock-transaction/2024-11-28T23:56:43+08:00https://flcube.com/gsk-partners-with-zuellig-pharma-for-vaccine-distribution-and-cold-chain-management-in-asia-pacific/2024-11-28T23:50:34+08:00https://flcube.com/luye-pharmas-parkinsons-disease-treatment-ly03003-receives-nmpa-review-acceptance/2024-11-28T23:43:47+08:00https://flcube.com/mabwell-bioscience-secures-licensing-deals-for-denosumab-biosimilars-in-egypt-and-pakistan/2024-11-28T23:40:12+08:00https://flcube.com/genemind-biosciences-secures-rmb-400-million-in-series-c-financing-to-expand-gene-testing/2024-11-28T23:32:56+08:00https://flcube.com/guangzhou-wondfo-biotech-partners-with-indonesias-kimia-farma-in-ivd-field/2024-11-28T23:26:47+08:00https://flcube.com/inxmed-partners-with-genequantum-healthcare-to-develop-innovative-adcs/2024-11-28T23:09:23+08:00https://flcube.com/sansure-biotech-partners-with-indonesian-firm-for-localized-molecular-diagnostic-production/2024-11-28T23:06:47+08:00https://flcube.com/huadong-medicines-arcalyst-receives-nmpa-approval-for-cryopyrin-associated-periodic-syndromes/2024-11-28T18:40:47+08:00https://flcube.com/huadong-medicines-elahere-mirvetuximab-soravtansine-approved-by-nmpa-for-ovarian-cancer-treatment/2024-11-28T18:25:48+08:00https://flcube.com/micurx-pharmaceuticals-mrx-4-combo-shows-positive-results-in-phase-iii-study/2024-11-28T18:19:07+08:00https://flcube.com/national-reimbursement-drug-list-2024-expands-coverage-with-91-new-drugs/2024-11-28T18:10:04+08:00https://flcube.com/allink-biotherapeutics-secures-42-million-in-series-a-financing-to-advance-bispecific-antibodies-and-adcs/2024-11-28T18:04:26+08:00https://flcube.com/chinas-nhc-aims-to-enhance-continuity-of-medical-services-with-referral-system-by-2030/2024-11-28T17:42:19+08:00https://flcube.com/jiangsu-kanion-pharmaceutical-secures-nmpa-approvals-for-kyhy2302-and-kyhy2303/2024-11-28T17:29:53+08:00https://flcube.com/nhsa-issues-guidelines-to-suspend-direct-online-listing-of-in-shortage-drugs/2024-11-28T17:20:44+08:00https://flcube.com/fosun-pharmaceuticals-daxxify-receives-nmpa-approval-for-cervical-muscle-tone-disorders/2024-11-28T16:40:58+08:00https://flcube.com/phil-rivers-technology-secures-ind-approval-for-pr00012-from-nmpas-cde/2024-11-28T16:24:16+08:00https://flcube.com/hansoh-pharmaceuticals-ameile-receives-nmpa-review-for-fifth-indication-in-nsclc-treatment/2024-11-28T16:15:55+08:00https://flcube.com/china-medical-system-holdings-gets-nmpa-approval-to-test-obesity-treatment-cms-d005/2024-11-28T16:08:20+08:00https://flcube.com/genesis-rmn-robotic-magnetic-navigation-system-approved-by-chinas-nmpa/2024-11-28T15:48:11+08:00https://flcube.com/gsk-plc-receives-ec-approval-for-single-vial-menveo-vaccine-for-meningococcal-disease/2024-11-28T15:32:07+08:00https://flcube.com/tennor-therapeutics-partners-with-grand-life-sciences-for-rifasutenizol-commercialization-in-china/2024-11-28T15:23:25+08:00https://flcube.com/immunochina-pharmaceuticals-im19-car-t-therapy-accepted-for-review-by-nmpa/2024-11-28T15:16:33+08:00https://flcube.com/thedermas-tap-1503-cream-approved-by-chinas-nmpa-for-atopic-dermatitis-treatment/2024-11-28T14:57:13+08:00https://flcube.com/novartiss-kisqali-approved-by-ec-for-adjuvant-treatment-of-high-risk-early-breast-cancer/2024-11-28T14:37:39+08:00https://flcube.com/sanofi-launches-modulus-a-pioneering-manufacturing-facility-in-singapore/2024-11-28T14:21:44+08:00https://flcube.com/our-united-corporations-linear-accelerator-approved-as-innovative-medical-device-by-nmpa/2024-11-28T13:18:42+08:00https://flcube.com/lees-pharmaceutical-subsidiary-zhaoke-ophthalmology-partners-with-eyebright-medical-technology/2024-11-28T13:07:58+08:00https://flcube.com/abm-therapeutics-abm-1310-earns-orphan-drug-designation-for-braf-v600-mutant-glioblastoma/2024-11-28T12:48:44+08:00https://flcube.com/huaboron-neutron-technology-secures-over-rmb-100-million-in-angel-financing-for-bnct-system/2024-11-28T12:42:05+08:00https://flcube.com/ice-bioscience-secures-series-b-financing-to-boost-integration-capabilities/2024-11-28T10:45:49+08:00https://flcube.com/sumitomo-pharma-and-otsukas-ulotaront-fails-to-meet-primary-endpoint-in-schizophrenia-trials/2024-11-28T10:40:17+08:00https://flcube.com/siemens-healthineers-reports-3-6-yoy-revenue-growth-in-q3-2023-financials/2024-11-28T10:34:44+08:00https://flcube.com/gilead-sciences-inc-reports-5-yoy-revenue-increase-in-q2-2023-financials/2024-11-28T10:28:08+08:00https://flcube.com/amgen-inc-reports-7-yoy-revenue-increase-in-q2-2023-financials/2024-11-28T10:24:59+08:00https://flcube.com/gsk-files-patent-infringement-lawsuit-against-pfizers-rsv-vaccine-abrysvo/2024-11-28T10:21:32+08:00https://flcube.com/novartis-ag-and-ionis-pharmaceuticals-renew-collaboration-on-lpa-driven-cvd-drug/2024-11-28T10:17:52+08:00https://flcube.com/grand-pharmaceutical-group-gets-nmpa-approval-for-generic-eplerenone-for-hypertension/2024-11-28T10:14:48+08:00https://flcube.com/davinci-single-port-system-launches-in-hainan-with-successful-surgeries/2024-11-28T09:55:18+08:00https://flcube.com/huidagene-strikes-licensing-deal-with-kactus-biosystems-for-gene-editing-enzyme-hfcas12max/2024-11-28T09:33:13+08:00https://flcube.com/novartis-chinas-business-growth-lead-zhu-jiakang-departs-for-personal-reasons/2024-11-28T09:27:41+08:00https://flcube.com/oramed-pharmaceuticals-and-hefei-tianhui-biotech-to-form-joint-venture-for-oral-insulin-product/2024-11-28T01:06:16+08:00https://flcube.com/biogen-and-sage-therapeutics-receive-fda-approval-for-postpartum-depression-treatment-zurzuvae/2024-11-28T01:04:39+08:00https://flcube.com/abvc-biopharma-grants-xinnovation-therapeutics-exclusive-rights-to-cns-drug-pipeline-in-china/2024-11-28T01:00:00+08:00https://flcube.com/astellas-pharmas-izervay-receives-fda-approval-for-geographic-atrophy-treatment/2024-11-28T00:45:45+08:00https://flcube.com/regeneron-pharmaceuticals-halts-enrollment-in-regn5678-clinical-trial-after-patient-deaths/2024-11-28T00:43:35+08:00https://flcube.com/ascentage-pharmas-lisaftoclax-apg-2575-gets-fda-green-light-for-phase-iii-study/2024-11-28T00:41:35+08:00https://flcube.com/jenscare-scientific-and-lifetech-scientific-achieve-milestone-with-first-compassionate-use-of-lux-valve-plus/2024-11-28T00:39:12+08:00https://flcube.com/guangdong-pharmaceutical-association-releases-updated-off-label-drug-list-for-2023/2024-11-28T00:34:22+08:00https://flcube.com/venus-medtech-receives-fda-ide-approval-for-venusp-valve-a-milestone-for-chinese-heart-valve-technology/2024-11-28T00:30:21+08:00https://flcube.com/microport-cardioflow-announces-positive-results-for-transcatheter-mitral-valve-replacement-system/2024-11-28T00:25:39+08:00https://flcube.com/hansoh-pharmaceutical-regains-rights-to-ameile-after-eqrx-partnership-cancellation/2024-11-28T00:22:39+08:00https://flcube.com/jumpcan-pharmaceutical-partners-with-nanjing-zenshine-for-exclusive-promotion-rights-of-zx-7101a-in-china/2024-11-28T00:17:52+08:00https://flcube.com/zai-lab-ltd-reports-q2-2023-financials-with-53-yoy-product-revenue-growth/2024-11-28T00:10:48+08:00https://flcube.com/beijings-gene-cradle-secures-pre-series-b-funding-led-by-cash-capital/2024-11-28T00:08:05+08:00https://flcube.com/gracell-biotechnologies-secures-100-million-in-private-placement-with-healthcare-investors/2024-11-28T00:04:40+08:00https://flcube.com/national-health-commission-unveils-10-measures-to-enhance-primary-healthcare-services/2024-11-28T00:02:14+08:00https://flcube.com/johnson-johnson-reaches-settlement-with-fresenius-kabi-and-formycon-ag-for-stelara-biosimilar/2024-11-27T23:57:38+08:00https://flcube.com/vistagens-fasedienol-phase-iii-success-sends-shares-soaring-over-600/2024-11-27T23:55:03+08:00https://flcube.com/nektar-therapeutics-and-eli-lilly-co-face-off-in-court-over-rezpeg-partnership-dispute/2024-11-27T23:50:27+08:00https://flcube.com/biocity-biopharma-receives-fda-ind-approval-for-cd3-egfr-bsab-bc3448/2024-11-27T23:45:50+08:00https://flcube.com/burning-rock-partners-with-astrazeneca-to-develop-companion-diagnostics-for-cancer-therapies/2024-11-27T23:43:39+08:00https://flcube.com/audit-reveals-illicit-payments-and-inflated-prices-in-pharmaceutical-industry/2024-11-27T23:40:21+08:00https://flcube.com/eli-lilly-co-reports-28-yoy-revenue-increase-in-q2-2023-financials/2024-11-27T23:37:38+08:00https://flcube.com/fibrogens-evrenzo-achieves-record-sales-in-china-outlook-for-2024-remains-promising/2024-11-27T23:15:14+08:00https://flcube.com/bayer-ag-reports-q2-h1-2023-financials-with-challenges-in-crop-science-and-pharmaceuticals/2024-11-27T23:12:22+08:00https://flcube.com/novo-nordisks-wegovy-demonstrates-20-reduction-in-cardiovascular-events-in-select-trial/2024-11-27T23:03:59+08:00https://flcube.com/shanghai-health-commission-issues-regulations-to-curb-unhealthy-pharmaceutical-practices/2024-11-27T23:02:14+08:00https://flcube.com/lynk-pharmaceuticals-lnk01001-shows-positive-results-in-atopic-dermatitis-phase-ii-study/2024-11-27T22:56:28+08:00https://flcube.com/organon-reports-q2-2023-revenue-growth-driven-by-womens-health-and-biosimilars/2024-11-27T22:54:34+08:00https://flcube.com/regeneron-pharmaceuticals-acquires-decibel-therapeutics-for-hearing-loss-gene-therapies/2024-11-27T22:51:33+08:00https://flcube.com/denali-therapeutics-and-takeda-halt-development-of-alzheimers-drug-candidate-tak-920-dnl919/2024-11-27T22:48:09+08:00https://flcube.com/poseida-therapeutics-secures-50-million-investment-from-astellas-for-cell-and-gene-therapy/2024-11-27T22:42:47+08:00https://flcube.com/lees-pharmaceuticals-subsidiary-completes-phase-iii-study-for-myopia-treatment-nvk002/2024-11-27T22:39:55+08:00https://flcube.com/eyebright-medical-technologys-intraocular-lenses-earn-fast-track-status-in-china/2024-11-27T22:36:41+08:00https://flcube.com/neurophth-biotechnology-secures-rmb700-million-in-series-c-financing-for-gene-therapy-development/2024-11-27T22:27:21+08:00https://flcube.com/novartis-reports-positive-phase-iii-results-for-remibrutinib-in-chronic-spontaneous-urticaria/2024-11-27T22:25:14+08:00https://flcube.com/hunan-hsa-implements-direct-bmi-fund-payments-for-vbp-winning-drugs-and-consumables/2024-11-27T22:22:55+08:00https://flcube.com/samr-and-nine-ministries-tighten-regulations-on-forums-and-conferences-in-china/2024-11-27T22:20:59+08:00https://flcube.com/cutia-therapeutics-cu-10201-enters-priority-review-for-acne-treatment-in-china/2024-11-27T22:19:19+08:00https://flcube.com/huadong-medicine-secures-exclusive-rights-to-arcutis-daxas-in-greater-china-and-south-east-asia/2024-11-27T22:17:06+08:00https://flcube.com/medtronic-partners-with-apmg-to-advance-orthopedic-treatment-services-in-china/2024-11-27T22:14:20+08:00https://flcube.com/everest-medicines-and-shanghai-pharmaceuticals-deepen-partnership-for-drug-distribution-in-china/2024-11-27T22:08:53+08:00https://flcube.com/nmpa-greenlights-oricell-therapeutics-oricar-017-for-clinical-trials-in-multiple-myeloma/2024-11-27T22:06:01+08:00https://flcube.com/beijing-balance-medical-receives-approval-for-innovative-expandable-artificial-heart-valve-in-china/2024-11-27T22:00:38+08:00https://flcube.com/beijing-balance-medical-technologys-transcatheter-aortic-valve-system-accepted-for-nmpa-review/2024-11-27T21:53:57+08:00https://flcube.com/beijing-balance-medical-secures-nmpa-approval-for-innovative-mitral-valve-annuloplasty-ring/2024-11-27T21:53:56+08:00https://flcube.com/beijing-balance-medical-secures-nmpa-nod-for-pioneering-heart-valve-patch/2024-11-27T21:53:55+08:00https://flcube.com/beijing-balance-medical-secures-nmpa-nod-for-renatus-transcatheter-aortic-valve-system/2024-11-27T21:53:54+08:00https://flcube.com/wuxi-biologics-and-boostimmune-forge-exclusive-rd-partnership/2024-11-27T21:49:37+08:00https://flcube.com/antengene-corp-secures-licensing-deal-with-hansoh-pharmaceutical-for-xpovio-in-china/2024-11-27T21:43:41+08:00https://flcube.com/novo-nordisks-h1-2023-financials-show-30-yoy-growth-driven-by-glp-1-drugs-and-obesity-sales/2024-11-27T21:40:29+08:00https://flcube.com/pfizer-faces-whistleblower-lawsuit-over-alleged-fcpa-violations-in-china/2024-11-27T21:38:17+08:00https://flcube.com/novartis-acquires-chinook-therapeutics-for-3-2-billion-eyes-kidney-disease-market/2024-11-27T21:36:15+08:00https://flcube.com/janssens-talvey-receives-fda-accelerated-approval-for-relapsed-refractory-multiple-myeloma/2024-11-27T21:31:45+08:00https://flcube.com/novo-nordisk-to-acquire-inversago-pharma-in-a-deal-valued-up-to-usd-1-1-billion/2024-11-27T21:28:56+08:00https://flcube.com/telix-pharmaceuticals-and-grand-pharma-initiate-phase-iii-trial-for-illucix-in-china/2024-11-27T21:23:41+08:00https://flcube.com/mirxes-holding-company-receives-fda-breakthrough-device-designation-for-gastroclea/2024-11-27T21:17:29+08:00https://flcube.com/china-unveils-state-council-measures-to-boost-foreign-direct-investment/2024-11-27T21:15:40+08:00https://flcube.com/bio-thera-solutions-bat8006-shows-positive-phase-i-results-in-solid-tumor-treatment/2024-11-27T21:13:22+08:00https://flcube.com/vcanbio-receives-orphan-drug-designation-for-vum02-in-idiopathic-pulmonary-fibrosis-treatment/2024-11-27T21:11:00+08:00https://flcube.com/asieris-pharmaceuticals-hexvix-meets-primary-endpoint-in-phase-iii-bladder-cancer-study/2024-11-27T21:04:10+08:00https://flcube.com/eli-lilly-completes-acquisition-of-dice-therapeutics-for-2-0-billion/2024-11-27T21:01:27+08:00https://flcube.com/sichuan-kelun-biotechs-skb264-achieves-primary-endpoint-in-phase-iii-tnbc-study/2024-11-27T20:55:54+08:00https://flcube.com/huadong-medicines-hdm3001-a-biosimilar-to-stelara-accepted-for-review-by-nmpa/2024-11-27T20:52:52+08:00https://flcube.com/cascade-pharmaceuticals-secures-rmb140-million-in-financing-to-advance-fxr-agonist-clinical-trials/2024-11-27T20:50:41+08:00https://flcube.com/migrasome-therapeutics-secures-over-rmb100-million-in-angel-funding-round/2024-11-27T20:46:43+08:00https://flcube.com/sichuan-kelun-biotechs-skb264-mk-2870-approved-by-nmpa-for-triple-negative-breast-cancer/2024-11-27T17:05:50+08:00https://flcube.com/nhc-aims-for-nationwide-inspection-result-sharing-in-medical-consortia-by-2030/2024-11-27T16:54:35+08:00https://flcube.com/arrowhead-and-sarepta-seal-11-38-billion-global-licensing-deal-for-rare-disease-treatments/2024-11-27T16:22:19+08:00https://flcube.com/pfizer-partners-with-cr-pharma-to-expand-cancer-drug-access-in-china/2024-11-27T16:06:21+08:00https://flcube.com/roches-evrysdi-receives-patent-term-extension-in-china-extending-protection-to-2035/2024-11-27T15:49:04+08:00https://flcube.com/jiangsu-hengrui-medicines-shr-1819-receives-nmpa-approval-for-atopic-dermatitis-clinical-trial/2024-11-27T15:20:23+08:00https://flcube.com/astrazenecas-truqap-meets-primary-endpoint-in-phase-iii-prostate-cancer-study/2024-11-27T14:56:25+08:00https://flcube.com/sichuan-huiyu-pharmaceuticals-hy-2003-approved-for-clinical-trials-by-chinas-nmpa/2024-11-27T14:44:54+08:00https://flcube.com/jjs-stelara-faces-new-biosimilar-competition-in-china-with-cspc-pharmaceuticals-entry/2024-11-27T14:18:32+08:00https://flcube.com/astrazenecas-alxn1850-efzimfotase-alfa-selected-for-chinas-rare-disease-care-plan/2024-11-27T14:00:45+08:00https://flcube.com/amgens-maritide-showcases-significant-weight-loss-in-phase-ii-study/2024-11-27T13:50:19+08:00https://flcube.com/vectorbuilder-and-zhejiang-dapu-biotechnology-form-partnership-to-advance-biotech-innovation/2024-11-27T13:37:50+08:00https://flcube.com/roches-skyscraper-01-study-tiragolumab-tecentriq-combo-misses-primary-endpoint-in-nsclc/2024-11-27T13:25:41+08:00https://flcube.com/jj-subsidiary-janssen-wins-fda-approval-for-akeega-in-brca-positive-mcrpc-treatment/2024-11-27T01:22:53+08:00https://flcube.com/sandoz-achieves-primary-endpoint-in-phase-iii-trial-for-biosimilar-aflibercept/2024-11-27T01:22:27+08:00https://flcube.com/hitgen-inc-partners-with-nested-therapeutics-for-precision-medicine-research/2024-11-27T01:21:06+08:00https://flcube.com/simcere-pharmaceuticals-cosela-receives-nmpa-review-for-es-sclc-indication/2024-11-27T01:16:01+08:00https://flcube.com/suzhou-leadsynbio-secures-series-d-funding-to-boost-rd-and-market-presence/2024-11-27T01:13:58+08:00https://flcube.com/sinomab-bioscience-receives-nmpa-approval-for-phase-i-clinical-study-of-sm17-asthma-therapy/2024-11-27T01:08:50+08:00https://flcube.com/medivirs-fostrox-in-combination-with-lenvima-shows-promise-in-phase-iia-hcc-trial/2024-11-27T00:59:06+08:00https://flcube.com/astrazeneca-to-invest-additional-usd-250-million-in-qingdao-for-aerosol-production-plant/2024-11-27T00:56:05+08:00https://flcube.com/eli-lilly-expands-portfolio-with-acquisitions-of-sigilon-therapeutics-and-versanis-bio/2024-11-27T00:53:20+08:00https://flcube.com/nhc-addresses-anti-corruption-efforts-in-pharmaceutical-industry-nationwide/2024-11-27T00:47:23+08:00https://flcube.com/pfizers-elrexfio-earns-accelerated-fda-approval-for-relapsed-refractory-multiple-myeloma/2024-11-27T00:45:28+08:00https://flcube.com/sanofi-misses-out-on-acquiring-reata-pharmaceuticals-to-biogen-in-usd-7-3-billion-deal/2024-11-27T00:41:24+08:00https://flcube.com/gilead-sciences-enters-collaboration-with-tentarix-biotherapeutics-for-polyspecific-antibodies/2024-11-27T00:30:41+08:00https://flcube.com/amoy-diagnostics-and-astrazeneca-expand-collaboration-on-companion-diagnostic-development/2024-11-27T00:25:06+08:00https://flcube.com/yichang-hec-changjiang-pharmaceuticals-yiqibuvir-receives-nmpa-review-for-hepatitis-c-treatment/2024-11-27T00:21:09+08:00https://flcube.com/everest-medicines-partner-venatorx-pharmaceuticals-receives-fda-priority-review-for-cefepime-taniborbactam/2024-11-27T00:18:35+08:00https://flcube.com/cstone-pharmaceuticals-reports-2023-interim-financials-and-business-milestones/2024-11-27T00:13:38+08:00https://flcube.com/inmagene-biopharmaceuticals-initiates-global-study-for-img-007-in-atopic-dermatitis/2024-11-27T00:10:30+08:00https://flcube.com/sinovac-biotech-reports-h1-2023-financials-with-significant-sales-decline-from-covid-19-boom/2024-11-26T23:52:32+08:00https://flcube.com/gracell-biotechnologies-reports-q2-2023-financials-highlights-gc012f-in-melanoma-treatment/2024-11-26T23:50:17+08:00https://flcube.com/yingli-pharmas-linperlislib-receives-priority-review-status-for-lymphoma-treatments/2024-11-26T23:47:20+08:00https://flcube.com/legend-biotech-corporation-reports-q2-and-h1-2023-financials-with-increased-revenues-and-rd-spending/2024-11-26T23:42:59+08:00https://flcube.com/aurisco-pharmaceutical-passes-us-fda-cgmp-inspection-at-jiangsu-plant/2024-11-26T23:40:04+08:00https://flcube.com/formosa-pharmaceuticals-and-eyenovia-inc-sign-licensing-deal-for-ocular-surgery-treatment/2024-11-26T23:32:50+08:00https://flcube.com/biocytogen-pharmaceuticals-opens-us-subsidiary-biocytogen-boston-corp-in-massachusetts/2024-11-26T23:27:39+08:00https://flcube.com/innovent-biologics-tafolecimab-receives-nmpa-approval-for-hypercholesterolemia-treatment/2024-11-26T23:14:37+08:00https://flcube.com/european-commission-approves-abbvies-aquipta-for-migraine-prevention-in-adults/2024-11-26T23:11:41+08:00https://flcube.com/bms-announces-positive-phase-i-ii-results-for-repotrectinib-in-ros1-positive-nsclc/2024-11-26T23:03:55+08:00https://flcube.com/immunofocos-imc008-earns-orphan-drug-designation-for-gastric-cancer-from-fda/2024-11-26T23:01:11+08:00https://flcube.com/seagens-tukysa-meets-primary-endpoint-in-phase-iii-study-for-her2-breast-cancer/2024-11-26T22:59:10+08:00https://flcube.com/medtronics-kanghui-partners-with-huashan-hospital-to-create-neuroscience-innovation-platform/2024-11-26T22:55:42+08:00https://flcube.com/jd-healthcare-reports-34-revenue-growth-and-triples-non-ifrs-profits-in-2023-interim-report/2024-11-26T22:09:04+08:00https://flcube.com/eisai-and-biogen-launch-alzheimers-drug-leqembi-in-china-following-market-approval/2024-11-26T22:05:46+08:00https://flcube.com/eisais-shanghai-unit-faces-rmb-900000-penalty-for-violating-drug-administration-law/2024-11-26T21:58:06+08:00https://flcube.com/roche-to-acquire-poseida-therapeutics-in-a-usd-1-5-billion-deal/2024-11-26T18:45:58+08:00https://flcube.com/lakeside-holdings-hupan-pharmaceutical-partners-with-sinopharm-group-hubei-for-supply-chain-services/2024-11-26T17:50:51+08:00https://flcube.com/nhsa-to-announce-nrdl-adjustment-results-at-november-28th-press-conference/2024-11-26T17:31:12+08:00https://flcube.com/nmpa-and-local-governments-streamline-drug-approval-processes-in-china/2024-11-26T17:21:39+08:00https://flcube.com/abbott-laboratories-expands-structural-heart-portfolio-with-tavi-balloon-expandable-system/2024-11-26T16:28:45+08:00https://flcube.com/mercks-winrevair-shows-positive-results-in-phase-iii-zenith-study-for-pah-2/2024-11-26T16:17:17+08:00https://flcube.com/boston-scientific-corporation-to-acquire-intera-oncology-inc-expanding-cancer-treatment-portfolio/2024-11-26T15:56:51+08:00https://flcube.com/nasal-phyto-pharmaceutical-receives-fda-clearance-for-first-ever-olfactory-drug-device-combo/2024-11-26T15:48:41+08:00https://flcube.com/gsks-blenrep-bla-for-multiple-myeloma-treatments-accepted-by-fda-for-review/2024-11-26T15:26:38+08:00https://flcube.com/insilico-medicine-gets-fda-approval-for-clinical-study-of-enpp1-inhibitor-ism5939/2024-11-26T15:14:00+08:00https://flcube.com/scg-cell-therapy-presents-phase-i-data-for-hbv-specific-tcr-t-therapy-scg101-at-aasld-2024/2024-11-26T15:06:46+08:00https://flcube.com/shenzhen-kangtai-begins-phase-i-clinical-trial-for-20-valent-pneumococcal-vaccine/2024-11-26T14:53:44+08:00https://flcube.com/kangtai-biological-expands-global-reach-with-varicella-vaccine-licensing-deals/2024-11-26T14:39:54+08:00https://flcube.com/kangtai-biological-partners-with-gennvax-egypt-to-commercialize-13-valent-pneumococcal-vaccine/2024-11-26T14:39:51+08:00https://flcube.com/kangtai-biological-partners-with-bahrain-pharma-firm-on-strategic-vaccine-production-agreement/2024-11-26T14:39:49+08:00https://flcube.com/kangtai-biological-products-co-ltd-expands-vaccine-access-in-south-asia-with-bangladesh-deal/2024-11-26T14:39:48+08:00https://flcube.com/kangtai-biological-partners-with-astrazeneca-and-beijing-daxing-district-to-boost-vaccine-market-presence/2024-11-26T14:39:45+08:00https://flcube.com/kangtai-biological-receives-nmpa-approval-for-20-valent-pneumococcal-vaccine-clinical-trial/2024-11-26T14:39:41+08:00https://flcube.com/sichuan-kelun-biotech-receives-nmpa-clearance-for-skb501-clinical-trial-in-solid-tumors/2024-11-26T14:34:17+08:00https://flcube.com/lepu-medical-technology-gains-nmpa-approval-for-obesity-and-diabetes-treatments-mwn109-and-mwn105/2024-11-26T14:10:28+08:00https://flcube.com/3sbio-inc-secures-licensing-deal-with-sunshine-lake-pharma-for-clifutinib-commercialization/2024-11-26T13:59:14+08:00https://flcube.com/chinas-insulin-volume-based-procurement-tender-results-renewed-with-17-higher-contracted-value/2024-11-26T13:40:11+08:00https://flcube.com/mercks-winrevair-shows-positive-results-in-phase-iii-zenith-study-for-pah/2024-11-26T13:22:28+08:00https://flcube.com/hubei-guangji-pharmaceutical-expands-ex-hospital-market-presence-with-new-partnerships/2024-11-26T13:06:33+08:00https://flcube.com/genequantum-healthcares-gq1011-amb302-receives-fda-approval-for-clinical-study/2024-11-26T12:49:04+08:00https://flcube.com/e-nitiate-biopharmaceuticals-strikes-licensing-deal-with-joincare-for-qy101-inhaler-rights/2024-11-26T12:27:20+08:00https://flcube.com/tigermed-establishes-international-headquarters-in-hong-kong-to-accelerate-global-expansion/2024-11-26T00:33:01+08:00https://flcube.com/nmpa-approves-rapid-medical-ltds-intracranial-thrombectomy-stent-for-marketing/2024-11-26T00:30:17+08:00https://flcube.com/luye-pharma-launches-rykindo-in-us-a-first-for-chinese-cns-drug/2024-11-26T00:28:00+08:00https://flcube.com/cytomed-therapeutics-partners-with-cnk-therapeutics-for-car-gene-grafting-technology/2024-11-26T00:25:21+08:00https://flcube.com/cspc-pharmaceutical-group-receives-fda-approval-for-nbl-028-bispecific-antibody-clinical-study/2024-11-26T00:04:43+08:00https://flcube.com/grand-pharmaceutical-group-initiates-phase-i-study-for-sepsis-treatment-apad/2024-11-26T00:02:08+08:00https://flcube.com/hutchmeds-orpathys-receives-breakthrough-therapy-designation-in-china-for-gastric-cancer/2024-11-25T23:54:06+08:00https://flcube.com/henan-leads-19-province-alliance-for-volume-based-drug-procurement-tender/2024-11-25T23:50:35+08:00https://flcube.com/gsks-rsv-vaccine-arexvy-launches-in-us-pharmacies-ahead-of-2023-24-season/2024-11-25T23:43:01+08:00https://flcube.com/eyebright-medical-technology-plans-grd-listing-on-six-exchange-to-raise-rmb-1-4-billion/2024-11-25T23:38:47+08:00https://flcube.com/gc-biopharma-presents-data-showing-higher-thrombotic-risk-with-roches-hemlibra/2024-11-25T23:26:11+08:00https://flcube.com/moderna-announces-immunogenicity-of-updated-covid-19-vaccine-against-new-variants/2024-11-25T23:19:32+08:00https://flcube.com/astrazenecas-forxiga-demonstrates-clinical-benefits-in-heart-failure-and-copd-patients/2024-11-25T23:16:48+08:00https://flcube.com/nhsa-releases-preliminary-review-results-for-national-reimbursement-drug-list-adjustments/2024-11-25T23:00:32+08:00https://flcube.com/novartis-sets-tentative-date-for-sandoz-spin-off-targets-october-4/2024-11-25T22:57:58+08:00https://flcube.com/astrazenecas-forxiga-gains-new-indication-approval-in-china-for-chronic-heart-failure/2024-11-25T22:49:10+08:00https://flcube.com/hua-medicine-achieves-development-milestone-for-huatangning-with-bayer-agreement/2024-11-25T22:45:44+08:00https://flcube.com/carsgen-therapeutics-partners-with-moderna-to-combine-car-t-therapy-with-mrna-cancer-vaccine/2024-11-25T22:38:00+08:00https://flcube.com/simcere-pharmaceutical-group-secures-exclusive-rights-to-cmab009-in-china/2024-11-25T22:28:28+08:00https://flcube.com/ezisurg-medical-partners-partners-with-vathin-for-global-disposable-endoscope-strategic-partnership/2024-11-25T22:17:46+08:00https://flcube.com/fosun-pharma-adjusts-investment-allocation-for-2022-non-public-offering-projects/2024-11-25T22:05:21+08:00https://flcube.com/hutchmeds-sovleplenib-achieves-primary-and-secondary-endpoints-in-eslim-01-phase-iii-trial/2024-11-25T22:00:57+08:00https://flcube.com/luye-pharmas-subsidiary-boan-biotech-strikes-licensing-deal-for-biosimilars-in-brazil/2024-11-25T21:02:22+08:00https://flcube.com/dizal-pharmaceutical-co-ltd-scales-back-private-placement-fundraising-to-usd-255-1-million/2024-11-25T20:55:14+08:00https://flcube.com/lundbeck-financial-results/2024-11-25T20:45:20+08:00https://flcube.com/national-allied-procurement-office-announces-round-10-vbp-tender-program-with-new-rules/2024-11-25T20:23:11+08:00https://flcube.com/jiangsu-chia-tai-fenghais-als-treatment-fhnd1002-selected-for-cdes-patient-centered-care-plan/2024-11-25T18:10:35+08:00https://flcube.com/acotec-scientific-holdings-receives-nmpa-approval-for-thrombus-aspiration-catheter-support-tube/2024-11-25T17:46:36+08:00https://flcube.com/henlius-biotech-initiates-phase-iii-study-for-hlx22-in-gastric-cancer-treatment/2024-11-25T17:40:34+08:00https://flcube.com/chinas-nhc-sets-sights-on-enhancing-grassroots-drug-management-and-access/2024-11-25T17:21:02+08:00https://flcube.com/microport-scientific-corp-s-bonafire-receives-nmpa-approval-as-first-whole-body-mri-safety-pacing-electrode-lead/2024-11-25T17:14:19+08:00https://flcube.com/base-therapeutics-nk510-receives-us-fda-clearance-for-advanced-solid-tumor-studies/2024-11-25T17:04:44+08:00https://flcube.com/merck-kgaa-partners-with-ntu-singapore-to-drive-digital-transformation-with-trust-technology/2024-11-25T16:54:34+08:00https://flcube.com/gsks-arexvy-receives-mhlw-approval-for-expanded-rsv-indication-in-japan/2024-11-25T16:44:40+08:00https://flcube.com/china-resources-double-crane-gets-nmpa-approval-for-semaglutide-biosimilar-clinical-trial/2024-11-25T16:28:01+08:00https://flcube.com/jj-submits-sbla-to-fda-for-subcutaneous-tremfya-regimen-in-ulcerative-colitis/2024-11-25T16:20:13+08:00https://flcube.com/serviers-vorasidenib-approved-in-boao-lecheng-medical-zone-for-diffuse-gliomas/2024-11-25T15:19:02+08:00https://flcube.com/leads-biolabs-lbl-024-earns-fda-orphan-drug-designation-for-neuroendocrine-cancer/2024-11-25T15:09:48+08:00https://flcube.com/signet-therapeutics-sigx1094-earns-orphan-drug-designation-for-gastric-cancer-from-fda/2024-11-25T14:56:36+08:00https://flcube.com/hanx-biopharmaceuticals-receives-nmpa-approval-for-hx009-combination-therapy-phase-ii-trial/2024-11-25T13:26:57+08:00https://flcube.com/hanx-biopharmaceuticals-hx009-receives-nmpa-clinical-trial-approval-for-pd-1-cd47-bispecific-antibody/2024-11-25T13:21:12+08:00https://flcube.com/hanx-biopharmaceuticals-files-for-ipo-on-hong-kong-stock-exchange/2024-11-25T13:16:28+08:00https://flcube.com/sciwind-biosciences-ecnoglutide-accepted-for-review-by-chinas-nmpa-for-type-2-diabetes/2024-11-25T12:41:24+08:00https://flcube.com/chinas-sciwind-biosciences-partners-with-hk-inno-n-for-ecnoglutide-rights-in-south-korea/2024-11-25T12:37:13+08:00https://flcube.com/novatims-kq-2003-and-ky-0118-advance-with-clinical-trial-approvals-in-china/2024-11-25T12:11:57+08:00https://flcube.com/sichuan-huiyu-pharmaceuticals-plerixafor-gains-marketing-approval-from-italian-medicines-agency/2024-11-25T12:06:00+08:00https://flcube.com/lifetech-scientific-corporation-receives-nmpa-approval-for-epione-navigation-system/2024-11-25T12:03:33+08:00https://flcube.com/jiahui-health-and-gleneagles-hong-kong-hospital-partner-for-integrated-healthcare-services/2024-11-25T11:58:00+08:00https://flcube.com/saints-sages-surgical-secures-series-b-funding-to-advance-energy-based-devices/2024-11-25T11:52:50+08:00https://flcube.com/hainan-huluwa-pharmaceutical-gets-nmpa-approval-for-generic-briviact-clinical-study/2024-11-25T11:45:00+08:00https://flcube.com/xtalpi-inc-partners-with-edelweiss-connect-to-revolutionize-skincare-safety-assessment/2024-11-25T11:39:17+08:00https://flcube.com/xtalpi-partners-with-parthenon-therapeutics-to-harness-ai-for-solid-tumor-antibody-development/2024-11-25T11:38:42+08:00https://flcube.com/xtalpi-inc-and-ck-life-sciences-expand-partnership-to-develop-ai-powered-cancer-diagnostics/2024-11-25T11:38:08+08:00https://flcube.com/xtalpi-inc-and-singapores-eddc-broaden-collaboration-in-ai-driven-drug-discovery/2024-11-25T11:37:29+08:00https://flcube.com/xtalpi-partners-with-university-of-hong-kongs-abic-to-advance-biomedical-technology-commercialization/2024-11-25T11:36:53+08:00https://flcube.com/xtalpi-forms-strategic-partnership-with-abb-robotics-to-automate-lab-workstations-in-china/2024-11-25T11:33:27+08:00https://flcube.com/xtalpis-ai-platform-xtalfold-secures-licensing-deal-with-janssen-biotech-enhancing-biologics-discovery/2024-11-25T11:33:12+08:00https://flcube.com/leman-biotech-secures-over-usd-13-9-million-in-series-a-financing-for-next-gen-cancer-immunotherapies/2024-11-25T11:22:40+08:00https://flcube.com/cspc-pharmaceutical-group-partners-with-insilico-and-xtalpi-for-ai-driven-drug-rd/2024-11-25T11:20:58+08:00https://flcube.com/luye-pharma-group-submits-market-approval-filing-for-lurbinectedin-in-metastatic-sclc-in-macau/2024-11-25T10:53:13+08:00https://flcube.com/magassist-receives-fda-breakthrough-device-designation-for-nyokassist-vad/2024-11-25T10:48:09+08:00https://flcube.com/auzone-biological-technology-gets-fda-approval-for-edaravone-oral-preparations-in-als/2024-11-25T10:42:18+08:00https://flcube.com/huadong-medicine-secures-exclusive-rights-to-oral-edaravone-candidate-ttyp01-in-major-licensing-deal/2024-11-25T10:39:47+08:00https://flcube.com/remegen-ltd-reports-20-56-yoy-revenue-growth-in-h1-2023-financial-results/2024-11-25T10:34:54+08:00https://flcube.com/gileads-magrolimab-phase-iii-trial-for-aml-faces-partial-hold-by-fda/2024-11-25T10:31:36+08:00https://flcube.com/ascentage-pharmas-2023-interim-report-49-yoy-revenue-growth-and-market-expansion/2024-11-25T10:29:19+08:00https://flcube.com/pfizers-rsv-vaccine-abrysvo-receives-fda-authorization-for-maternal-immunization/2024-11-25T10:25:49+08:00https://flcube.com/jjs-teclistamab-granted-priority-review-in-china-for-relapsed-multiple-myeloma/2024-11-25T10:22:32+08:00https://flcube.com/ascletis-pharma-inc-reports-21-7-revenue-increase-in-h1-2023-led-by-ritonavir-sales/2024-11-25T10:18:48+08:00https://flcube.com/new-horizon-health-ltd-reports-264-6-yoy-revenue-increase-and-first-recurring-profits/2024-11-25T10:15:06+08:00https://flcube.com/amgens-lumakras-faces-full-registration-review-by-fda-for-kras-mutated-nsclc/2024-11-25T10:11:20+08:00https://flcube.com/cordavis-launches-first-biosimilar-novartis-hyrimoz-to-compete-with-humira/2024-11-25T00:12:48+08:00https://flcube.com/pfizers-rsv-vaccine-abrysvo-receives-european-commission-approval-for-maternal-immunization/2024-11-25T00:11:27+08:00https://flcube.com/kintor-pharmaceutical-completes-enrollment-in-phase-ii-study-of-gt20029-for-androgenetic-alopecia/2024-11-25T00:07:22+08:00https://flcube.com/novartiss-leqvio-inclisiran-approved-in-china-for-hypercholesterolemia-treatment/2024-11-25T00:04:16+08:00https://flcube.com/lynk-pharmaceuticals-lnk01001-shows-positive-results-in-ankylosing-spondylitis-phase-ii-study/2024-11-25T00:01:34+08:00https://flcube.com/allist-pharmaceuticals-furmonertinib-wins-nmpa-nod-for-egfr-mutated-nsclc-treatment/2024-11-24T23:58:51+08:00https://flcube.com/zai-labs-repotrectinib-targets-breakthrough-therapy-designation-for-trk-positive-tumors/2024-11-24T23:56:12+08:00https://flcube.com/hangzhou-minsheng-healthcare-aims-to-raise-rmb890-million-in-shenzhen-gem-ipo/2024-11-24T23:52:56+08:00https://flcube.com/remegens-telitacicept-shows-positive-phase-iii-results-in-rheumatoid-arthritis-study/2024-11-24T23:46:43+08:00https://flcube.com/shanxi-jinbo-bio-pharmaceutical-plans-fundraise-with-private-placement-and-ipo-proceeds/2024-11-24T23:43:02+08:00https://flcube.com/ccdi-cartoon-exposes-prescription-data-rebates-corruption-in-chinas-healthcare-system/2024-11-24T23:35:00+08:00https://flcube.com/roche-subsidiary-genentech-addresses-accidental-disclosure-of-tiragolumab-trial-data/2024-11-24T23:30:53+08:00https://flcube.com/shanghai-updates-biomedical-rd-import-pilot-for-streamlined-customs-clearance/2024-11-24T23:27:52+08:00https://flcube.com/bayer-partners-with-mahana-therapeutics-to-market-digital-health-technologies/2024-11-24T23:21:37+08:00https://flcube.com/european-commission-grants-conditional-approval-for-janssens-talvey-in-multiple-myeloma/2024-11-24T23:03:20+08:00https://flcube.com/gsks-shingrix-proves-100-efficacy-in-phase-iv-trial-for-chinese-patients/2024-11-24T22:59:35+08:00https://flcube.com/immuneonco-biopharmaceuticals-launches-ipo-to-raise-hkd-319-million-on-hong-kong-stock-exchange/2024-11-24T22:57:10+08:00https://flcube.com/dizal-pharmaceuticals-sunvozertinib-approved-by-chinas-nmpa-for-nsclc-treatment/2024-11-24T22:54:35+08:00https://flcube.com/hinova-pharmaceuticals-hp518-for-mcrpc-accepted-for-review-by-chinas-nmpa/2024-11-24T22:51:35+08:00https://flcube.com/labway-clinical-laboratory-partners-with-10x-genomics-for-precision-medicine-advancements/2024-11-24T22:42:46+08:00https://flcube.com/akeso-biopharmas-ebdarokimab-ak101-nda-accepted-for-review-by-chinas-cde/2024-11-24T22:37:38+08:00https://flcube.com/beijing-drafts-regulations-for-internet-diagnosis-and-treatment-prohibits-ai-prescriptions/2024-11-24T22:35:01+08:00https://flcube.com/innovent-biologics-reports-20-6-yoy-revenue-growth-in-h1-2023-financials/2024-11-24T22:31:55+08:00https://flcube.com/eli-lillys-retevmo-meets-primary-endpoint-in-phase-iii-trial-for-ret-mutant-medullary-thyroid-cancer/2024-11-24T22:29:01+08:00https://flcube.com/fda-grants-priority-review-to-pfizer-and-astellas-xtandi-for-high-risk-prostate-cancer/2024-11-24T22:25:42+08:00https://flcube.com/scott-moncrieff-associates-preparing-50-cases-against-astrazeneca-over-vaccine-concerns/2024-11-24T22:22:27+08:00https://flcube.com/nanjing-fs-pharmatech-secures-first-generic-approval-for-novartiss-entresto-in-china/2024-11-24T22:17:35+08:00https://flcube.com/wuxi-biologics-reports-17-8-revenue-growth-and-expands-service-scope-in-h1-2023/2024-11-24T22:13:55+08:00https://flcube.com/johnson-johnson-completes-spinoff-of-kenvue-as-independent-company/2024-11-24T22:09:55+08:00https://flcube.com/everest-medicines-reports-q1-2023-revenue-growth-and-pipeline-progress/2024-11-24T22:06:28+08:00https://flcube.com/neurodawn-pharmaceutical-and-china-medical-system-holdings-ink-licensing-deal-for-y-3/2024-11-24T22:03:38+08:00https://flcube.com/jiangsu-kanion-pharmaceutical-gets-nmpa-approval-for-sle-clinical-trial-with-kys202002a/2024-11-24T21:57:58+08:00https://flcube.com/everest-medicines-nefecon-nda-for-igan-accepted-for-review-in-macao/2024-11-24T21:51:59+08:00https://flcube.com/china-releases-third-list-of-pediatric-drugs-to-guide-development-and-filings/2024-11-24T21:39:08+08:00https://flcube.com/nmpa-releases-72nd-batch-of-reference-drugs-for-gqce/2024-11-24T21:36:21+08:00https://flcube.com/fda-approves-gileads-veklury-for-covid-19-treatment-in-patients-with-hepatic-impairment/2024-11-24T21:30:20+08:00https://flcube.com/astrazeneca-restructures-to-capture-opportunities-in-guangdong-hong-kong-macao-greater-bay-area/2024-11-24T21:21:16+08:00https://flcube.com/microport-ep-medtechs-cryoablation-catheter-and-equipment-approved-as-innovative-devices-in-china/2024-11-24T20:57:14+08:00https://flcube.com/cspc-pharmaceuticals-generic-entresto-approved-in-china-for-heart-failure-treatment/2024-11-24T20:48:34+08:00https://flcube.com/akeso-biopharmas-ivonescimab-heads-for-priority-review-for-nsclc-treatment/2024-11-24T20:40:22+08:00https://flcube.com/3sbio-inc-reports-h1-2023-revenue-growth-and-expansion-in-digital-marketing/2024-11-24T20:37:00+08:00https://flcube.com/janssen-submits-rybrevant-for-fda-review-as-first-line-nsclc-treatment/2024-11-24T20:34:49+08:00https://flcube.com/sandoz-receives-fda-clearance-for-first-biosimilar-to-biogens-tysabri/2024-11-24T18:32:29+08:00https://flcube.com/cde-seeks-public-feedback-on-biological-product-changes-during-clinical-trials/2024-11-24T18:29:04+08:00https://flcube.com/chinese-pharma-consortium-eyes-polands-neuca-in-strategic-european-market-acquisition/2024-11-24T18:26:31+08:00https://flcube.com/abbvie-partners-with-sinopharm-to-enhance-novel-drug-accessibility-and-patient-management/2024-11-24T18:21:38+08:00https://flcube.com/youcare-pharmaceutical-partners-with-sinopharm-heilongjiang-to-broaden-market-presence/2024-11-24T18:21:37+08:00https://flcube.com/sinopharm-plans-to-privatize-china-traditional-medicine-holdings-in-a-usd-2-billion-deal/2024-11-24T18:21:35+08:00https://flcube.com/sinopharm-and-fresenius-kabi-expand-partnership-to-enhance-drug-distribution-and-healthcare-services/2024-11-24T18:21:35+08:00https://flcube.com/former-sinopharm-executive-yang-xiaoming-removed-from-national-peoples-congress-over-alleged-serious-violations/2024-11-24T18:21:34+08:00https://flcube.com/tonghua-dongbao-pharmaceuticals-partners-with-sinopharm-for-supply-chain-and-market-expansion/2024-11-24T18:21:33+08:00https://flcube.com/sinopharm-and-ruidio-pharmaceutical-advance-in-priority-review-for-innovative-drugs-and-vaccines/2024-11-24T18:21:32+08:00https://flcube.com/sinopharms-innostar-bio-tech-becomes-first-pharma-company-to-ipo-on-star-in-2024/2024-11-24T18:21:31+08:00https://flcube.com/sinopharm-holding-appoints-new-chairman-and-president-following-leadership-changes/2024-11-24T18:21:31+08:00https://flcube.com/bi-partners-with-sinopharm-for-promotion-of-sifrol-and-pradaxa-in-china/2024-11-24T18:21:30+08:00https://flcube.com/tasly-pharmaceuticals-gets-nmpa-approval-for-stro-002-clinical-study-in-solid-tumors/2024-11-24T18:17:23+08:00https://flcube.com/youcare-pharmaceuticals-ykyyo17-receives-ethical-approval-for-covid-19-treatment-study/2024-11-24T18:09:49+08:00https://flcube.com/novartis-defends-entresto-patents-as-generic-approvals-trigger-legal-response/2024-11-24T16:27:11+08:00https://flcube.com/csh-medi-secures-series-a-funding-to-advance-biomagnetic-equipment-technology/2024-11-24T16:18:47+08:00https://flcube.com/junshi-biosciences-senaparib-nda-accepted-by-nmpa-for-ovarian-cancer-maintenance-treatment/2024-11-24T16:12:30+08:00https://flcube.com/luye-pharma-groups-subsidiary-boan-biotechnology-reports-18-4-revenue-growth-in-h1-2023/2024-11-24T16:09:41+08:00https://flcube.com/csrc-aims-to-rebalance-primary-and-secondary-markets-with-new-regulatory-measures/2024-11-24T16:06:18+08:00https://flcube.com/immunotech-biopharms-eal-earns-breakthrough-therapy-designation-for-hcc-recurrence-prevention/2024-11-24T16:04:31+08:00https://flcube.com/mabwell-bioscience-secures-deal-with-unilab-for-biosimilar-humira-in-the-philippines/2024-11-24T15:52:26+08:00https://flcube.com/hanchorbio-and-henlius-pharmaceutical-enter-strategic-collaboration-for-immunotherapies/2024-11-24T15:49:33+08:00https://flcube.com/novocures-ttfields-misses-overall-survival-endpoint-in-ovarian-cancer-phase-iii-trial/2024-11-24T15:41:05+08:00https://flcube.com/harbour-biomeds-hbm9033-adc-receives-us-fda-ind-clearance-for-clinical-trials/2024-11-24T15:35:27+08:00https://flcube.com/sandoz-expands-anti-infective-portfolio-with-acquisition-of-astellas-pharmas-antifungal-mycamine/2024-11-24T15:32:27+08:00https://flcube.com/bms-partners-with-cellares-for-automated-car-t-cell-therapy-production/2024-11-24T14:58:28+08:00https://flcube.com/takeda-and-bridgene-biosciences-achieve-milestone-in-neurodegenerative-disorder-target-identification/2024-11-24T14:53:26+08:00https://flcube.com/lundbeck-a-s-reports-10-h1-2023-revenue-increase-with-record-breaking-sales/2024-11-24T14:49:00+08:00https://flcube.com/janssen-submits-indication-extension-application-for-balversa-in-urothelial-carcinoma-treatment/2024-11-24T14:42:44+08:00https://flcube.com/zhejiang-huahai-pharmaceutical-receives-fda-approval-for-generic-vyvanse/2024-11-24T14:40:11+08:00https://flcube.com/antengenes-xpovio-price-reduced-by-37-in-china-aiding-patient-access/2024-11-24T14:36:24+08:00https://flcube.com/chinas-9th-national-vbp-tender-round-targets-cns-drugs-and-includes-oncology-therapies/2024-11-24T14:32:22+08:00https://flcube.com/nmpa-revises-drug-conditional-approval-procedures-streamlined-processes-and-requirements/2024-11-24T14:30:15+08:00https://flcube.com/genfleet-therapeutics-and-verastem-oncology-ink-licensing-deal-for-ras-pathway-cancer-therapies/2024-11-24T14:27:59+08:00https://flcube.com/boehringer-ingelheim-submits-three-inds-for-survodutide-phase-iii-trials-in-china/2024-11-24T14:22:52+08:00https://flcube.com/harbour-biomed-reports-first-profitable-half-year-in-h1-2023-financial-results/2024-11-24T14:17:13+08:00https://flcube.com/three-senior-executives-of-henan-topfond-pharmaceutical-under-investigation/2024-11-24T12:02:24+08:00https://flcube.com/china-meheco-group-appoints-yang-guang-as-chairman-and-legal-representative/2024-11-24T11:55:28+08:00https://flcube.com/leman-biotech-enters-zhongshan-life-science-park-to-accelerate-car-t-innovation/2024-11-24T10:55:06+08:00https://flcube.com/ronovo-surgical-secures-pre-series-b-funding-to-advance-modular-surgical-robots/2024-11-24T01:31:04+08:00https://flcube.com/aim-vaccine-co-ltd-launches-phase-iii-trial-for-23-valent-pneumococcal-vaccine/2024-11-24T01:26:41+08:00https://flcube.com/kangpu-biopharmaceuticals-secures-series-b-funding-to-advance-molecular-glue-therapies/2024-11-24T01:23:42+08:00https://flcube.com/epigenic-therapeutics-secures-32-million-in-series-a-funding-for-gene-modulation-therapy/2024-11-24T01:17:55+08:00https://flcube.com/biocytogen-pharmaceuticals-eucure-biopharma-expands-partnership-with-syncromune-on-immunotherapies/2024-11-24T01:15:18+08:00https://flcube.com/cspc-pharmaceuticals-biosimilar-ozempic-equivalent-gets-nmpa-clinical-trial-approval/2024-11-24T01:05:48+08:00https://flcube.com/jiangsu-yahong-meditech-gets-nmpa-approval-for-apl1401-ulcerative-colitis-trial/2024-11-24T01:02:09+08:00https://flcube.com/luye-pharma-group-reports-h1-2023-revenue-growth-with-strong-oncology-and-cns-sales/2024-11-24T00:58:58+08:00https://flcube.com/fosun-pharma-reports-moderate-revenue-growth-and-increased-rd-spend-in-2023-interim-report/2024-11-24T00:56:21+08:00https://flcube.com/roches-evrysdi-receives-ec-approval-for-expanded-indication-in-infants-with-sma/2024-11-24T00:48:10+08:00https://flcube.com/msds-keytruda-gains-ec-approval-for-first-line-her2-positive-gastric-cancer-treatment/2024-11-24T00:45:19+08:00https://flcube.com/dizal-pharmaceuticals-golidocitinib-earns-priority-review-for-r-r-ptcl-treatment-in-china/2024-11-24T00:25:26+08:00https://flcube.com/adagenes-adg126-shows-promising-results-in-phase-ib-ii-study-for-mss-crc-at-esmo-2024/2024-11-23T22:42:56+08:00https://flcube.com/sfda-embraces-transparency-regular-press-briefings-and-personnel-rotations-announced/2024-11-23T22:41:36+08:00https://flcube.com/ruijin-hospital-unveils-five-new-mutations-in-rare-adrenal-hyperplasia-study/2024-11-23T22:40:59+08:00https://flcube.com/guangdongs-sunlight-purchase-system-sparks-drug-pricing-war-and-uncovers-pricing-anomalies/2024-11-23T22:40:08+08:00https://flcube.com/chinas-sfda-mandates-official-position-rotation-to-boost-transparency/2024-11-23T22:39:26+08:00https://flcube.com/ruijin-hospital-researchers-uncover-five-new-mutations-in-rare-17ohd-endocrine-disorder/2024-11-23T22:38:14+08:00https://flcube.com/novartis-sees-15-global-sales-growth-and-significant-investment-in-china-for-2006/2024-11-23T22:37:26+08:00https://flcube.com/india-launches-anti-dumping-campaign-against-chinese-vitamin-b12-and-ceftriaxone-sodium-producers/2024-11-23T22:36:09+08:00https://flcube.com/china-unveils-tcm-development-guidelines-a-strategic-defense-of-traditional-medicine/2024-11-23T22:35:21+08:00https://flcube.com/shanghai-to-launch-chinas-largest-adr-database-enhancing-pharmaceutical-oversight/2024-11-23T22:34:22+08:00https://flcube.com/china-biopharma-posts-216-revenue-increase-eyes-us10-million-in-2007-with-vaccine-distribution-and-new-treatments/2024-11-23T22:33:43+08:00https://flcube.com/china-launches-unprecedented-multi-center-hypertension-study-with-global-implications/2024-11-23T22:33:02+08:00https://flcube.com/chinas-ministry-of-health-tightens-organ-transplant-regulations-with-expert-conference/2024-11-23T22:31:44+08:00https://flcube.com/guangzhou-pharma-and-biocubafarma-chart-new-course-with-joint-biologics-rd-and-exchange-deal/2024-11-23T22:31:04+08:00https://flcube.com/cuban-chinese-pharma-synergy-joint-rd-and-sales-initiative-targets-usd-24-53-billion-in-sales/2024-11-23T22:30:07+08:00https://flcube.com/thermo-fisher-scientific-develops-serology-test-to-detect-covid-19-antibodies-in-collaboration-with-wuxi-diagnostics-and-mayo-clinic/2024-11-23T22:28:42+08:00https://flcube.com/enhancing-clinical-trial-success-cdes-new-adaptive-design-framework-opens-for-comment/2024-11-23T22:27:53+08:00https://flcube.com/luye-pharma-expands-latin-american-reach-with-exclusive-seroquel-promotion-agreement-in-brazil-and-mexico/2024-11-23T22:26:57+08:00https://flcube.com/innovent-biologics-and-eli-lilly-co-s-tyvyt-achieves-primary-endpoints-in-phase-ii-escc-clinical-study/2024-11-23T22:25:46+08:00https://flcube.com/asymchem-laboratories-secures-rmb-2-31-billion-private-placement-with-hill-house-capital-subscription/2024-11-23T22:21:08+08:00https://flcube.com/genscripts-car-t-therapy-jnj-4528-demonstrates-100-effective-rate-in-long-term-myeloma-study/2024-11-23T22:20:25+08:00https://flcube.com/chinas-western-pharmaceutical-exports-soar-23-in-2006-led-by-antibiotics/2024-11-23T22:19:09+08:00https://flcube.com/fidson-healthcare-partners-with-chinese-entities-to-establish-drug-plant-in-nigeria/2024-11-23T22:18:22+08:00https://flcube.com/shanghai-roche-pharmaceuticals-launches-erlotinib-for-advanced-non-small-cell-lung-cancer-in-china/2024-11-23T22:17:59+08:00https://flcube.com/huadong-medicines-ror1-targeting-adc-hdm2005-cleared-for-clinical-trials-by-chinas-nmpa/2024-11-23T22:15:34+08:00https://flcube.com/kintor-pharmaceutical-initiates-phase-ii-clinical-trial-for-acne-treatment-gt20029-in-china/2024-11-23T22:14:08+08:00https://flcube.com/aidea-pharmaceutical-to-boost-stake-in-nanda-pharmaceutical-to-51-1256/2024-11-23T22:13:18+08:00https://flcube.com/johnson-johnson-appoints-edward-zhou-as-medtech-china-president/2024-11-23T22:12:31+08:00https://flcube.com/microport-medical-reports-17-revenue-growth-in-2024h1-driven-by-subsidiaries-performance/2024-11-23T22:11:36+08:00https://flcube.com/junshi-biosciences-logs-17-37-revenue-growth-in-2024h1-fueled-by-loqtorzi-sales-surge/2024-11-23T22:10:57+08:00https://flcube.com/tiantan-biological-to-acquire-wuhan-zhongyuan-ruide-for-185-million-expanding-plasma-resources/2024-11-23T22:10:04+08:00https://flcube.com/wuxi-biologics-to-acquire-full-control-of-vaccine-contract-services-subsidiary-for-108-5-million/2024-11-23T22:09:08+08:00https://flcube.com/roche-diagnostics-to-double-down-on-china-with-rmb-3-billion-suzhou-plant-expansion/2024-11-23T22:08:15+08:00https://flcube.com/bioage-labs-taps-former-gsk-ceo-jean-pierre-garnier-as-chairman/2024-11-23T22:06:22+08:00https://flcube.com/china-expands-medical-insurance-coverage-to-include-assisted-reproductive-technology-in-19-regions/2024-11-23T22:03:56+08:00https://flcube.com/hainan-province-unveils-ambitious-three-year-plan-for-digital-health-innovation-and-economy-expansion/2024-11-23T22:03:02+08:00https://flcube.com/nmpa-unveils-82nd-batch-of-reference-drugs-for-generic-quality-evaluation/2024-11-23T22:02:12+08:00https://flcube.com/baheal-pharmaceutical-group-to-establish-rd-center-for-myocardial-repair-with-cams-fuwai-hospital/2024-11-23T22:01:13+08:00https://flcube.com/shandong-buchang-pharmaceuticals-rhepo-fc-for-ckd-anemia-accepted-for-review-by-chinas-cde/2024-11-23T22:00:20+08:00https://flcube.com/micurx-pharmaceuticals-reports-44-revenue-growth-and-increased-rd-spending-in-2024h1/2024-11-23T21:59:31+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-shanghai-mycology-lab-to-advance-fungal-infection-diagnostics/2024-11-23T21:58:33+08:00https://flcube.com/bayers-finerenone-shows-promise-in-heart-failure-treatment-outperforms-placebo-in-phase-iii-trial/2024-11-23T21:57:32+08:00https://flcube.com/latin-america-accelerates-covid-19-fight-with-vaccine-and-treatment-initiatives-across-the-region/2024-11-23T21:56:26+08:00https://flcube.com/shanghai-boosts-community-healthcare-with-enhanced-reimbursement-and-services/2024-11-23T21:55:21+08:00https://flcube.com/novo-nordisk-acquires-global-license-for-vect-horus-molecular-cargo-delivery-platform/2024-11-23T21:51:21+08:00https://flcube.com/merck-and-daiichi-sankyos-her3-dxd-adc-patritumab-deruxtecan-passes-phase-3-trial-after-fda-rejection/2024-11-23T21:50:17+08:00https://flcube.com/iteos-therapeutics-and-gsks-belrestotug-dostarlimab-combo-shows-promising-results-in-nsclc/2024-11-23T21:49:12+08:00https://flcube.com/mercks-keytruda-gains-expanded-approval-for-first-line-melanoma-treatment-in-china/2024-11-23T21:47:08+08:00https://flcube.com/microport-scientifics-firesorb-bioabsorbable-stent-begins-clinical-use-in-china/2024-11-23T21:46:06+08:00https://flcube.com/nhsa-concludes-2024-nrdl-review-announces-submission-deadlines-for-drug-manufacturers/2024-11-23T21:45:12+08:00https://flcube.com/harbour-biomeds-2024-h1-revenues-decline-amid-rd-optimization-and-pipeline-advancements/2024-11-23T21:44:03+08:00https://flcube.com/ascletis-pharma-initiates-phase-i-trials-for-monthly-subcutaneous-and-daily-oral-obesity-treatment-asc30-in-the-us/2024-11-23T21:43:14+08:00https://flcube.com/cstone-pharmaceuticals-sugemalimab-shows-promising-long-term-survival-data-at-esmo-202/2024-11-23T21:42:05+08:00https://flcube.com/alphamab-oncologys-jskn003-adc-achieves-positive-safety-and-efficacy-outcomes-in-phase-i-studies/2024-11-23T21:41:23+08:00https://flcube.com/abbisko-therapeutics-fgfr4-inhibitor-irpagratinib-shows-positive-phase-i-results-at-esmo-congress/2024-11-23T21:40:33+08:00https://flcube.com/astrazenecas-imfinzi-imjudo-combo-sets-new-longevity-benchmark-in-liver-cancer-treatment/2024-11-23T21:39:39+08:00https://flcube.com/gsks-blenrep-bordex-combo-earns-breakthrough-therapy-designation-in-china-for-multiple-myeloma/2024-11-23T21:38:29+08:00https://flcube.com/altamira-therapeutics-and-nuance-pharma-expand-bentrios-reach-in-asia/2024-11-23T21:32:44+08:00https://flcube.com/i-mabs-plonmarlimab-receives-breakthrough-therapy-designation-in-china-for-r-r-mas-treatment/2024-11-23T21:31:37+08:00https://flcube.com/transcentas-osemitamab-combo-therapy-shows-promising-results-in-g-gej-cancer-treatment-at-esmo-2024/2024-11-23T21:30:36+08:00https://flcube.com/keymed-biosciences-stapokibart-receives-first-prescription-in-china-for-il-4r%ce%b1-targeting-therapy/2024-11-23T21:28:18+08:00https://flcube.com/astrazenecas-tagrisso-achieves-milestones-in-phase-iii-laura-study-for-egfr-mutated-nsclc-at-esmo-2024/2024-11-23T21:27:21+08:00https://flcube.com/cspc-pharmaceutical-secures-nmpa-approval-for-omalizumab-biosimilar/2024-11-23T21:26:03+08:00https://flcube.com/biocytogen-pharmaceuticals-inks-antibody-deal-with-neurocrine-biosciences/2024-11-23T21:25:15+08:00https://flcube.com/european-commission-approves-takedas-hyqvia-for-chronic-inflammatory-demyelinating-polyneuropathy/2024-11-23T21:24:32+08:00https://flcube.com/sino-medical-sciences-gains-pakistani-nod-for-sc-honkytonk-and-nc-rockstar-catheters/2024-11-23T21:23:29+08:00https://flcube.com/dr-reddys-launches-biosimilar-versavo-in-uk-to-challenge-roches-cancer-therapy-avastin/2024-11-23T21:22:36+08:00https://flcube.com/junshi-biosciences-toripalimab-approved-for-first-line-rcc-treatment-in-china/2024-11-23T21:21:38+08:00https://flcube.com/largev-instruments-ipo-on-star-board-halted-following-filing-and-sponsorship-withdrawal/2024-11-23T21:20:48+08:00https://flcube.com/novartiss-kesimpta-shows-sustained-efficacy-in-6-year-relapsing-ms-study/2024-11-23T21:20:11+08:00https://flcube.com/abbvies-rinvoq-meets-main-goal-in-late-stage-giant-cell-arteritis-trial/2024-11-23T21:15:56+08:00https://flcube.com/gsks-shingrix-vaccine-maintains-high-efficacy-for-over-a-decade-phase-iii-data-show/2024-11-23T21:09:29+08:00https://flcube.com/chinas-cde-issues-guidelines-for-pediatric-drug-labeling-updates/2024-11-23T21:06:09+08:00https://flcube.com/innovent-biologics-pemazyre-wins-macau-approval-for-cholangiocarcinoma-treatment/2024-11-23T21:04:14+08:00https://flcube.com/zai-labs-optune-approved-by-chinas-nmpa-offering-new-hope-for-glioblastoma-patients/2024-11-23T21:03:19+08:00https://flcube.com/sichuan-biokin-gets-nmpa-green-light-for-bl-b01d1-adc-in-nsclc-clinical-trial/2024-11-23T21:01:20+08:00https://flcube.com/guangzhou-lbp-earns-nmpa-nod-for-her2-detection-reagent-to-guide-breast-cancer-treatment/2024-11-23T21:00:31+08:00https://flcube.com/beijing-sanbo-hospital-and-age-dr-hospital-management-group-join-forces-in-brain-disease-care/2024-11-23T20:59:23+08:00https://flcube.com/impact-therapeutics-boosts-war-chest-with-55-2-million-series-d-round-for-cancer-drugs/2024-11-23T20:58:25+08:00https://flcube.com/careray-digital-medical-invests-15-million-for-stake-in-x-ray-detector-maker-isid/2024-11-23T20:55:08+08:00https://flcube.com/takeda-scores-fda-nod-for-subcutaneous-vedolizumab-to-treat-inflammatory-bowel-disease/2024-11-23T20:53:12+08:00https://flcube.com/roches-alecensa-approved-by-fda-as-first-alk-inhibitor-for-adjuvant-treatment-of-nsclc/2024-11-23T20:39:56+08:00https://flcube.com/kind-pharmaceuticals-resolves-trade-secrets-dispute-with-fibrogen-amid-hif-phi-pipeline-development/2024-11-23T20:38:30+08:00https://flcube.com/joincare-pharmaceuticals-tg-1000-shows-promise-in-phase-iii-flu-treatment-trial/2024-11-23T20:37:42+08:00https://flcube.com/gsks-gepotidacin-shows-non-inferior-efficacy-in-phase-iii-gonorrhoea-tria/2024-11-23T20:37:03+08:00https://flcube.com/bayer-ceo-joins-german-chancellor-on-china-visit-announces-new-investments/2024-11-23T20:36:21+08:00https://flcube.com/abbisko-therapeutics-irpagratinib-earns-orphan-drug-designation-from-us-fda-for-hepatocellular-carcinoma/2024-11-23T20:33:23+08:00https://flcube.com/shanghai-junshi-biosciences-pd-1-inhibitor-toripalimab-files-for-two-indications-in-hong-kong/2024-11-23T20:32:34+08:00https://flcube.com/hua-medicine-reports-2023-revenues-of-rmb-76-6-million-driven-by-hypoglycemic-agent-huatangning/2024-11-23T20:31:39+08:00https://flcube.com/viatris-q1-2024-results-show-slight-dip-in-base-business-brands-amid-overall-stabilization/2024-11-23T20:30:35+08:00https://flcube.com/c-q-pharmaceutical-and-jd-com-join-forces-to-revolutionize-pharmaceutical-supply-chain/2024-11-23T20:29:26+08:00https://flcube.com/sanofis-tolebrutinib-shows-mixed-results-in-phase-iii-multiple-sclerosis-trials/2024-11-23T20:26:51+08:00https://flcube.com/chinas-nhc-charts-ambitious-healthcare-reform-path-with-emphasis-on-tcm-and-technology/2024-11-23T20:25:02+08:00https://flcube.com/china-unveils-blueprint-for-service-trade-expansion-through-strategic-opening-up/2024-11-23T20:24:09+08:00https://flcube.com/immuneonco-receives-second-payment-from-instil-bio-highlighting-ongoing-licensing-deal/2024-11-23T20:23:13+08:00https://flcube.com/beijing-wantai-biological-and-fujian-provincial-cdc-collaborate-on-vaccine-development-and-public-health-initiatives/2024-11-23T20:22:33+08:00https://flcube.com/fosun-pharma-to-acquire-full-stake-in-fosun-kite-biotechnology-for-usd-27-million/2024-11-23T20:20:19+08:00https://flcube.com/ascentage-pharmas-olverembatinib-shows-promise-in-sdh-deficient-gist-at-esmo-congress/2024-11-23T20:19:18+08:00https://flcube.com/roches-ocrevus-zunovo-receives-fda-nod-as-first-twice-yearly-ms-treatment/2024-11-23T20:18:34+08:00https://flcube.com/lillys-once-monthly-atopic-dermatitis-treatment-ebglyss-gets-green-light-from-fda/2024-11-23T20:17:44+08:00https://flcube.com/roches-tecentriq-hybreza-becomes-first-subcutaneous-anti-pd-l1-immunotherapy-in-the-us/2024-11-23T20:16:50+08:00https://flcube.com/sanofi-secures-global-rights-to-radioligand-therapy-alphamexi-in-deal-with-radiomedix-and-orano-med/2024-11-23T20:16:04+08:00https://flcube.com/johnson-johnsons-tremfya-gains-fda-approval-for-ulcerative-colitis-treatment/2024-11-23T20:14:59+08:00https://flcube.com/innovent-biologics-launches-phase-i-clinical-trial-for-ibr822-cell-injection-solution-in-solid-tumors/2024-11-23T20:14:22+08:00https://flcube.com/novartis-cemiplimab-approved-in-china-for-moderate-to-severe-atopic-dermatitis/2024-11-23T20:13:32+08:00https://flcube.com/walsun-biotech-achieves-top-esg-rating-underscores-commitment-to-sustainability/2024-11-23T20:12:41+08:00https://flcube.com/shanghai-pharmaceuticals-dual-targeting-car-t-therapy-advances-with-ind-re-acceptance/2024-11-23T20:11:38+08:00https://flcube.com/kangfang-biotechs-yivoxi-shows-promising-results-in-treating-r-m-hnscc-at-esmo-congress/2024-11-23T20:10:49+08:00https://flcube.com/kangfang-biotechs-yivoxi-shows-promising-results-in-first-line-tnbc-treatment-at-esmo-congress/2024-11-23T20:10:03+08:00https://flcube.com/kangfang-biotech-presents-groundbreaking-mcrc-treatment-data-at-esmo-congress/2024-11-23T20:09:25+08:00https://flcube.com/mgi-tech-joins-forces-with-dasa-to-enhance-precision-medicine-in-brazil-through-advanced-genomic-sequencing/2024-11-23T20:08:25+08:00https://flcube.com/shanghai-fudan-zhangjiang-enrolls-first-patient-in-u-s-phase-ii-study-for-port-wine-stain-treatment/2024-11-23T17:42:56+08:00https://flcube.com/gsk-appoints-li-weidong-as-vaccine-business-head-for-china/2024-11-23T17:28:01+08:00https://flcube.com/sanofis-consumer-health-unit-attracts-binding-offers-potential-eur-15-billion-deal/2024-11-23T17:27:19+08:00https://flcube.com/medilink-therapeutics-partners-with-amgen-for-clinical-trial-in-small-cell-lung-cancer/2024-11-23T17:26:24+08:00https://flcube.com/innovent-biologics-and-ask-pharma-forge-strategic-partnership-for-limertinib-in-lung-cancer-treatment/2024-11-23T17:25:31+08:00https://flcube.com/astrazeneca-strikes-exclusive-licensing-deal-with-cspc-pharma-for-oral-lpa-disruptor/2024-11-23T17:24:53+08:00https://flcube.com/nmpa-expands-generic-quality-consistency-evaluation-with-83rd-batch-of-reference-drugs/2024-11-23T17:23:13+08:00https://flcube.com/microport-endovascular-medtechs-fiber-wool-plug-spring-coil-gains-nmpa-marketing-approval/2024-11-23T17:22:24+08:00https://flcube.com/jiangsu-aidea-pharmaceutical-secures-nmpa-approval-for-expanded-indication-of-fubangde-in-hiv-treatment/2024-11-23T17:21:37+08:00https://flcube.com/bio-thera-solutions-ltd-strikes-licensing-deal-with-gedeon-richter-for-bat1706-biosimilar/2024-11-23T17:20:55+08:00https://flcube.com/spc-pharmaceuticals-adc-cpo301-earns-second-fast-track-designation-in-the-us-for-nsclc-treatment/2024-11-23T17:07:30+08:00https://flcube.com/ningbo-menovo-pharmaceutical-partners-with-nanjing-huawe-medicine-for-high-end-product-development/2024-11-23T17:06:49+08:00https://flcube.com/joincare-pharmaceutical-secures-nmpa-approval-for-triptorelin-microspheres-to-treat-endometriosis/2024-11-23T17:05:53+08:00https://flcube.com/boehringer-ingelheims-survodutide-earns-fda-breakthrough-therapy-designation-for-mash-treatment/2024-11-23T17:05:33+08:00https://flcube.com/gilead-sciences-to-withdraw-accelerated-approval-of-trodelvy-in-urothelial-carcinoma/2024-11-23T17:05:23+08:00https://flcube.com/beijing-biostar-pharmaceuticals-set-to-go-public-on-hkex-with-focus-on-oncology-innovation/2024-11-23T17:05:17+08:00https://flcube.com/astrazenecas-soliris-gains-approval-for-pediatric-generalized-myasthenia-gravis-in-japan/2024-11-23T16:31:33+08:00https://flcube.com/novo-nordisk-acquires-embark-biotech-to-boost-obesity-and-cardiometabolic-drug-development/2024-11-23T16:30:51+08:00https://flcube.com/shandong-buchang-pharmaceuticals-bc001-for-mcrc-accepted-for-review-by-nmpa/2024-11-23T16:29:47+08:00https://flcube.com/sirnaomics-stp707-sirna-drug-shows-promising-results-in-phase-i-solid-tumor-study/2024-11-23T16:25:29+08:00https://flcube.com/servier-groups-pancreatic-cancer-therapy-onivyde-launches-in-major-chinese-cities/2024-11-23T16:22:40+08:00https://flcube.com/junshi-biosciences-reports-h1-2023-revenue-dip-amid-commercial-success-and-rd-focus/2024-11-23T16:17:56+08:00https://flcube.com/cde-releases-73rd-batch-of-chemical-generic-reference-preparations-with-updates/2024-11-23T16:12:08+08:00https://flcube.com/lees-pharmaceutical-holdings-ltd-reports-h1-2023-revenue-dip-amid-product-portfolio-growth/2024-11-23T16:09:18+08:00https://flcube.com/watchmaker-genomics-and-exact-sciences-corporation-ink-deal-to-advance-taps-technology/2024-11-23T16:06:20+08:00https://flcube.com/takeda-secures-exclusive-rights-to-immunogens-elahere-in-japan-through-new-agreement/2024-11-23T15:50:21+08:00https://flcube.com/johnson-johnson-reports-h1-2023-sales-growth-following-kenvue-spinoff/2024-11-23T15:46:53+08:00https://flcube.com/zhejiang-dian-diagnostics-reports-2023h1-revenue-dip-strategic-expansion-continues/2024-11-23T15:39:11+08:00https://flcube.com/pfizer-and-biontech-receive-positive-chmp-opinion-for-comirnaty-vaccine/2024-11-23T15:32:39+08:00https://flcube.com/eoc-pharma-group-and-nanopeptide-biotechnology-forge-partnership-for-sirna-drug-development/2024-11-23T15:29:14+08:00https://flcube.com/rapid-medicals-tigertriever-receives-chinese-approval-as-adjustable-thrombectomy-device/2024-11-23T15:21:34+08:00https://flcube.com/genexines-eftansomatropin-alfa-achieves-phase-iii-endpoints-in-growth-hormone-deficiency-trial/2024-11-23T15:16:02+08:00https://flcube.com/huadong-medicine-secures-exclusive-rights-to-mc2-therapeutics-plaque-psoriasis-therapy-in-china/2024-11-23T15:11:09+08:00https://flcube.com/innovac-therapeutics-secures-18-million-in-pre-series-a-financing-for-mrna-vaccine-development/2024-11-23T15:06:21+08:00https://flcube.com/astrazeneca-and-daiichi-sankyos-enhertu-earns-two-btds-for-her2-malignancies/2024-11-23T14:59:17+08:00https://flcube.com/bayer-funds-landmark-trials-for-kerendia-in-heart-failure-treatment-expansion/2024-11-23T14:56:06+08:00https://flcube.com/ema-and-fda-review-abbvies-skyrizi-for-ulcerative-colitis-indication-extension/2024-11-23T14:53:02+08:00https://flcube.com/brl-medicine-inc-secures-nearly-30-million-in-b-round-financing-to-advance-pipeline/2024-11-23T14:46:20+08:00https://flcube.com/bio-bank-corp-aims-for-hkex-ipo-with-focus-on-pdgf-drug-development/2024-11-23T13:45:27+08:00https://flcube.com/protein-drug-developer-bk-co-ltd-from-qingdao-eyes-hong-kong-ipo/2024-11-23T13:43:08+08:00https://flcube.com/chinese-biopharma-bio-bank-corp-aims-for-hkex-ipo-focused-on-pdgf-therapies/2024-11-23T13:34:28+08:00https://flcube.com/shanghai-biotech-cataya-secures-35-million-in-series-b-financing-for-synthetic-biology/2024-11-23T00:40:27+08:00https://flcube.com/shanghai-junshi-biosciences-js207-bispecific-antibody-receives-nmpa-clinical-trial-approval/2024-11-23T00:31:37+08:00https://flcube.com/united-laboratories-ubt251-receives-tacit-approval-for-obesity-clinical-study-in-china/2024-11-23T00:14:43+08:00https://flcube.com/zai-labs-margenza-margetuximab-approved-by-chinas-nmpa-for-her2-positive-breast-cancer/2024-11-23T00:11:05+08:00https://flcube.com/micurx-pharmaceuticals-initiates-phase-iii-trial-for-mrx-4-in-complex-skin-infections/2024-11-23T00:07:40+08:00https://flcube.com/pilot-gene-technology-secures-13-8-million-in-series-b-financing-for-diagnostic-expansion/2024-11-23T00:05:06+08:00https://flcube.com/novo-nordisks-esperoct-on-track-for-priority-review-in-hemophilia-a-treatment/2024-11-22T23:53:33+08:00https://flcube.com/bayer-subsidiarys-parkinsons-treatment-bemdaneprocel-shows-promise-in-phase-i/2024-11-22T23:50:42+08:00https://flcube.com/astrazenecas-calquence-approved-by-nmpa-for-chronic-lymphocytic-leukemia-treatment/2024-11-22T23:43:39+08:00https://flcube.com/roches-alecensa-achieves-milestone-in-adjuvant-therapy-trial-for-early-stage-nsclc/2024-11-22T23:40:40+08:00https://flcube.com/amgen-and-horizon-therapeutics-reach-agreement-with-ftc-to-proceed-with-acquisition/2024-11-22T23:38:02+08:00https://flcube.com/japans-mhlw-reviews-gsks-nucala-for-chronic-rhinosinusitis-with-nasal-polyps-indication/2024-11-22T23:32:56+08:00https://flcube.com/eli-lillys-verzenios-receives-nmpa-approval-for-extended-indication-in-early-stage-breast-cancer/2024-11-22T23:29:36+08:00https://flcube.com/seagen-and-genmab-announce-positive-phase-iii-results-for-tivdak-in-cervical-cancer/2024-11-22T23:26:40+08:00https://flcube.com/sinomab-biosciences-suciraslimab-files-for-market-approval-in-china-for-rheumatoid-arthritis/2024-11-22T23:23:22+08:00https://flcube.com/weight-loss-drug-demand-pushes-novo-nordisk-to-peak-european-market-capitalization/2024-11-22T23:20:26+08:00https://flcube.com/janssen-sues-distributors-over-counterfeit-antiretroviral-therapies-in-the-us/2024-11-22T23:17:08+08:00https://flcube.com/columbia-university-study-weighs-cost-effectiveness-of-weight-loss-treatments-for-adolescents/2024-11-22T23:14:23+08:00https://flcube.com/shanghai-pharmaceuticals-executives-under-investigation-for-serious-disciplinary-violations/2024-11-22T23:10:56+08:00https://flcube.com/bdgene-technology-announces-clinical-milestone-for-crispr-cas9-gene-therapy-in-hsk/2024-11-22T22:40:46+08:00https://flcube.com/sanofi-announces-management-restructuring-with-new-leadership-roles-in-china/2024-11-22T22:37:17+08:00https://flcube.com/immuneonco-biopharmaceuticals-begins-trading-on-hkex-with-successful-ipo/2024-11-22T22:33:08+08:00https://flcube.com/sihuan-pharmaceuticals-birociclib-nda-accepted-for-review-by-chinas-nmpa/2024-11-22T22:30:46+08:00https://flcube.com/bloomage-biotech-terminates-joint-venture-with-medytox-inc-for-botulinum-toxin-development/2024-11-22T22:28:07+08:00https://flcube.com/jointown-medicals-covid-19-drug-candidate-shen211-accepted-for-review-by-nmpa/2024-11-22T22:21:48+08:00https://flcube.com/hansoh-pharmaceutical-receives-nmpa-approval-for-generic-ofev-nintedanib/2024-11-22T22:14:37+08:00https://flcube.com/sinovac-biotech-directors-reject-alternative-liquiditys-lowball-tender-offer/2024-11-22T22:08:56+08:00https://flcube.com/abbott-to-acquire-insulin-management-firm-bigfoot-biomedical/2024-11-22T22:00:06+08:00https://flcube.com/taizhou-port-designated-as-drug-import-port-by-nmpa-and-general-administration-of-customs/2024-11-22T21:53:11+08:00https://flcube.com/sandoz-reports-h1-2023-financials-with-8-yoy-growth-separation-from-novartis-looms/2024-11-22T21:50:35+08:00https://flcube.com/li-li-appointed-as-new-director-of-nmpa/2024-11-22T21:45:39+08:00https://flcube.com/nhsa-mandates-national-standards-for-medical-consumables-in-basic-medical-insurance/2024-11-22T21:43:21+08:00https://flcube.com/bristol-myers-squibb-acquires-rights-to-zenas-biopharmas-obexelimab-for-autoimmune-diseases/2024-11-22T21:40:33+08:00https://flcube.com/neurophth-biotechnologys-nfs-05-gene-therapy-gets-australian-clinical-trial-approval-for-adoa/2024-11-22T21:30:07+08:00https://flcube.com/mgi-tech-partners-with-eight-companies-to-expand-g99-based-sequencing-applications/2024-11-22T21:24:06+08:00https://flcube.com/harbin-gloria-pharmaceuticals-zimberelimab-receives-nmpa-approval-for-cervical-cancer-treatment/2024-11-22T21:17:41+08:00https://flcube.com/janssen-appoints-cherry-huang-as-president-of-xian-janssen-in-china-management-shake-up/2024-11-22T21:11:52+08:00https://flcube.com/hutchmed-anticipates-milestone-payment-as-takeda-launches-fruzaqla-in-japan-for-crc/2024-11-22T19:02:30+08:00https://flcube.com/first-patient-dosed-in-abbiskos-phase-ii-trial-of-absk061-and-absk043-in-fgfr2-3-altered-tumors/2024-11-22T18:55:12+08:00https://flcube.com/bayers-nubeqa-files-for-fda-approval-in-mhspc/2024-11-22T18:46:53+08:00https://flcube.com/zai-lab-ltd-partners-with-pfizer-for-commercialization-of-xacduro-in-china/2024-11-22T18:28:35+08:00https://flcube.com/medtronic-reports-5-organic-revenue-growth-in-q2-fy25-with-strong-portfolio-performance/2024-11-22T17:59:22+08:00https://flcube.com/pfizer-and-flagship-pioneering-expand-partnership-with-two-new-biotechnology-agreements/2024-11-22T17:43:47+08:00https://flcube.com/easton-pharmaceutical-secures-nmpa-approval-for-generic-jakavi-and-urocit-k/2024-11-22T17:27:40+08:00https://flcube.com/innornas-mrna-drug-in015-earns-orphan-drug-designation-for-pfic-treatment/2024-11-22T17:15:51+08:00https://flcube.com/kura-oncology-and-kyowa-kirin-ink-licensing-deal-for-menin-inhibitor-ziftomenib/2024-11-22T17:04:03+08:00https://flcube.com/inxmeds-ifebemtinib-earns-breakthrough-therapy-designation-for-nsclc-treatment-in-china/2024-11-22T16:20:34+08:00https://flcube.com/hua-medicine-and-bayer-ag-terminate-co-promotion-agreement-for-huatangning/2024-11-22T15:58:11+08:00https://flcube.com/united-imaging-installs-ai-powered-umr-omega-at-xranms-breast-health-center/2024-11-22T15:32:11+08:00https://flcube.com/astrazenecas-ultomiris-faces-fda-rejection-for-nmosd-indication-extension/2024-11-22T14:51:14+08:00https://flcube.com/novo-nordisk-and-broad-institute-collaborate-on-diabetes-and-cardiometabolic-research/2024-11-22T14:49:46+08:00https://flcube.com/janssens-rybrevant-combo-meets-primary-endpoint-in-advanced-nsclc-study/2024-11-22T14:41:54+08:00https://flcube.com/fda-addresses-looming-migraine-treatment-shortage-with-tonix-pharmaceuticals-commitment/2024-11-22T14:33:03+08:00https://flcube.com/henan-zhongshuais-dexmethylphenidate-hydrochloride-capsules-target-priority-review-for-pediatric-adhd/2024-11-22T14:16:50+08:00https://flcube.com/amneal-pharmaceuticals-receives-china-approval-for-sevelamer-carbonate/2024-11-22T14:11:11+08:00https://flcube.com/cspc-pharmaceuticals-narlumosbart-approved-by-nmpa-for-bone-giant-cell-tumors/2024-11-22T14:06:16+08:00https://flcube.com/jiangsu-hengruis-her2-targeted-adc-shr-a1811-aims-for-cdes-btd-status/2024-11-22T13:57:53+08:00https://flcube.com/nmpa-drafts-guidelines-for-supervising-online-drug-exchange-platforms/2024-11-22T13:51:14+08:00https://flcube.com/genentech-files-for-fda-approval-of-crovalimab-for-pnh-challenging-soliris/2024-11-22T13:48:48+08:00https://flcube.com/ubrigene-and-yoltech-therapeutics-join-forces-to-advance-mrna-therapy-and-gene-therapy/2024-11-22T13:44:38+08:00https://flcube.com/cdes-2022-drug-review-report-a-year-of-pandemic-response-and-regulatory-milestones/2024-11-22T13:20:30+08:00https://flcube.com/hainan-haiyao-concludes-phase-i-clinical-study-for-paienjiabin-a-novel-kcnq-agonist/2024-11-22T13:15:26+08:00https://flcube.com/sino-medical-sciences-technology-to-acquire-majority-stake-in-us-endovascular-device-firm-elum/2024-11-22T13:00:22+08:00https://flcube.com/acotec-scientific-holdings-receives-marketing-approvals-for-vericor-14-microcatheter-in-japan-and-thailand/2024-11-22T12:53:34+08:00https://flcube.com/brii-biosciences-announces-positive-interim-data-for-brii-179-vaccine-in-chronic-hepatitis-b/2024-11-22T12:49:47+08:00https://flcube.com/roche-and-alnylams-zilebesiran-achieves-primary-endpoint-in-hypertension-phase-ii-trial/2024-11-22T12:41:42+08:00https://flcube.com/cde-annual-report-clinical-trials-for-innovative-drugs-in-china-reach-record-high/2024-11-22T12:37:59+08:00https://flcube.com/pfizer-and-valnevas-lyme-disease-vaccine-vla15-shows-promise-as-booster-in-pediatric-trials/2024-11-22T12:32:03+08:00https://flcube.com/cutia-therapeutics-cu-40102-meets-primary-endpoint-in-phase-iii-study-for-androgenic-alopecia/2024-11-22T12:08:31+08:00https://flcube.com/chengdu-kanghua-receives-fda-approval-for-clinical-trial-of-norovirus-vaccine/2024-11-22T11:59:23+08:00https://flcube.com/chengdu-kanghua-strikes-licensing-deal-with-hillevax-for-recombinant-norovirus-vaccine/2024-11-22T11:56:33+08:00https://flcube.com/chengdu-kanghua-biological-products-soars-with-16-81-yoy-revenue-growth-in-h1-2024-report/2024-11-22T11:56:32+08:00https://flcube.com/chengdu-kanghua-biological-products-reports-16-81-yoy-revenue-growth-in-h1-2024-financial-results/2024-11-22T11:56:30+08:00https://flcube.com/chengdu-kanghua-biological-products-inks-five-year-partnership-to-boost-sichuans-biotech-and-vaccine-industries/2024-11-22T11:56:29+08:00https://flcube.com/biocytogen-pharmaceuticals-enters-agreement-with-myricx-bio-for-adc-development/2024-11-22T11:32:55+08:00https://flcube.com/danaher-partners-with-beijings-changping-district-to-accelerate-science-and-technology-innovation-center/2024-11-22T11:28:55+08:00https://flcube.com/chongqing-unveils-three-year-public-health-action-plan-draft-for-public-feedback/2024-11-22T11:21:43+08:00https://flcube.com/immunofocos-imc008-earns-orphan-drug-designation-for-pancreatic-cancer-from-fda/2024-11-22T11:17:57+08:00https://flcube.com/shanghai-haihe-pharmaceuticals-glumetinib-filed-for-marketing-in-japan-for-nsclc-treatment/2024-11-22T10:59:34+08:00https://flcube.com/eminence-biotechnology-launches-fully-operational-cell-culture-media-facility-in-suzhou/2024-11-22T10:54:13+08:00https://flcube.com/liquik-study-interim-results-to-showcase-lucences-liquid-biopsy-advancements-at-wclc-2023/2024-11-22T10:46:50+08:00https://flcube.com/cloudr-partners-with-hong-kong-magicure-medical-center-to-enhance-cross-border-medical-access/2024-11-22T10:28:38+08:00https://flcube.com/mindray-launches-te-air-wireless-handheld-ultrasound-solution-in-the-us-market/2024-11-22T10:19:48+08:00https://flcube.com/mindray-to-acquire-21-12-stake-in-apt-medical-for-rmb-6-652-billion/2024-11-22T10:03:33+08:00https://flcube.com/caprico-biotechnologies-and-mindray-medical-form-comprehensive-flow-testing-partnership/2024-11-22T10:03:31+08:00https://flcube.com/eurofarma-invests-in-abcuro-as-part-of-100-million-disruptive-startups-and-biotech-initiative/2024-11-22T00:29:04+08:00https://flcube.com/ema-reviews-janssens-balversa-for-advanced-urothelial-carcinoma-with-fgfr3-alterations/2024-11-22T00:21:41+08:00https://flcube.com/united-laboratories-receives-tacit-approval-for-jak1-inhibitor-tul01101-clinical-trial/2024-11-22T00:19:04+08:00https://flcube.com/otsuka-and-shape-therapeutics-partner-on-ophthalmology-gene-therapies-development/2024-11-22T00:13:26+08:00https://flcube.com/cde-indicates-btd-status-for-visirnas-vsa001-sperogenixs-vamorolone-and-zai-labs-efgartigimod/2024-11-22T00:05:25+08:00https://flcube.com/shanghai-junshi-biosciences-to-acquire-stake-in-anlingke-biopharmaceutical-for-cancer-therapy-programs/2024-11-21T23:56:36+08:00https://flcube.com/broncus-medical-inc-to-acquire-fibernova-holding-corporation-for-usd-2-7-million/2024-11-21T23:48:30+08:00https://flcube.com/lepu-medical-technology-receives-nmpa-approval-for-memosorb-biodegradable-pfo-occluder/2024-11-21T23:39:42+08:00https://flcube.com/ea-pharma-and-transthera-sciences-collaborate-on-gi-and-liver-disease-therapies/2024-11-21T23:36:15+08:00https://flcube.com/grit-biotechnology-secures-rmb-400-million-in-series-b-financing-to-advance-til-pipeline/2024-11-21T23:26:54+08:00https://flcube.com/oriomics-secures-series-b-funding-to-advance-liver-and-digestive-cancer-screening/2024-11-21T23:12:16+08:00https://flcube.com/sichuan-kelun-pharmaceutical-submits-biosimilar-cetuximab-for-nmpa-approval/2024-11-21T23:07:40+08:00https://flcube.com/biotyx-medical-secures-over-rmb-200-million-in-series-b-financing-for-iron-based-stents/2024-11-21T22:58:06+08:00https://flcube.com/united-laboratories-ubt251-receives-tacit-approval-for-nafld-clinical-study-in-china/2024-11-21T22:49:33+08:00https://flcube.com/abbisko-therapeutics-receives-ema-approval-for-phase-iii-study-of-pimicotinib-for-tgct/2024-11-21T22:46:34+08:00https://flcube.com/aribio-files-for-phase-iii-clinical-trial-approval-in-china-for-alzheimers-drug-ar1001/2024-11-21T22:43:18+08:00https://flcube.com/allist-pharmaceuticals-and-arrivent-biopharma-release-promising-interim-data-on-furmonertinib-for-nsclc/2024-11-21T22:38:34+08:00https://flcube.com/iotasciences-partners-with-quantum-design-china-for-single-cell-handling-platform-distribution/2024-11-21T22:34:15+08:00https://flcube.com/bms-announces-positive-outcomes-for-bms-986278-in-progressive-pulmonary-fibrosis-study/2024-11-21T22:12:12+08:00https://flcube.com/sino-biopharmaceutical-submits-nda-for-anlotinib-and-penpulimab-combo-in-hcc-to-nmpa/2024-11-21T18:19:45+08:00https://flcube.com/sihuan-pharmaceuticals-huisheng-pharm-strikes-exclusive-deal-for-semaglutide-biosimilar-in-china/2024-11-21T18:06:33+08:00https://flcube.com/innovent-biologics-ibi354-earns-breakthrough-therapy-designation-for-ovarian-cancer-treatment/2024-11-21T17:53:24+08:00https://flcube.com/cde-includes-double-cranes-hydroxocobalamine-and-sanofi-genzymes-fitusiran-in-rare-disease-care-plan/2024-11-21T17:38:57+08:00https://flcube.com/apeiron-therapeutics-initiates-phase-ia-b-study-for-gta182-in-solid-tumors-with-mtap-deficiency/2024-11-21T17:22:20+08:00https://flcube.com/medtronic-receives-us-approval-for-inpen-app-with-missed-meal-dose-detection/2024-11-21T16:53:26+08:00https://flcube.com/nmpa-approves-alpha-biopharmas-zorifertinib-for-first-line-nsclc-treatment-with-cns-metastases/2024-11-21T16:30:50+08:00https://flcube.com/pfizers-hympavzi-receives-european-commission-approval-for-hemophilia-a-and-b/2024-11-21T16:13:51+08:00https://flcube.com/guangdong-zhongsheng-pharmaceuticals-ray1225-shows-positive-results-in-phase-ii-study/2024-11-21T15:49:15+08:00https://flcube.com/shenzhen-chipscreen-biosciences-announces-private-placement-to-fund-drug-rd-and-expansion/2024-11-21T15:38:31+08:00https://flcube.com/us-fda-grants-odd-to-ractigens-sirna-therapy-rag-21-for-als-treatment/2024-11-21T15:30:15+08:00https://flcube.com/ucbs-bimzelx-receives-us-fda-approval-for-moderate-to-severe-hidradenitis-suppurativa/2024-11-21T14:53:02+08:00https://flcube.com/alloy-therapeutics-partners-with-takeda-on-ipsc-derived-car-t-and-car-nk-therapies/2024-11-21T14:39:46+08:00https://flcube.com/clover-biopharmaceuticals-launches-adimflu-s-the-only-imported-quadrivalent-influenza-vaccine-in-china/2024-11-21T12:33:34+08:00https://flcube.com/hutchmed-advances-tazverik-phase-ii-trial-for-follicular-lymphoma-in-china/2024-11-21T12:29:42+08:00https://flcube.com/hybio-pharmaceuticals-semaglutide-clinical-trial-filing-accepted-by-chinas-nmpa/2024-11-21T12:22:03+08:00https://flcube.com/hasten-biopharmaceutical-secures-licensing-deal-for-libs-lerodalcibep-in-greater-china/2024-11-21T12:08:38+08:00https://flcube.com/fda-extends-pfizers-comirnaty-vaccine-indication-for-omicron-xbb-1-5-variant/2024-11-21T12:00:13+08:00https://flcube.com/amgens-lumakras-combo-shows-promising-results-in-kras-mutated-nsclc-early-stage-trial/2024-11-21T11:57:10+08:00https://flcube.com/wecare-medical-secures-pre-series-a-funding-to-advance-brain-health-technology/2024-11-21T11:30:08+08:00https://flcube.com/sandoz-inks-deal-with-samsung-bioepis-for-ustekinumab-biosimilar-sb17/2024-11-21T11:23:32+08:00https://flcube.com/china-updates-narcotics-and-psychotropic-substances-catalog-adds-three-substances/2024-11-21T11:14:47+08:00https://flcube.com/sinovac-biotech-advances-sa55-covid-19-neutralizing-antibody-into-phase-ii-trials/2024-11-21T11:12:16+08:00https://flcube.com/shanghai-haoyuan-chemexpress-aims-to-raise-rmb-1-16-billion-with-convertible-bonds/2024-11-21T11:05:50+08:00https://flcube.com/sinomab-bioscience-receives-nmpa-approval-for-phase-i-study-of-atopic-dermatitis-drug-sm17/2024-11-21T10:39:55+08:00https://flcube.com/merck-co-becomes-first-multinational-to-register-unit-in-hainans-lecheng-pilot-zone/2024-11-21T10:32:48+08:00https://flcube.com/immuneoncos-imm2510-and-imm27m-achieve-milestones-in-phase-i-clinical-trials/2024-11-21T10:26:01+08:00https://flcube.com/haisco-pharmaceutical-gets-nmpa-approval-for-hsk21542-chronic-pruritus-clinical-study/2024-11-21T10:24:37+08:00https://flcube.com/suzhou-porton-biologics-partners-with-brl-medicine-to-advance-gene-and-cell-therapy-pipeline/2024-11-21T01:05:34+08:00https://flcube.com/astrazenecas-tagrisso-combination-therapy-shows-improved-efficacy-in-egfr-mutated-nsclc/2024-11-21T00:59:48+08:00https://flcube.com/jiangsu-recbio-and-yikang-biological-partner-to-develop-rsv-preventative-vaccine/2024-11-21T00:57:32+08:00https://flcube.com/janssen-reports-positive-results-from-phase-ib-ii-study-of-rybrevant-combo-in-egfr-mutated-nsclc/2024-11-21T00:51:42+08:00https://flcube.com/astrazenecas-enhertu-shows-promising-results-in-phase-ii-her2-mutant-nsclc-trial/2024-11-21T00:49:06+08:00https://flcube.com/innovent-biologics-plans-share-placement-to-raise-hkd-2-36-billion-for-global-expansion/2024-11-21T00:46:50+08:00https://flcube.com/nmpa-pilots-priority-review-for-rare-disease-formula-foods-aims-to-reduce-approval-time/2024-11-21T00:44:22+08:00https://flcube.com/huadong-medicines-subsidiary-viora-ltds-v20-accepted-for-nmpa-review/2024-11-21T00:41:41+08:00https://flcube.com/gan-lee-pharmaceuticals-initiates-phase-ii-clinical-study-for-weekly-insulin-gzr4/2024-11-21T00:36:23+08:00https://flcube.com/grand-pharmaceutical-receives-nmpa-approval-for-generic-carbaglu-for-hyperammonemia-treatment/2024-11-21T00:33:30+08:00https://flcube.com/jw-therapeutics-and-2seventy-bio-expand-partnership-for-cell-therapy-development/2024-11-21T00:30:49+08:00https://flcube.com/wuhan-yzy-biopharma-aims-to-raise-hkd-220-million-in-hong-kong-ipo/2024-11-21T00:21:06+08:00https://flcube.com/exelixis-secures-global-rights-to-develop-insilico-medicines-usp1-inhibitor-ism3091/2024-11-21T00:16:36+08:00https://flcube.com/burning-rocks-cancatch-mrd-product-shows-superiority-in-postoperative-nsclc-monitoring/2024-11-21T00:09:21+08:00https://flcube.com/genesis-medtech-receives-chinese-market-approval-for-antibacterial-absorbable-sutures/2024-11-21T00:02:58+08:00https://flcube.com/grand-pharmaceuticals-gsp301-ns-meets-primary-endpoint-in-phase-iii-sar-study/2024-11-20T23:58:03+08:00https://flcube.com/canton-biologics-secures-over-rmb-300-million-in-series-c-financing-for-expansion/2024-11-20T23:55:19+08:00https://flcube.com/menarini-group-secures-exclusive-license-for-astellas-smyraf-in-taiwan/2024-11-20T23:49:17+08:00https://flcube.com/haisco-pharmaceuticals-hsk16149-for-post-herpes-neuralgia-accepted-for-nmpa-review/2024-11-20T23:42:47+08:00https://flcube.com/astrazenecas-fasenra-shows-non-inferior-efficacy-to-nucala-in-egpa-phase-iii-results/2024-11-20T23:35:05+08:00https://flcube.com/innocare-pharma-and-arrivent-biopharma-partner-on-clinical-study-for-advanced-nsclc-treatment/2024-11-20T23:31:36+08:00https://flcube.com/ema-approves-astellas-xtandi-for-non-metastatic-hormone-sensitive-prostate-cancer/2024-11-20T23:28:22+08:00https://flcube.com/fda-accepts-takedas-filing-for-subcutaneous-entyvio-as-maintenance-therapy-for-crohns-disease/2024-11-20T23:25:16+08:00https://flcube.com/abbvies-skyrizi-outperforms-janssens-stelara-in-phase-iii-crohns-disease-trial/2024-11-20T23:22:12+08:00https://flcube.com/boehringer-ingelheim-gets-nmpa-approval-for-brigimadlin-safety-and-efficacy-study-in-china/2024-11-20T23:19:08+08:00https://flcube.com/nhsa-unveils-measures-to-enhance-smart-monitoring-and-auditing-of-basic-medical-insurance-funds/2024-11-20T23:06:24+08:00https://flcube.com/astellas-pharma-invests-eur-330-million-in-state-of-the-art-manufacturing-plant-in-ireland/2024-11-20T23:03:08+08:00https://flcube.com/china-launches-fourth-national-volume-based-procurement-tender-focusing-on-medical-consumables/2024-11-20T22:49:54+08:00https://flcube.com/jj-rebrands-pharmaceutical-and-medtech-segments-post-kenvue-separation/2024-11-20T22:47:35+08:00https://flcube.com/japans-mhlw-reviews-gsks-momelotinib-for-myelofibrosis-treatment/2024-11-20T22:44:21+08:00https://flcube.com/astrazeneca-and-daiichi-sankyo-report-positive-results-for-datopotamab-deruxtecan-combo-in-nsclc/2024-11-20T22:40:04+08:00https://flcube.com/sichuan-kelun-pharmaceutical-secures-exclusive-rights-to-tbm-001-for-bone-metastasis-diagnosis/2024-11-20T22:36:26+08:00https://flcube.com/chongqing-lummy-pharmaceuticals-subsidiary-receives-nmpa-approval-for-cud002-mrna-vaccine/2024-11-20T22:25:30+08:00https://flcube.com/dialaibo-biotechnology-secures-series-a-funding-to-boost-rd-and-manufacturing/2024-11-20T22:21:07+08:00https://flcube.com/jiangsu-aidea-pharmaceutical-partners-with-national-medical-center-for-infectious-disease-on-hiv-drug-development/2024-11-20T22:12:11+08:00https://flcube.com/dizal-pharmaceuticals-golidocitinib-nda-accepted-for-review-by-nmpa/2024-11-20T22:09:28+08:00https://flcube.com/gsks-linerixibat-demonstrates-efficacy-in-phase-iii-glisten-study-for-cholestatic-pruritus/2024-11-20T17:31:13+08:00https://flcube.com/astellas-pharmas-izervay-snda-for-geographic-atrophy-receives-fda-complete-response-letter/2024-11-20T17:22:33+08:00https://flcube.com/bayer-ag-secures-exclusive-rights-to-cytokinetics-aficamten-in-japan/2024-11-20T17:02:11+08:00https://flcube.com/servier-and-dana-farber-launch-shinedoc-program-enroll-first-phd-student/2024-11-20T16:31:54+08:00https://flcube.com/new-horizon-health-registers-three-medical-devices-in-hong-kongs-department-of-health/2024-11-20T16:09:55+08:00https://flcube.com/nmpa-launches-medical-service-price-items-column-with-comprehensive-sub-sections/2024-11-20T15:46:23+08:00https://flcube.com/brii-biosciences-elebsiran-shows-promising-results-in-phase-ii-ensure-study-for-chronic-hbv/2024-11-20T15:32:08+08:00https://flcube.com/epigenic-therapeutics-receives-approval-for-epi-003-clinical-study-in-new-zealand/2024-11-20T15:23:20+08:00https://flcube.com/ucb-and-biogens-dapirolizumab-pegol-shows-promise-in-phase-iii-sle-study/2024-11-20T15:12:19+08:00https://flcube.com/beijing-balance-medical-technologys-eptfe-implant-accepted-for-nmpa-review/2024-11-20T14:56:47+08:00https://flcube.com/betta-pharmaceuticals-mcla-129-approved-for-clinical-trial-in-advanced-solid-tumors/2024-11-20T14:44:08+08:00https://flcube.com/hangzhou-jiuyuan-gene-engineering-plans-hkex-ipo-to-raise-up-to-usd-73-2-million/2024-11-20T14:38:54+08:00https://flcube.com/shanghai-junshi-biosciences-enters-licensing-agreement-for-dual-targeted-fusion-proteins/2024-11-20T14:29:44+08:00https://flcube.com/biogen-and-samsung-bioepis-win-ec-approval-for-opuviz-biosimilar-in-europe/2024-11-20T14:20:32+08:00https://flcube.com/worg-pharmaceuticals-secures-major-financing-for-allergy-and-autoimmune-disease-therapies/2024-11-20T13:19:26+08:00https://flcube.com/tonghua-dongbao-pharmaceuticals-partners-with-king-friend-biochemical-on-insulin-development/2024-11-20T12:47:08+08:00https://flcube.com/nanjing-kingfriend-biochemical-gets-fda-nod-for-dacarbazine-manufacture-at-sagent-facility/2024-11-20T12:42:14+08:00https://flcube.com/chinas-kingfriend-biochemical-acquires-u-s-listed-adalimumab-biosimilar-yusimry-for-usd-40-million/2024-11-20T12:41:42+08:00https://flcube.com/emas-chmp-backs-enhertu-for-advanced-nsclc-with-her2-mutations/2024-11-20T12:35:19+08:00https://flcube.com/bms-expands-partnership-with-samsung-biologics-for-oncology-drug-manufacturing/2024-11-20T12:31:49+08:00https://flcube.com/novartiss-kisqali-reduces-cancer-recurrence-risk-in-hr-her2-early-breast-cancer-phase-iii-results/2024-11-20T12:21:53+08:00https://flcube.com/akeso-biopharmas-ak132-receives-green-light-for-clinical-trial-in-advanced-solid-tumors/2024-11-20T11:58:36+08:00https://flcube.com/acornmed-receives-fda-breakthrough-device-designation-for-urothelial-carcinoma-liquid-biopsy/2024-11-20T11:55:31+08:00https://flcube.com/baidu-health-partners-with-hob-biotech-to-innovate-allergy-detection-and-treatment/2024-11-20T11:50:55+08:00https://flcube.com/tuodao-medicals-percutaneous-puncture-surgery-robot-np100-approved-in-china/2024-11-20T11:44:35+08:00https://flcube.com/cspc-pharmaceutical-group-receives-nmpa-approval-for-irinotecan-liposome-injection/2024-11-20T11:39:57+08:00https://flcube.com/jenscare-scientifics-tricuspid-valve-replacement-system-joins-fdas-tap-program/2024-11-20T11:35:18+08:00https://flcube.com/cure-genetics-and-frametact-ltd-partner-on-aav-vectors-for-neurological-diseases/2024-11-20T11:14:30+08:00https://flcube.com/caliway-biopharmaceuticals-cbl-514-achieves-milestones-in-dercums-disease-trial/2024-11-20T11:06:18+08:00https://flcube.com/brim-biotechnology-raises-45-8-million-in-premium-share-issue-for-pipeline-expansion/2024-11-20T11:01:06+08:00https://flcube.com/suzhou-acumen-biomedical-secures-13-8-million-in-series-a-funding-round/2024-11-20T10:54:02+08:00https://flcube.com/microport-medbots-skywalker-robot-approved-for-orthopedic-surgery-by-nmpa/2024-11-20T10:48:31+08:00https://flcube.com/zhejiang-medicine-gets-nmpa-approval-for-ncb003-clinical-study-for-advanced-solid-tumors/2024-11-20T10:45:20+08:00https://flcube.com/zelgen-biopharmaceuticals-rhtsh-achieves-primary-endpoint-in-phase-iii-study/2024-11-20T10:40:03+08:00https://flcube.com/chinas-cde-proposes-removal-of-ambroxol-inhalation-solution-and-four-other-drugs/2024-11-20T10:35:51+08:00https://flcube.com/csbios-albenatide-shows-positive-results-in-two-phase-iii-diabetes-trials/2024-11-20T10:25:50+08:00https://flcube.com/hebei-changshan-biochemicals-albenatide-file-for-type-2-diabetes-accepted-by-chinas-nmpa/2024-11-20T10:18:15+08:00https://flcube.com/changshan-biochemical-gets-marketing-nod-for-enoxaparin-in-kyrgyzstan-for-venous-thromboembolic-diseases/2024-11-20T10:18:14+08:00https://flcube.com/gsks-ojjaara-approved-by-fda-for-anemic-myelofibrosis-patients/2024-11-20T10:14:14+08:00https://flcube.com/sandoz-receives-positive-chmp-review-for-trastuzumab-biosimilar-in-her2-positive-cancers/2024-11-20T10:11:19+08:00https://flcube.com/nmpa-drafts-quality-management-norms-for-online-medical-device-sales/2024-11-20T10:08:08+08:00https://flcube.com/nmpa-seeks-comments-on-medical-device-classification-draft-proposal/2024-11-20T10:04:38+08:00https://flcube.com/gileads-kite-car-t-therapy-yescarta-achieves-71-cmr-in-phase-ii-trial-for-r-r-lbcl-patients/2024-11-20T10:01:28+08:00https://flcube.com/pharmanovia-bolsters-neurology-portfolio-with-acquisition-of-sanofis-cns-products/2024-11-20T09:57:47+08:00https://flcube.com/kinnate-biopharma-announces-restructuring-and-job-cuts-amid-financial-pressures/2024-11-20T01:19:18+08:00https://flcube.com/pfizers-cibinqo-and-everest-medicines-cefepime-taniborbactam-selected-for-priority-reviews-by-cde/2024-11-20T01:11:12+08:00https://flcube.com/emas-chmp-supports-gileads-veklury-for-covid-19-patients-with-hepatic-impairment/2024-11-20T01:05:58+08:00https://flcube.com/eli-lilly-partners-with-boundless-bio-to-develop-chk1-inhibitor-for-solid-tumors/2024-11-20T01:03:41+08:00https://flcube.com/nhsa-clears-retagliptin-and-ambroxol-for-national-reimbursement-drug-list-inclusion/2024-11-20T00:59:03+08:00https://flcube.com/astellas-pharmas-xtandi-nda-for-mhspc-treatment-accepted-by-chinas-cde/2024-11-20T00:52:04+08:00https://flcube.com/pfizers-litfulo-earns-eu-approval-as-first-treatment-for-severe-alopecia-areata-in-teens/2024-11-20T00:49:39+08:00https://flcube.com/tianjin-century-kangtai-biomedical-raises-hundreds-of-millions-in-series-a-and-b-financings/2024-11-20T00:47:06+08:00https://flcube.com/walvax-biotechnology-receives-indonesian-fda-approval-for-phase-iii-pneumococcal-vaccine-trial/2024-11-20T00:38:19+08:00https://flcube.com/sunshine-guojian-pharmaceutical-gets-nmpa-approval-for-ssgj-611-phase-ii-copd-study/2024-11-20T00:34:23+08:00https://flcube.com/abbvies-allergan-aesthetics-secures-nmpa-approval-for-juvederm-voluma-with-lidocaine/2024-11-20T00:30:02+08:00https://flcube.com/northeast-pharmaceutical-partners-with-muscat-changming-for-middle-east-expansion/2024-11-20T00:24:36+08:00https://flcube.com/roches-genentech-partners-with-orionis-biosciences-for-molecular-glue-therapies/2024-11-20T00:19:25+08:00https://flcube.com/abbott-expands-biosimilars-portfolio-with-mabxience-in-license-agreement/2024-11-20T00:19:03+08:00https://flcube.com/aim-vaccines-serum-free-rabies-vaccine-completes-phase-iii-safety-observation/2024-11-20T00:17:28+08:00https://flcube.com/jiangsu-yahongs-cevira-meets-primary-endpoint-in-phase-iii-cervical-hsil-study/2024-11-20T00:11:10+08:00https://flcube.com/hybio-pharmaceutical-gets-nmpa-approval-for-covid-19-nasal-spray-hy3000/2024-11-20T00:05:26+08:00https://flcube.com/merck-forges-partnerships-with-benevolentai-and-exscientia-for-precision-drug-discovery/2024-11-19T23:57:44+08:00https://flcube.com/novartiss-aimovig-approved-by-chinas-nmpa-for-preventive-migraines-treatment/2024-11-19T23:50:06+08:00https://flcube.com/organons-liptruzet-approved-in-china-for-hypercholesterolemia-treatment/2024-11-19T23:46:56+08:00https://flcube.com/wuxi-xdc-expands-manufacturing-capacity-with-new-gmp-facilities-in-wuxi/2024-11-19T23:37:09+08:00https://flcube.com/cde-releases-74th-batch-of-generic-reference-preparations-with-58-new-specifications/2024-11-19T23:33:49+08:00https://flcube.com/roches-genentech-partners-with-peptidream-for-first-in-class-pdcs-in-radioisotope-therapy/2024-11-19T23:32:11+08:00https://flcube.com/lynk-pharmaceuticals-secures-series-c2-financing-to-advance-pipeline/2024-11-19T22:57:25+08:00https://flcube.com/hainan-poly-pharm-submits-dmf-for-tecovirimat-api-to-us-fda/2024-11-19T22:49:10+08:00https://flcube.com/south-africas-competition-commission-investigates-jj-for-mdr-tb-drug-pricing-and-evergreening/2024-11-19T22:46:19+08:00https://flcube.com/tonghua-golden-horses-octohydroaminoacridine-succinate-meets-phase-iii-endpoints-in-alzheimers-disease/2024-11-19T22:42:09+08:00https://flcube.com/tonghua-golden-horse-ucb-seek-china-approvals-for-alzheimers-myasthenia-gravis-drugs/2024-11-19T22:40:05+08:00https://flcube.com/abbott-laboratories-expands-global-diabetes-care-with-new-kilkenny-facility/2024-11-19T20:40:39+08:00https://flcube.com/abbvies-elahere-receives-ec-approval-for-fr%ce%b1-positive-ovarian-cancer-treatment/2024-11-19T20:31:12+08:00https://flcube.com/rona-therapeutics-rn0191-showcases-positive-phase-i-results-at-aha-scientific-sessions/2024-11-19T20:21:09+08:00https://flcube.com/eli-lillys-tirzepatide-meets-primary-endpoints-in-phase-iii-summit-heart-failure-study/2024-11-19T20:04:54+08:00https://flcube.com/zai-lab-ltd-announces-secondary-public-offering-worth-230-million/2024-11-19T19:55:26+08:00https://flcube.com/astrazenecas-tagrisso-receives-positive-chmp-opinion-for-egfr-mutated-nsclc/2024-11-19T19:46:44+08:00https://flcube.com/everest-medicines-nefecon-receives-full-approval-from-south-koreas-mfds-for-igan-treatment/2024-11-19T17:29:25+08:00https://flcube.com/eli-lillys-muvalaplin-demonstrates-potent-lpa-reduction-in-phase-ii-study/2024-11-19T17:00:53+08:00https://flcube.com/sunshine-guojian-pharmaceuticals-ssgj-608-files-for-nmpa-approval-in-plaque-psoriasis/2024-11-19T16:54:27+08:00https://flcube.com/huahui-healths-libevitug-earns-fda-breakthrough-designation-for-chronic-hepatitis-delta-virus/2024-11-19T16:37:49+08:00https://flcube.com/xeltis-ag-enrolls-first-patient-in-us-pivotal-trial-for-axess-with-fda-btd-status/2024-11-19T16:29:11+08:00https://flcube.com/shanghai-leadingtac-pharmaceutical-secures-13-81-million-in-series-a-financing/2024-11-19T16:10:39+08:00https://flcube.com/huadong-medicines-dr10624-receives-nmpa-approval-for-mafld-and-mash-clinical-trials/2024-11-19T16:00:55+08:00https://flcube.com/nmpas-cde-issues-guidelines-for-leveraging-real-world-data-in-drug-regulation/2024-11-19T15:45:31+08:00https://flcube.com/biosion-secures-licensing-deal-with-aclaris-therapeutics-for-global-rights-to-bsi-045b-and-bsi-502/2024-11-19T15:38:13+08:00https://flcube.com/ratio-therapeutics-partners-with-novartis-on-sstr2-radiotherapeutic-for-cancer/2024-11-19T15:25:15+08:00https://flcube.com/huadong-medicines-hdm1005-receives-fda-approval-for-mash-clinical-study/2024-11-19T15:16:33+08:00https://flcube.com/tennor-therapeutics-rifasutenizol-shows-high-eradication-rate-in-h-pylori-phase-iii-study/2024-11-19T15:09:22+08:00https://flcube.com/beijing-wantai-receives-nmpa-clearance-for-nine-valent-hpv-vaccine-targeting-male-population/2024-11-19T15:00:16+08:00https://flcube.com/hasten-biopharmaceutical-initiates-phase-iii-clinical-trial-for-lerodalcibep-in-china/2024-11-19T14:52:08+08:00https://flcube.com/velavigo-and-avenzo-therapeutics-ink-global-partnership-for-nectin4-trop2-bispecific-adc/2024-11-19T14:41:23+08:00https://flcube.com/youjia-biomedical-and-yiling-pharmaceutical-collaborate-on-rnai-metabolic-disease-treatments/2024-11-19T14:28:42+08:00https://flcube.com/sanofis-dupixent-secures-nmpa-approval-for-pruritigo-nodosa-treatment-in-china/2024-11-19T14:02:31+08:00https://flcube.com/eu-chamber-of-commerce-in-china-releases-position-paper-addresses-pharma-and-healthcare/2024-11-19T13:55:33+08:00https://flcube.com/eli-lilly-sues-us-sellers-of-counterfeit-mounjaro-products/2024-11-19T13:50:59+08:00https://flcube.com/gurnet-point-capital-and-novo-holdings-acquire-paratek-pharmaceuticals-for-462-million/2024-11-19T13:48:16+08:00https://flcube.com/microport-scientific-reports-19-revenue-growth-in-h1-2023-driven-by-diverse-interventions/2024-11-19T13:43:05+08:00https://flcube.com/amgen-launches-global-collaboration-network-to-advance-oncology-research/2024-11-19T13:40:10+08:00https://flcube.com/suzhou-zelgen-biopharmaceuticals-zg005-receives-nmpa-approval-for-solid-tumor-trial/2024-11-19T13:26:44+08:00https://flcube.com/antengenes-anti-cd24-antibody-atg-031-gets-green-light-for-phase-i-study-at-md-anderson/2024-11-19T13:21:21+08:00https://flcube.com/inmagene-biopharmaceuticals-and-aditum-bio-launch-jv-celexor-bio-to-target-autoimmune-diseases/2024-11-19T13:16:13+08:00https://flcube.com/mabwell-biosciences-9mw3011-earns-us-fda-fast-track-designation-for-polycythemia-vera-treatment/2024-11-19T13:05:53+08:00https://flcube.com/sansure-biotech-secures-ce-mark-for-60-molecular-diagnostic-products-including-procalcitonin-assay-kit/2024-11-19T12:59:24+08:00https://flcube.com/hepagene-therapeutics-hpg7233-receives-us-fda-ind-approval-for-nash-treatment/2024-11-19T12:43:03+08:00https://flcube.com/abbisko-therapeutics-irpagratinib-receives-fda-clearance-for-phase-i-study-in-hcc/2024-11-19T12:28:20+08:00https://flcube.com/sino-biopharmaceutical-submits-ind-application-for-at2r-antagonist-trd205-to-fda/2024-11-19T12:24:56+08:00https://flcube.com/fosun-pharmas-serplulimab-approved-for-esophageal-squamous-cell-carcinoma-and-grafalon-for-gvhd-study/2024-11-19T12:22:17+08:00https://flcube.com/jj-and-hhs-expand-public-health-initiative-with-asha-therapeutics/2024-11-19T12:00:10+08:00https://flcube.com/cdc-provisionally-recommends-pfizers-abrysvo-for-maternal-immunization-against-rsv/2024-11-19T11:54:45+08:00https://flcube.com/boehringer-ingelheim-and-eli-lillys-jardiance-wins-fda-approval-for-ckd-prevention/2024-11-19T11:51:35+08:00https://flcube.com/betta-pharmaceuticals-cft8919-accepted-for-review-by-chinas-nmpa-for-egfr-l858r-solid-tumors/2024-11-19T11:40:18+08:00https://flcube.com/simcere-pharmaceutical-reports-25-2-revenue-growth-in-2023-interim-financials/2024-11-19T11:15:01+08:00https://flcube.com/3d-medicines-h1-2023-report-highlights-70-3-yoy-growth-in-envafolimab-sales/2024-11-19T11:11:58+08:00https://flcube.com/acotec-scientific-holdings-receives-japanese-marketing-approval-for-peripheral-support-catheter-vericor/2024-11-19T11:07:40+08:00https://flcube.com/chime-biologics-partners-with-panolos-bioscience-to-speed-up-multi-specific-protein-development/2024-11-19T11:01:25+08:00https://flcube.com/cnipa-upholds-alynlam-pharmaceuticals-pcsk9-sirna-patent-against-junshi-biosciences-challenge/2024-11-19T10:44:49+08:00https://flcube.com/everest-medicines-partners-with-kezar-life-sciences-to-commercialize-zetomipzomib-in-asia/2024-11-19T10:37:11+08:00https://flcube.com/i-mab-regains-global-rights-to-cd47-antibody-lemzoparlimab-following-abbvie-deal-termination/2024-11-19T10:31:24+08:00https://flcube.com/ec-approves-abbvies-tepkinly-for-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-11-19T10:24:12+08:00https://flcube.com/sanofis-altuviiio-receives-marketing-approval-from-japans-mhlw-for-hemophilia-a-treatment/2024-11-19T10:21:39+08:00https://flcube.com/lepu-scientech-reports-33-revenue-growth-in-2023-interim-report/2024-11-19T10:18:00+08:00https://flcube.com/japans-mhlw-approves-eisai-and-bioarctics-leqembi-for-alzheimers-treatment/2024-11-19T10:14:01+08:00https://flcube.com/novartis-lutathera-meets-primary-endpoint-in-phase-iii-trial-for-gep-nets/2024-11-19T09:56:11+08:00https://flcube.com/affamed-therapeutics-luminate-receives-clinical-trial-approval-for-dry-amd-in-china/2024-11-19T09:53:03+08:00https://flcube.com/hansoh-pharmaceutical-gets-nmpa-approval-for-hs-20105-clinical-study-in-solid-tumors/2024-11-19T09:49:25+08:00https://flcube.com/shanghai-junshis-tuoyi-meets-primary-efficacy-endpoint-in-phase-iii-melanoma-study/2024-11-19T09:45:53+08:00https://flcube.com/abbisko-therapeutics-gets-nmpa-approval-for-irpagratinib-combination-study-in-hcc/2024-11-19T09:42:00+08:00https://flcube.com/cde-introduces-new-guidelines-for-generic-drug-quality-and-efficacy-consistency-evaluation/2024-11-19T09:39:00+08:00https://flcube.com/regeneron-pharmaceuticals-acquires-decibel-therapeutics-to-advance-hearing-loss-treatments/2024-11-19T00:05:27+08:00https://flcube.com/novo-nordisk-partners-with-valo-health-to-develop-cardiometabolic-disease-therapies/2024-11-18T23:58:25+08:00https://flcube.com/coherus-biosciences-awaits-fda-decision-on-toripalimab-with-year-end-approval-forecast/2024-11-18T23:48:53+08:00https://flcube.com/cutia-therapeutics-files-for-market-approval-of-cu-10201-with-nmpa-for-acne-treatment/2024-11-18T23:45:41+08:00https://flcube.com/united-laboratories-receives-fda-approval-for-clinical-study-of-ubt251-for-obesity-treatment/2024-11-18T23:43:28+08:00https://flcube.com/biotroy-therapeutics-receives-us-fda-ind-approval-for-anti-tumor-drug-bt02/2024-11-18T23:30:52+08:00https://flcube.com/sichuan-kelun-biotechs-kl-a167-and-skb264-gain-tacit-clinical-trial-approval-in-china/2024-11-18T23:26:32+08:00https://flcube.com/sino-biopharmaceutical-reports-h1-2023-revenue-growth-focus-on-innovative-drugs/2024-11-18T23:24:05+08:00https://flcube.com/suzhou-novoprotein-and-shanghai-model-organisms-center-ink-global-partnership/2024-11-18T23:22:07+08:00https://flcube.com/sihuan-pharmaceutical-reports-h1-2023-revenue-dip-amid-rd-focus/2024-11-18T23:12:42+08:00https://flcube.com/hunchun-port-designated-as-medical-materials-import-port-by-nmpa-and-gac/2024-11-18T23:01:59+08:00https://flcube.com/baxter-appoints-wu-xin-as-china-general-manager-amid-spin-off-of-kidney-care-business/2024-11-18T22:59:58+08:00https://flcube.com/china-grand-pharmaceutical-reports-h1-2023-revenues-and-pipeline-progress/2024-11-18T22:55:30+08:00https://flcube.com/grand-pharmaceutical-group-expands-distribution-partnership-with-sirtex-medical-in-china/2024-11-18T17:49:35+08:00https://flcube.com/keymed-biosciences-enters-global-licensing-agreement-with-platina-medicines-for-cm336/2024-11-18T17:28:40+08:00https://flcube.com/hangzhou-jiuyuan-gene-engineering-passes-hkex-ipo-hearing-for-orthopedic-treatments/2024-11-18T16:34:11+08:00https://flcube.com/nk-celltech-partners-with-3sbio-to-advance-nk-cell-therapy-technology/2024-11-18T16:23:28+08:00https://flcube.com/shanghais-matwings-secures-over-13-8-million-in-series-a-financing-for-ai-protein-design/2024-11-18T16:13:30+08:00https://flcube.com/emas-chmp-recommends-approval-for-bmss-opdivo-yervoy-combo-in-mcrc/2024-11-18T15:51:14+08:00https://flcube.com/boston-scientific-expands-neuromodulation-portfolio-with-axonics-acquisition/2024-11-18T15:13:35+08:00https://flcube.com/sandoz-receives-ec-approval-for-biosimilar-to-eylea-for-retinal-diseases/2024-11-18T14:56:42+08:00https://flcube.com/peijia-medical-achieves-first-compassionate-use-of-taurus-trio-tavr-system-in-hong-kong/2024-11-18T14:43:30+08:00https://flcube.com/sanofis-dupixent-sbla-for-chronic-spontaneous-urticaria-accepted-by-fda-for-review/2024-11-18T14:35:35+08:00https://flcube.com/novo-nordisk-launches-semaglutide-for-weight-management-in-china/2024-11-18T14:27:56+08:00https://flcube.com/sichuan-kelun-biotech-secures-nmpa-approval-for-two-antibody-drug-conjugates/2024-11-18T14:22:40+08:00https://flcube.com/rainbow-genomes-gene-therapy-exg110-earns-orphan-drug-status-for-fabry-disease/2024-11-18T14:15:40+08:00https://flcube.com/exegenesis-bio-secures-multi-million-dollar-series-b-financing-for-gene-therapy-pipeline/2024-11-18T14:13:25+08:00https://flcube.com/shenzhen-weiguang-biological-partners-with-suat-to-boost-life-science-and-health-industry/2024-11-18T13:17:34+08:00https://flcube.com/janssen-cilags-lazcluze-rybrevant-combo-receives-positive-ema-opinion-for-nsclc-treatment/2024-11-18T13:06:11+08:00https://flcube.com/shanghai-junshi-biosciences-toripalimab-wins-uk-approval-for-nasopharyngeal-and-oesophageal-cancers/2024-11-18T12:51:32+08:00https://flcube.com/c-ray-therapeutics-secures-over-100-million-in-series-a-financing-for-radiopharmaceuticals/2024-11-18T12:44:11+08:00https://flcube.com/orbusneich-medical-group-partners-with-abbotts-csi-as-sole-distributor/2024-11-18T12:13:15+08:00https://flcube.com/novo-nordisk-and-evotec-launch-lab-en%c2%b2-to-accelerate-drug-discovery-for-rare-diseases/2024-11-18T12:06:59+08:00https://flcube.com/roche-secures-global-rights-to-ionis-pharmaceuticals-alzheimers-and-huntingtons-disease-candidates/2024-11-18T12:02:29+08:00https://flcube.com/takeda-receives-fda-approval-for-subcutaneous-entyvio-as-uc-maintenance-therapy/2024-11-18T11:58:04+08:00https://flcube.com/neusoft-medicals-neurt-aurora-receives-nmpa-approval-for-advanced-radiotherapy-platform/2024-11-18T11:55:18+08:00https://flcube.com/cstone-pharmaceuticals-pdgfra-mutation-detection-kit-receives-nmpa-approval/2024-11-18T11:33:43+08:00https://flcube.com/remegen-and-akeso-biopharma-initiate-phase-ii-study-for-gastric-cancer-combo-therapy/2024-11-18T11:13:28+08:00https://flcube.com/eli-lillys-insulin-biosimilar-youbian-approved-for-diabetes-treatment-in-china/2024-11-18T11:06:11+08:00https://flcube.com/everest-medicines-xerava-receives-marketing-approval-from-tfda-for-ciai-treatment/2024-11-18T11:03:30+08:00https://flcube.com/sino-medical-sciences-receives-turkish-approval-for-ht-supreme-drug-eluting-stent-system/2024-11-18T10:59:39+08:00https://flcube.com/elpiscience-biopharmaceuticals-initiates-phase-i-trial-for-anti-lilrb2-antibody-es009/2024-11-18T10:49:07+08:00https://flcube.com/triastek-inc-secures-20-5-million-in-pre-series-c-financing-for-3d-printing-pipeline/2024-11-18T10:28:56+08:00https://flcube.com/tasly-pharmaceuticals-gets-nmpa-approval-for-b1344-clinical-study-in-nash/2024-11-18T10:26:54+08:00https://flcube.com/immuneonco-initiates-phase-i-trial-for-cd24-targeted-monoclonal-antibody-imm47/2024-11-18T10:21:12+08:00https://flcube.com/mitrassist-lifesciences-secures-100-million-in-series-c-financing-for-cardiovascular-devices/2024-11-18T10:17:04+08:00https://flcube.com/mabwell-bioscience-initiates-phase-ib-ii-study-for-nectin-4-targeting-adc-9mw2821/2024-11-18T10:09:59+08:00https://flcube.com/leo-pharma-initiates-phase-iii-clinical-trial-for-delgocitinib-in-china/2024-11-18T10:07:13+08:00https://flcube.com/beijing-insurance-bureau-launches-pilot-to-boost-access-to-nrdl-drugs/2024-11-18T10:02:30+08:00https://flcube.com/beijing-tianjin-hebei-region-initiates-drug-vbp-with-37-medicines-including-biologics/2024-11-18T09:59:57+08:00https://flcube.com/takeda-initiates-global-withdrawal-of-exkivity-following-phase-iii-trial-results/2024-11-17T22:22:17+08:00https://flcube.com/janssen-and-sanofi-partner-for-development-of-first-in-class-e-coli-vaccine/2024-11-17T22:07:42+08:00https://flcube.com/kyowa-hakko-kirin-to-acquire-orchard-therapeutics-for-477-6-million/2024-11-17T21:59:24+08:00https://flcube.com/pharmaessentia-announces-licensing-agreement-with-wuxi-biologics-for-antibody-development/2024-11-17T21:50:31+08:00https://flcube.com/boehringer-ingelheim-collaborates-with-zeiss-medical-technology-on-retinal-disease-detection/2024-11-17T21:42:19+08:00https://flcube.com/guangdong-medicine-exchange-announces-volume-based-procurement-for-medical-devices/2024-11-17T21:36:26+08:00https://flcube.com/cardinal-health-acquires-medalliance-for-1-135-billion-to-enhance-vascular-intervention-portfolio/2024-11-17T21:34:05+08:00https://flcube.com/hong-kong-government-partners-with-astrazeneca-tigermed-and-simcere-to-boost-innovation/2024-11-17T21:27:04+08:00https://flcube.com/everest-medicines-and-calliditas-present-new-data-on-nefecon-for-iga-nephropathy/2024-11-17T21:18:18+08:00https://flcube.com/zhaoke-ophthalmology-completes-patient-enrollment-for-phase-iii-trials-of-tab014-and-epinastine/2024-11-17T20:58:06+08:00https://flcube.com/amicus-therapeutics-secures-fda-approval-for-pombiliti-and-opfolda-combination-therapy/2024-11-17T20:54:13+08:00https://flcube.com/vela-diagnostics-partners-with-srl-inc-to-expand-molecular-diagnostics-in-japan/2024-11-17T20:48:26+08:00https://flcube.com/transcenta-secures-fda-approval-for-phase-iii-trial-of-osemitamab/2024-11-17T20:39:52+08:00https://flcube.com/beijing-joins-jiangxis-interferon-volume-based-procurement-initiative/2024-11-17T20:31:40+08:00https://flcube.com/sanofi-enters-collaboration-with-teva-for-ibd-drug-tev574-development/2024-11-17T20:30:10+08:00https://flcube.com/astrazeneca-reports-positive-phase-iii-results-for-forxiga-in-children-with-type-2-diabetes/2024-11-17T19:46:01+08:00https://flcube.com/sandoz-becomes-independent-after-spin-off-from-novartis/2024-11-17T19:33:15+08:00https://flcube.com/eli-lilly-acquires-point-biopharma-to-enhance-oncology-portfolio/2024-11-17T19:30:22+08:00https://flcube.com/sanofis-nexviazyme-approved-in-china-as-enzyme-replacement-therapy-for-pompe-disease/2024-11-17T19:26:33+08:00https://flcube.com/nmpa-and-nhc-tighten-regulations-on-etomidate-and-modafinil/2024-11-17T19:24:16+08:00https://flcube.com/hangzhou-healsun-biopharm-secures-rmb-200-million-in-series-b-financing/2024-11-17T19:21:47+08:00https://flcube.com/viatris-to-divest-womens-health-and-api-businesses-offloading-12-factories-and-6000-employees/2024-11-17T19:15:43+08:00https://flcube.com/canadas-sgc-partners-with-hitgen-to-enhance-drug-discovery-using-del-technology/2024-11-17T19:12:33+08:00https://flcube.com/adlai-nortye-completes-successful-ipo-on-nasdaq-raising-57-5-million/2024-11-17T18:57:48+08:00https://flcube.com/eli-lilly-launches-three-new-oncology-programs-targeting-kras-and-nectin-4/2024-11-17T18:51:51+08:00https://flcube.com/fda-rejects-eli-lillys-application-for-lebrikizumab-in-atopic-dermatitis-treatment/2024-11-17T18:49:44+08:00https://flcube.com/bayer-partners-with-twist-bioscience-for-antibody-discovery-in-multiple-disease-areas/2024-11-17T18:12:52+08:00https://flcube.com/beijing-launches-comprehensive-plan-to-eliminate-cervical-cancer-by-2030/2024-11-17T18:06:44+08:00https://flcube.com/zhenge-biotech-partners-with-glyco-therapy-to-develop-antibody-drug-conjugate-platform/2024-11-17T18:04:21+08:00https://flcube.com/alphamab-oncology-enters-licensing-agreement-with-grand-life-sciences-for-kn057-in-greater-china/2024-11-17T17:54:23+08:00https://flcube.com/chongqing-zhifei-partners-with-gsk-for-shingrix-distribution-in-china/2024-11-17T17:52:03+08:00https://flcube.com/mabwell-bioscience-enters-licensing-agreement-with-laboratorios-legrand-for-biosimilars-in-colombia-and-ecuador/2024-11-17T17:48:23+08:00https://flcube.com/innovent-biologics-doses-first-patient-in-phase-3-study-of-ibi302-for-neovascular-amd/2024-11-17T17:46:07+08:00https://flcube.com/nhsa-issues-guidelines-to-strengthen-medical-insurance-payment-management/2024-11-17T17:12:13+08:00https://flcube.com/sino-medical-sciences-ht-supreme-stent-system-included-in-french-reimbursement-list/2024-11-17T17:09:08+08:00https://flcube.com/hutchmed-and-takeda-submit-fruquintinib-nda-for-metastatic-crc-in-japan/2024-11-17T17:05:15+08:00https://flcube.com/bio-thera-solutions-bat1806-receives-us-fda-approval-as-biosimilar-to-actemra-roactemra/2024-11-17T17:00:08+08:00https://flcube.com/sichuan-biokins-izalontamab-gets-us-fda-greenlight-for-nsclc-clinical-study/2024-11-17T16:53:01+08:00https://flcube.com/innovent-biologics-withdraws-parsaclisib-filing-in-china-halts-development/2024-11-17T16:41:06+08:00https://flcube.com/china-nt-pharma-group-enters-mou-with-global-fund-to-expand-orthopedic-product-line/2024-11-17T16:31:36+08:00https://flcube.com/biocity-biopharma-partners-with-astrazeneca-for-phase-ib-ii-study-in-hepatocellular-carcinoma/2024-11-17T16:25:24+08:00https://flcube.com/nhsa-completes-expert-review-for-national-reimbursement-drug-list-updates/2024-11-17T16:20:16+08:00https://flcube.com/shanghai-shende-wuchuang-secures-28-million-in-series-d-financing-for-medical-device-innovation/2024-11-17T16:17:47+08:00https://flcube.com/atom-bioscience-initiates-global-phase-iii-clinical-study-for-gout-drug-abp-671/2024-11-17T16:07:54+08:00https://flcube.com/chinas-national-health-commission-launches-three-year-patient-safety-campaign/2024-11-17T16:05:25+08:00https://flcube.com/glubio-pharmaceutical-secures-22-million-in-a-round-financing-to-advance-protein-degradation-drugs/2024-11-17T16:02:01+08:00https://flcube.com/glubio-pharmaceuticals-glb-002-receives-nmpa-approval-for-clinical-trials-in-hematological-tumors/2024-11-17T16:00:37+08:00https://flcube.com/med-vision-secures-a-round-financing-to-accelerate-digital-therapy-commercialization/2024-11-17T15:50:49+08:00https://flcube.com/med-visions-sleep-disorder-software-receives-category-ii-approval-in-china/2024-11-17T15:45:23+08:00https://flcube.com/luye-pharma-files-nda-for-paliperidone-palmitate-injectable-suspension-with-us-fda/2024-11-17T15:39:44+08:00https://flcube.com/apeloa-pharmaceutical-expands-global-footprint-with-apeloa-europe-gmbh-in-germany/2024-11-17T15:37:10+08:00https://flcube.com/abbvie-acquires-mitokinin-advancing-pink1-activator-for-parkinsons-disease/2024-11-17T15:33:19+08:00https://flcube.com/shanghai-bdgenes-bd112-earns-orphan-drug-designation-from-us-fda-for-huntingtons-disease/2024-11-17T15:27:28+08:00https://flcube.com/shanghai-bdgene-partners-with-sph-rd-to-develop-hemophilia-treatments-using-bdlendi-insulator-technology/2024-11-17T15:16:00+08:00https://flcube.com/astrazeneca-alum-yu-yuping-appointed-vice-president-at-merck-kgaas-china-unit/2024-11-17T15:13:51+08:00https://flcube.com/affamed-technologies-secures-exclusive-rights-to-sifis-intraocular-lens-products-in-greater-china/2024-11-17T11:54:47+08:00https://flcube.com/simcere-pharmaceutical-secures-exclusive-rights-to-andicons-anti-influenza-candidate-adc189/2024-11-17T11:40:38+08:00https://flcube.com/jjs-janssen-reports-favorable-spravato-data-in-late-stage-trd-trial/2024-11-17T11:37:21+08:00https://flcube.com/bms-to-acquire-mirati-therapeutics-in-a-4-8-billion-deal/2024-11-17T11:34:34+08:00https://flcube.com/cochlears-artificial-cochlear-sound-processor-gains-nmpa-approval-for-marketing-in-china/2024-11-17T11:29:03+08:00https://flcube.com/jiangsu-recbio-forms-strategic-cooperation-for-vaccine-production-in-zimbabwe/2024-11-17T11:22:45+08:00https://flcube.com/roches-forimtamig-receives-tacit-approval-for-multiple-myeloma-clinical-trials/2024-11-17T11:16:53+08:00https://flcube.com/sanofi-partners-with-biomap-to-accelerate-ai-driven-drug-discovery/2024-11-17T11:14:29+08:00https://flcube.com/sino-biopharmaceutical-sells-84-2-stake-in-shanghai-cp-general-pharmaceutical/2024-11-17T11:10:43+08:00https://flcube.com/jiangsu-qyuns-therapeutics-plans-ipo-on-hong-kong-stock-exchange/2024-11-17T11:08:07+08:00https://flcube.com/janssen-unveils-promising-clinical-data-on-il-23-blockers-for-psoriasis/2024-11-17T11:03:23+08:00https://flcube.com/microport-secures-market-approvals-for-ulys-icds-and-invicta-leads-in-japan/2024-11-17T11:01:04+08:00https://flcube.com/hainan-implements-new-regulations-for-import-drugs-and-medical-devices-in-medical-tourism-zone/2024-11-17T10:52:41+08:00https://flcube.com/bayer-opens-first-cell-therapy-production-facility-in-the-u-s-to-advance-research/2024-11-17T10:50:57+08:00https://flcube.com/astrazeneca-seeks-approval-for-capivasertib-in-combination-with-faslodex-for-breast-cancer-treatment/2024-11-17T10:48:39+08:00https://flcube.com/biontech-acquires-biotheus-for-800-million-enhancing-oncology-pipeline/2024-11-17T10:24:17+08:00https://flcube.com/novo-nordisk-halts-phase-iii-ozempic-study-on-renal-impairment-in-diabetes-patients/2024-11-17T09:39:15+08:00https://flcube.com/henlius-pharmaceutical-secures-gmp-compliance-for-pd-1-inhibitor-serplulimab-in-indonesia/2024-11-17T00:39:11+08:00https://flcube.com/medilink-therapeutics-enters-global-licensing-agreement-with-biontech-for-her3-targeted-antibody-drug-conjugates/2024-11-17T00:35:51+08:00https://flcube.com/jiangsu-bioperfectus-secures-nmpa-approval-for-norovirus-nucleic-acid-detection-kit/2024-11-17T00:31:34+08:00https://flcube.com/kintor-pharmaceutical-secures-nmpa-approval-for-phase-ii-study-of-gt1708f-in-idiopathic-pulmonary-fibrosis/2024-11-17T00:24:03+08:00https://flcube.com/yiling-pharmaceutical-secures-nmpa-approval-for-phase-i-study-of-g201-na-in-premenopausal-women/2024-11-17T00:21:26+08:00https://flcube.com/gritgen-therapeutics-secures-hundreds-of-millions-in-a-round-financing-for-gene-therapy-pipeline/2024-11-17T00:17:26+08:00https://flcube.com/gritgen-therapeutics-commences-operations-of-commercial-gmp-facilities-in-suzhou/2024-11-17T00:12:33+08:00https://flcube.com/genfleet-therapeutics-cdk9-inhibitor-sls009-earns-orphan-drug-status-for-aml/2024-11-17T00:03:36+08:00https://flcube.com/novartis-halts-phase-ii-clinical-study-for-mij821-in-major-depressive-disorder/2024-11-17T00:00:34+08:00https://flcube.com/bayer-ag-plans-continued-investment-in-china-amidst-global-challenges/2024-11-16T23:54:56+08:00https://flcube.com/bms-expands-car-t-collaboration-with-cellares-on-automation-tech/2024-11-16T23:49:11+08:00https://flcube.com/fda-approves-pfizers-braftovi-mektovi-combo-for-braf-v600e-metastatic-nsclc/2024-11-16T23:46:15+08:00https://flcube.com/china-introduces-trial-measures-for-science-and-technology-ethics-review/2024-11-16T23:43:30+08:00https://flcube.com/roches-ocrevus-demonstrates-long-term-efficacy-in-multiple-sclerosis-treatment/2024-11-16T23:40:27+08:00https://flcube.com/china-releases-first-supplement-to-2020-pharmacopoeia-with-47-new-drug-varieties/2024-11-16T23:19:58+08:00https://flcube.com/sichuan-huiyu-pharmaceuticals-hyp2090ptsa-gains-nmpa-approval-for-kras-g12c-solid-tumors/2024-11-16T23:15:23+08:00https://flcube.com/lanssonpharm-secures-series-a-funding-to-accelerate-cns-drug-development/2024-11-16T23:12:11+08:00https://flcube.com/livzon-pharmaceutical-secures-licensing-agreement-for-lanssonpharms-pde4-inhibitor-in-china/2024-11-16T23:07:08+08:00https://flcube.com/abbvies-rinvoq-demonstrates-sustained-efficacy-in-late-stage-atopic-dermatitis-study/2024-11-16T22:36:08+08:00https://flcube.com/chinas-healthcare-landscape-key-insights-from-the-2022-statistical-communique/2024-11-16T22:26:15+08:00https://flcube.com/lees-pharmaceuticals-subsidiary-announces-positive-results-for-myopia-treatment-nvk002/2024-11-16T22:23:07+08:00https://flcube.com/jjs-cetrelimab-and-tar-200-gain-tacit-approvals-for-bladder-cancer-trials/2024-11-16T22:06:49+08:00https://flcube.com/nanjing-geneseeqs-nsclc-tmb-detection-kit-approved-by-nmpa/2024-11-16T14:25:40+08:00https://flcube.com/remegen-secures-nmpa-approval-for-phase-ii-study-of-disitamab-vedotin-in-breast-cancer/2024-11-16T14:14:03+08:00https://flcube.com/genetron-holdings-enters-privatization-agreement-with-consortium/2024-11-16T14:08:35+08:00https://flcube.com/ascentage-pharma-initiates-phase-iii-study-for-apg-2575-and-calquence-in-cll-sll/2024-11-16T13:47:40+08:00https://flcube.com/betta-pharmaceuticals-secures-nmpa-approval-for-befotertinib-in-nsclc-treatment/2024-11-16T13:43:06+08:00https://flcube.com/kpc-pharmaceuticals-secures-who-prequalification-for-dihydroartemisinin-piperaquine/2024-11-16T13:37:37+08:00https://flcube.com/suzhou-ribo-life-science-receives-eu-approval-for-phase-ii-trial-of-rbd5044/2024-11-16T13:20:06+08:00https://flcube.com/ascentage-pharma-submits-application-for-lisaftoclax-a-novel-oral-bcl-2-inhibitor/2024-11-16T12:49:28+08:00https://flcube.com/c-ray-therapeutics-secures-over-100-million-in-a-round-financing/2024-11-16T12:36:08+08:00https://flcube.com/novo-nordisk-strikes-1-3-billion-deal-for-kbp-biosciences-ocedurenone/2024-11-15T17:04:22+08:00https://flcube.com/merck-kgaa-reports-3-8-organic-growth-in-q3-2024-financials/2024-11-15T17:02:15+08:00https://flcube.com/impact-therapeutics-secures-34-5-million-in-series-d-financing-for-senaparib-commercialization/2024-11-15T16:55:36+08:00https://flcube.com/gsks-blenrep-shows-survival-benefit-in-phase-iii-multiple-myeloma-study/2024-11-15T16:48:29+08:00https://flcube.com/janssen-cilags-nipocalimab-shows-promise-in-phase-ii-study-for-sjogrens-disease/2024-11-15T16:42:49+08:00https://flcube.com/sanofis-sarclisa-receives-chmp-recommendation-for-newly-diagnosed-multiple-myeloma/2024-11-15T16:34:29+08:00https://flcube.com/jj-medtech-secures-exclusive-distribution-deal-with-responsive-arthroscopy/2024-11-15T16:25:36+08:00https://flcube.com/eisai-and-biogens-lecanemab-receives-positive-chmp-opinion-for-early-alzheimers-treatment/2024-11-15T15:58:35+08:00https://flcube.com/china-releases-comprehensive-ai-application-guidelines-for-healthcare-industry/2024-11-15T15:25:05+08:00https://flcube.com/beijing-biostar-partners-with-baheal-for-utidelone-market-promotion-in-china/2024-11-15T14:59:17+08:00https://flcube.com/baheal-pharmaceutical-group-to-launch-industry-fund-focused-on-life-sciences/2024-11-15T14:53:23+08:00https://flcube.com/nmpa-issues-interim-provisions-for-overseas-mahs-designated-domestic-responsible-persons/2024-11-15T14:46:08+08:00https://flcube.com/sino-biopharmaceuticals-tqb3002-receives-fda-clearance-for-phase-i-study/2024-11-15T14:36:42+08:00https://flcube.com/pegbio-files-for-ipo-on-hong-kong-stock-exchange/2024-11-15T14:27:16+08:00https://flcube.com/mabwell-bioscience-receives-nmpa-approval-for-9mw2821-clinical-trials/2024-11-15T14:15:57+08:00https://flcube.com/wuxi-biologics-expands-sterile-filling-capabilities-in-germany-with-new-line/2024-11-15T14:09:09+08:00https://flcube.com/jiangxi-jemincares-jmx-2002-liposome-injection-gets-nmpa-clinical-clearance/2024-11-15T14:03:51+08:00https://flcube.com/lion-tcr-gains-nmpa-approval-for-mrna-tcr-t-therapy-gzl-016-in-hcc/2024-11-15T13:49:13+08:00https://flcube.com/kelun-biotech-to-present-skb264-study-results-for-metastatic-breast-cancer-at-esmo/2024-11-15T13:21:37+08:00https://flcube.com/chinas-9th-national-vbp-round-sets-rules-for-42-drugs-tender/2024-11-15T13:17:11+08:00https://flcube.com/vcanbio-receives-nmpa-approval-for-stem-cell-therapy-vum02-clinical-trial/2024-11-15T13:14:20+08:00https://flcube.com/nona-biosciences-partners-with-ingenia-for-immunological-therapeutics-development/2024-11-15T13:11:05+08:00https://flcube.com/sciclone-pharmaceuticals-gains-fda-nod-for-thymalfasin-covid-19-vaccine-booster-study/2024-11-15T13:07:29+08:00https://flcube.com/atom-bioscience-secures-82m-series-d-to-advance-gout-treatment-abp-671/2024-11-15T13:04:26+08:00https://flcube.com/shanghai-pharma-health-commerce-secures-68m-in-series-c-funding-round/2024-11-15T12:57:17+08:00https://flcube.com/hainan-poly-pharms-pl002-accepted-for-fda-review-for-liver-cancer-surgery/2024-11-15T12:39:48+08:00https://flcube.com/nmpa-announces-pathway-for-developing-generic-drugs-without-reference-preparation/2024-11-15T12:36:16+08:00https://flcube.com/novo-nordisk-reports-33-yoy-sales-increase-boosts-glp-1-drug-sales-forecast/2024-11-15T12:33:40+08:00https://flcube.com/shandong-saito-biotech-to-acquire-majority-stake-in-yingu-pharmaceutical/2024-11-15T12:31:01+08:00https://flcube.com/pfizers-velsipity-approved-by-fda-for-ulcerative-colitis-treatment/2024-11-15T12:20:16+08:00https://flcube.com/chinas-new-drug-quality-management-measures-to-take-effect-in-2024/2024-11-15T12:15:37+08:00https://flcube.com/pfizer-adjusts-2023-revenue-projections-amidst-decreased-covid-19-solution-demand/2024-11-15T12:13:13+08:00https://flcube.com/ascentage-pharma-and-astrazeneca-expand-collaboration-on-cll-sll-treatment/2024-11-15T12:02:50+08:00https://flcube.com/asieris-pharma-launches-generic-votrient-for-renal-cell-carcinoma-in-china/2024-11-15T11:58:36+08:00https://flcube.com/eli-lillys-tirzepatide-shows-robust-weight-loss-results-in-phase-iii-study/2024-11-15T11:18:38+08:00https://flcube.com/simceres-sim0237-receives-nmpa-approval-for-bladder-cancer-trial/2024-11-15T11:16:04+08:00https://flcube.com/abbisko-therapeutics-to-unveil-phase-i-data-for-absk011-and-absk043-at-esmo-2023/2024-11-15T11:13:02+08:00https://flcube.com/microport-cardioflow-medtechs-third-generation-tavi-product-achieves-initial-clinical-success/2024-11-15T10:59:30+08:00https://flcube.com/suzhou-inhal-pharma-secures-series-a-funding-for-expansion-and-clinical-advances/2024-11-15T10:55:40+08:00https://flcube.com/canbridges-maralixibat-receives-priority-review-for-pfic-treatment-in-china/2024-11-15T10:45:34+08:00https://flcube.com/wuxi-biologics-launches-wuxiui-a-revolutionary-biotech-patent-platform/2024-11-15T10:39:43+08:00https://flcube.com/fosun-pharma-initiates-phase-iii-trial-for-et-26-anesthetic-in-china/2024-11-15T10:36:45+08:00https://flcube.com/bayer-partners-with-halo-precision-diagnostics-to-develop-gadoquatrane-for-mri-applications/2024-11-15T01:09:14+08:00https://flcube.com/hong-kong-winhealth-pharma-enters-strategic-partnership-with-nippon-shinyaku-for-irsogladine/2024-11-15T01:03:56+08:00https://flcube.com/gilead-partners-with-assembly-biosciences-in-84-8-million-collaboration-for-antiviral-therapies/2024-11-15T00:59:18+08:00https://flcube.com/jj-reports-strong-q3-2023-sales-growth-amid-diverse-business-performance/2024-11-15T00:52:37+08:00https://flcube.com/huadong-medicine-secures-global-licensing-agreement-for-atgc-110-botulinum-toxin-a-injection/2024-11-15T00:49:38+08:00https://flcube.com/apeloa-pharmaceutical-enters-ten-year-partnership-with-wuhan-hesheng-technology/2024-11-15T00:46:39+08:00https://flcube.com/mabwell-to-present-promising-clinical-data-at-2023-esmo-congress/2024-11-15T00:23:45+08:00https://flcube.com/sirius-therapeutics-secures-usd-60-million-in-series-b-financing-for-sirna-therapy-development/2024-11-15T00:16:50+08:00https://flcube.com/sciclone-pharmaceuticals-partners-with-shanghai-pharmaceutical-and-menarini-group/2024-11-15T00:12:35+08:00https://flcube.com/baidu-launches-interactive-ai-medication-instructions-service-at-baidu-world-2023/2024-11-15T00:04:30+08:00https://flcube.com/belief-biomed-partners-with-takeda-for-bbm-h901-commercialization-in-asia/2024-11-15T00:00:21+08:00https://flcube.com/micurx-pharmaceuticals-initiates-phase-i-study-for-mrx-5-in-australia/2024-11-14T23:57:00+08:00https://flcube.com/genscript-reports-152-million-in-sales-for-carvykti-as-of-september-30-2023/2024-11-14T23:54:51+08:00https://flcube.com/novartis-launches-leqvio-in-china-at-rmb-9988-per-shot/2024-11-14T23:50:25+08:00https://flcube.com/zhejiang-huahai-pharmaceutical-secures-orphan-drug-designation-for-hb0034/2024-11-14T23:47:34+08:00https://flcube.com/merck-kgaa-partners-with-porton-pharma-for-next-gen-adc-platform-development/2024-11-14T23:43:29+08:00https://flcube.com/lepu-medical-gains-nmpa-approval-for-semi-automatic-external-defibrillator/2024-11-14T23:40:51+08:00https://flcube.com/huidagene-receives-fda-rare-pediatric-disease-designation-for-mecp2-syndrome-therapy/2024-11-14T23:19:48+08:00https://flcube.com/huidagene-and-synthego-form-strategic-partnership-for-crispr-based-therapies/2024-11-14T23:09:09+08:00https://flcube.com/huidagenes-mecp2-duplication-syndrome-therapy-earns-positive-ema-opinion/2024-11-14T23:09:09+08:00https://flcube.com/huidagene-receives-fda-clinical-clearance-for-hg202-in-neovascular-amd-treatment/2024-11-14T23:09:08+08:00https://flcube.com/huidagene-secures-patent-for-innovative-crispr-cas12i-system-in-china/2024-11-14T23:09:08+08:00https://flcube.com/kyowa-hakko-kirin-doubles-manufacturing-capacity-with-shanghai-plant-expansion/2024-11-14T23:03:32+08:00https://flcube.com/sansure-biotech-partners-with-shaanxi-lifegen-to-boost-molecular-diagnostics/2024-11-14T22:57:20+08:00https://flcube.com/alebund-pharmaceuticals-secures-exclusive-rights-to-roches-mircera-in-china/2024-11-14T22:44:17+08:00https://flcube.com/astrazenecas-soliris-gains-approval-in-china-for-nmosd-treatment/2024-11-14T22:21:44+08:00https://flcube.com/cnipa-upholds-alnylams-pcsk9-targeted-sirna-patent-against-junshi-biosciences-challenge/2024-11-14T22:18:21+08:00https://flcube.com/qilu-pharmaceutical-presents-promising-data-for-ql1706-and-ql1209-at-esmo-2023/2024-11-14T22:09:16+08:00https://flcube.com/guangdong-zhongsheng-launches-ai-qa-bot-for-leritrelvir-drug-support/2024-11-14T22:04:03+08:00https://flcube.com/wuxi-xdc-partners-with-hong-kong-science-park-to-boost-crdmo-value-chain/2024-11-14T21:58:15+08:00https://flcube.com/alphagen-therapeutics-secures-seed-funding-for-pb-212-radioligand-therapy-development/2024-11-14T21:52:28+08:00https://flcube.com/boehringer-ingelheims-vitiligo-drug-ei-001-approved-for-clinical-trials-by-nmpa/2024-11-14T21:45:41+08:00https://flcube.com/pharmaron-beijing-to-establish-singapore-jv-rxilient-biohub-for-cdmo-services/2024-11-14T21:43:00+08:00https://flcube.com/haisco-pharmaceuticals-hsk21542-accepted-for-nmpa-review-in-postoperative-pain-management/2024-11-14T21:33:59+08:00https://flcube.com/nmpa-issues-guidelines-for-temporary-import-of-urgently-needed-medical-devices/2024-11-14T21:31:20+08:00https://flcube.com/abbott-reports-8-7-drop-in-q3-2023-global-sales-hit-by-lower-sars-cov-2-test-demand/2024-11-14T21:29:21+08:00https://flcube.com/roches-alecensa-shows-unprecedented-76-improvement-in-disease-free-survival-in-nsclc-trial/2024-11-14T21:24:43+08:00https://flcube.com/eli-lilly-acquires-mablink-bioscience-to-expand-next-gen-adc-portfolio/2024-11-14T21:19:12+08:00https://flcube.com/eli-lillys-tirzepatide-shows-sustained-weight-loss-in-176-week-study/2024-11-14T16:42:39+08:00https://flcube.com/ge-healthcares-signa-magnus-mri-scanner-receives-fda-510k-clearance/2024-11-14T16:33:03+08:00https://flcube.com/cullgen-and-pulmatrix-merge-to-form-nasdaq-listed-protein-degradation-company/2024-11-14T16:25:34+08:00https://flcube.com/immuneonco-initiates-phase-ii-study-for-imm27m-in-er-advanced-breast-cancer/2024-11-14T16:10:29+08:00https://flcube.com/huadong-medicines-biosimilar-sailexin-receives-first-national-prescription-in-china/2024-11-14T15:57:51+08:00https://flcube.com/zucara-therapeutics-secures-20m-series-b-financing-led-by-sanofi-and-pxv-fund/2024-11-14T15:51:09+08:00https://flcube.com/novartis-pluvicto-accepted-for-review-by-chinas-nmpa-for-prostate-cancer-treatment/2024-11-14T15:29:32+08:00https://flcube.com/daiichi-sankyo-and-astrazeneca-file-bla-for-datopotamab-deruxtecan-in-nsclc/2024-11-14T15:16:08+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-snn-crha-for-optic-nerve-disease-research/2024-11-14T15:05:06+08:00https://flcube.com/biontech-seals-acquisition-of-chinas-biotheus-for-up-to-950m/2024-11-14T14:53:32+08:00https://flcube.com/arctic-vision-and-santen-ink-deal-for-arvn001-commercialization-in-china/2024-11-14T14:32:58+08:00https://flcube.com/pfizer-considers-sale-of-hospital-unit-amid-pressure-from-starboard-value/2024-11-14T14:07:43+08:00https://flcube.com/jenscares-lux-valve-plus-completes-compassionate-use-cases-in-asia-pacific/2024-11-14T13:53:48+08:00https://flcube.com/fosun-pharmaceutical-to-acquire-14-stake-in-unitedhealthcare-for-usd-34-million/2024-11-14T13:49:22+08:00https://flcube.com/beijing-sl-pharmaceutical-gains-nmpa-approval-for-phase-i-trial-of-mbt-1608-for-hepatitis-c/2024-11-14T13:45:33+08:00https://flcube.com/skyline-therapeutics-gains-nmpa-approval-for-skg0106-in-neovascular-amd-treatment/2024-11-14T13:39:57+08:00https://flcube.com/accuredit-therapeutics-initiates-first-dosing-of-gene-therapy-art001-for-attr/2024-11-14T13:35:05+08:00https://flcube.com/bayer-healthcare-launches-first-innovation-center-in-beijings-etown/2024-11-14T13:30:01+08:00https://flcube.com/chinas-state-council-unveils-plan-to-boost-patent-commercialization-by-2025/2024-11-14T13:26:55+08:00https://flcube.com/bmss-sotyktu-receives-nmpa-approval-for-psoriasis-treatment/2024-11-14T13:24:34+08:00https://flcube.com/cde-grants-priority-review-to-pearl-biotechs-breatinib-for-glioblastoma-treatment/2024-11-14T13:21:31+08:00https://flcube.com/roches-q3-2023-report-shows-1-global-growth-amid-lower-covid-19-product-demand/2024-11-14T13:14:21+08:00https://flcube.com/bmss-subcutaneous-opdivo-meets-phase-iii-study-endpoints-in-ccrcc/2024-11-14T13:11:10+08:00https://flcube.com/novo-nordisk-partners-with-ge-healthcare-to-develop-non-invasive-treatment-for-chronic-diseases/2024-11-14T12:50:14+08:00https://flcube.com/janssens-tar-200-shows-high-complete-response-rate-in-bladder-cancer-study/2024-11-14T12:05:40+08:00https://flcube.com/novartis-kisqali-plus-endocrine-therapy-shows-improved-survival-in-early-breast-cancer-study/2024-11-14T12:01:46+08:00https://flcube.com/boehringer-ingelheim-appoints-mohammed-tawil-as-new-ceo-for-greater-china-region/2024-11-14T11:59:12+08:00https://flcube.com/pfizers-penbraya-receives-fda-approval-for-meningococcal-immunization/2024-11-14T11:56:13+08:00https://flcube.com/national-vbp-tender-program-invites-drugs-approved-before-october-30-for-round-9/2024-11-14T11:50:06+08:00https://flcube.com/msd-cancels-development-of-two-pre-clinical-adcs-from-sichuan-kelun-biotech/2024-11-14T11:47:23+08:00https://flcube.com/health-canada-approves-pfizer-and-sumitomo-pharmas-myfembree-for-endometriosis-pain-management/2024-11-14T11:28:34+08:00https://flcube.com/shanghai-henlius-receives-gmp-certification-from-anvisa-for-biosimilar-manufacturing/2024-11-14T11:08:21+08:00https://flcube.com/shanghai-fudan-zhangjiangs-adc-fz-ad005-accepted-for-nmpa-review-in-advanced-solid-tumors/2024-11-14T10:40:45+08:00https://flcube.com/acuvu-medical-partners-with-hologic-for-us-distribution-of-hummingscope-hysteroscopy-system/2024-11-14T10:34:34+08:00https://flcube.com/cbc-hip-secures-usd-875-million-for-life-science-real-assets-venture-clsra/2024-11-14T10:27:16+08:00https://flcube.com/jacobio-pharmas-glecirasib-combo-shows-promising-results-in-esmo-congress-2023-presentation/2024-11-14T10:16:16+08:00https://flcube.com/hotgen-biotech-partners-with-genoval-therapeutics-for-rnai-drug-development/2024-11-14T10:10:12+08:00https://flcube.com/hansoh-pharmaceutical-and-gsk-ink-global-licensing-deal-for-innovative-adc-hs-20089/2024-11-14T09:56:32+08:00https://flcube.com/inxmed-presents-positive-data-for-fak-inhibitor-ifebemtinib-at-esmo-2023/2024-11-14T09:50:40+08:00https://flcube.com/foundation-medicine-expands-genomic-profiling-partnership-with-sequanta-technologies-in-china/2024-11-14T09:41:12+08:00https://flcube.com/orbimed-raises-over-usd-4-3-billion-for-private-investment-funds-focused-on-healthcare/2024-11-14T00:59:22+08:00https://flcube.com/changchun-bcht-biotechnology-invests-in-influenza-vaccine-production-expansion/2024-11-14T00:57:53+08:00https://flcube.com/yiling-pharmaceutical-gains-nmpa-approval-for-xy0206-in-aml-trial/2024-11-14T00:55:27+08:00https://flcube.com/chengdu-kanghong-receives-fda-nod-for-clinical-trial-of-novel-depression-therapy-kh607/2024-11-14T00:49:26+08:00https://flcube.com/blue-sail-medical-enrolls-first-patient-in-study-for-rapamycin-coated-balloon-catheter/2024-11-14T00:46:45+08:00https://flcube.com/transcenta-holdings-unveils-updated-osemitamab-data-in-advanced-gastric-cancer-at-esmo/2024-11-14T00:41:38+08:00https://flcube.com/vcanbio-receives-nmpa-approval-for-clinical-study-of-vum02-in-sr-agvhd-treatment/2024-11-14T00:36:46+08:00https://flcube.com/roche-agrees-to-acquire-telavant-for-7-1-billion-to-boost-ibd-treatment-portfolio/2024-11-14T00:29:03+08:00https://flcube.com/organon-inks-deal-to-acquire-dermavant-bolstering-dermatology-portfolio-with-vtama-cream/2024-11-14T00:22:58+08:00https://flcube.com/roche-expands-beyond-oncology-with-usd-2-7-billion-carmot-therapeutics-acquisition/2024-11-14T00:22:58+08:00https://flcube.com/jj-medtech-partners-with-ced-medical-for-neurointerventional-solutions/2024-11-14T00:18:37+08:00https://flcube.com/alphamab-oncology-presents-promising-data-for-kn046-and-kn026-at-esmo-2023/2024-11-14T00:11:17+08:00https://flcube.com/shandong-luoxins-lx-039-demonstrates-promise-in-phase-i-oncology-study-at-esmo/2024-11-14T00:07:41+08:00https://flcube.com/kintors-proxalutamide-shows-promise-in-metastatic-breast-cancer-study-at-esmo/2024-11-13T23:49:49+08:00https://flcube.com/walvax-biotechnology-secures-bpom-approval-for-weuphoria-pneumococcal-vaccine/2024-11-13T23:44:18+08:00https://flcube.com/nmpa-implements-new-measures-for-drug-manufacturing-outsourcing-by-mahs/2024-11-13T23:39:31+08:00https://flcube.com/ascentage-pharmas-pelcitoclax-shows-promise-in-esmo-study-for-nsclc/2024-11-13T23:36:46+08:00https://flcube.com/astrazeneca-licenses-nanoforms-starmap-ai-platform-to-enhance-drug-development/2024-11-13T23:32:15+08:00https://flcube.com/ec-approves-astrazeneca-and-daiichi-sankyos-enhertu-for-advanced-her2-nsclc/2024-11-13T23:25:42+08:00https://flcube.com/dizals-sunvozertinib-shows-promising-efficacy-in-advanced-nsclc-at-esmo-2023/2024-11-13T23:19:27+08:00https://flcube.com/abbvie-partners-with-lupus-therapeutics-to-advance-rinvoq-in-sle-treatment/2024-11-13T23:13:55+08:00https://flcube.com/bmss-bms-986278-receives-fda-breakthrough-therapy-designation-for-pulmonary-fibrosis/2024-11-13T23:11:27+08:00https://flcube.com/bms-revenue-slips-due-to-revlimid-erosion-q3-2023-insights/2024-11-13T23:09:39+08:00https://flcube.com/bms-secures-orm-6151-for-acute-myeloid-leukemia-treatment-with-orum-therapeutics-deal/2024-11-13T23:09:38+08:00https://flcube.com/bms-and-karyopharm-partner-to-evaluate-mezigdomide-and-xpovio-in-relapsed-refractory-multiple-myeloma/2024-11-13T23:09:38+08:00https://flcube.com/bmss-augtyro-receives-fda-approval-for-ros1-positive-nsclc/2024-11-13T23:09:37+08:00https://flcube.com/emas-chmp-issues-positive-opinion-for-roches-tecentriq-sc-subcutaneous-formulation/2024-11-13T23:09:37+08:00https://flcube.com/bms-and-2seventy-bios-abecma-faces-fda-review-extension/2024-11-13T23:09:36+08:00https://flcube.com/bms-and-avidity-biosciences-join-forces-on-2-2-billion-cardiology-antibody-oligonucleotide-conjugate-deal/2024-11-13T23:09:36+08:00https://flcube.com/bms-broadens-scope-of-imid-collaboration-aiming-for-deeper-insights-into-sjogrens-and-atopic-dermatitis/2024-11-13T23:09:35+08:00https://flcube.com/sichuan-biokin-and-bristol-myers-squibb-ink-usd-8-4-billion-licensing-deal-for-adc-candidate/2024-11-13T23:09:02+08:00https://flcube.com/bms-advances-tigitxcd96-bispecific-antibody-into-phase-ii-dose-expansion/2024-11-13T23:09:02+08:00https://flcube.com/bms-partners-with-terray-therapeutics-for-ai-driven-drug-discovery/2024-11-13T23:09:01+08:00https://flcube.com/bms-presents-promising-golcadomide-trial-results-for-non-hodgkin-lymphomas/2024-11-13T23:09:01+08:00https://flcube.com/sanofi-expands-oncology-portfolio-with-nk-cell-engager-in-license-from-innate-pharma/2024-11-13T23:09:00+08:00https://flcube.com/bms-expands-oncology-portfolio-with-4-1-billion-rayzebio-acquisition/2024-11-13T23:08:59+08:00https://flcube.com/bms-to-acquire-karuna-therapeutics-for-14-billion-expanding-psychosis-treatment-portfolio/2024-11-13T23:08:59+08:00https://flcube.com/bms-augtyro-receives-ema-review-for-advanced-lung-cancer-and-solid-tumors-treatments/2024-11-13T23:08:58+08:00https://flcube.com/bmss-abraxane-approved-in-china-for-first-line-metastatic-pancreatic-cancer-treatment/2024-11-13T23:08:57+08:00https://flcube.com/bmss-sotyktu-first-tyk2-inhibitor-hits-chinese-market/2024-11-13T23:08:57+08:00https://flcube.com/bmss-opdivo-yervoy-combo-cuts-cancer-progression-risk-by-79-in-phase-iii-study/2024-11-13T23:08:56+08:00https://flcube.com/international-society-for-cell-gene-therapy-comments-on-fdas-car-t-investigation/2024-11-13T23:08:56+08:00https://flcube.com/bristol-myers-squibbs-subcutaneous-opdivo-shows-noninferiority-in-phase-iii-ccrcc-trial/2024-11-13T23:08:55+08:00https://flcube.com/bms-sees-mixed-results-in-2023-growth-in-new-products-offset-by-loss-of-exclusivity/2024-11-13T23:08:55+08:00https://flcube.com/bms-reports-positive-long-term-data-for-zeposia-in-multiple-sclerosis-trials/2024-11-13T23:08:54+08:00https://flcube.com/bms-seeks-fda-priority-review-for-krazati-in-advanced-colorectal-cancer/2024-11-13T23:08:54+08:00https://flcube.com/fda-advisory-committee-backs-wider-use-of-abecma-in-relapsed-or-refractory-multiple-myeloma/2024-11-13T23:08:53+08:00https://flcube.com/bmss-opdivo-secures-fda-approval-for-first-line-urothelial-carcinoma-treatment/2024-11-13T23:08:53+08:00https://flcube.com/bristol-myers-squibbs-breyanzi-receives-fda-accelerated-approval-for-cll-sll-treatment/2024-11-13T23:08:52+08:00https://flcube.com/astrazeneca-to-acquire-fusion-pharmaceuticals-in-a-deal-valued-at-usd-2-4-billion/2024-11-13T23:08:52+08:00https://flcube.com/bms-reports-positive-phase-iii-results-for-opdivo-and-yervoy-in-advanced-hcc/2024-11-13T23:08:19+08:00https://flcube.com/bristol-myers-squibbs-zeposia-fails-to-meet-primary-endpoint-in-crohns-disease-trial/2024-11-13T23:08:19+08:00https://flcube.com/bristol-myers-squibbs-krazati-trial-yields-positive-phase-iii-results-in-nsclc/2024-11-13T23:08:18+08:00https://flcube.com/bristol-myers-squibbs-abecma-receives-fda-approval-for-wider-use-in-multiple-myeloma-treatment/2024-11-13T23:08:18+08:00https://flcube.com/bristol-myers-squibb-reports-positive-long-term-data-for-karxt-in-schizophrenia-trial/2024-11-13T23:08:17+08:00https://flcube.com/bristol-myers-squibb-enhances-car-t-manufacturing-with-cellares-platform-securing-exclusive-access/2024-11-13T23:08:17+08:00https://flcube.com/bristol-myers-squibb-reports-6-yoy-revenue-growth-in-q1-2024-driven-by-eliquis-and-reblozyl/2024-11-13T23:08:16+08:00https://flcube.com/nabla-bio-forges-partnerships-with-top-pharma-companies-to-tackle-challenging-drug-targets/2024-11-13T23:08:16+08:00https://flcube.com/bmss-sotyktu-sustains-clinical-response-in-long-term-psoriasis-treatment/2024-11-13T23:08:15+08:00https://flcube.com/bristol-myers-squibb-invests-in-uk-immuno-oncology-firm-neophores-series-b-extension-round/2024-11-13T23:08:15+08:00https://flcube.com/bms-strikes-deal-with-prothena-for-potential-disease-modifying-neurology-drug-prx019/2024-11-13T23:08:14+08:00https://flcube.com/novartis-halts-development-of-kras-inhibitor-opnurasib-due-to-competitive-market/2024-11-13T23:08:13+08:00https://flcube.com/fda-extends-indication-for-bms-car-t-therapy-breyanzi-to-include-relapsed-mcl-in-adults/2024-11-13T23:08:13+08:00https://flcube.com/bristol-myers-squibbs-breyanzi-shows-promising-results-in-three-lymphoma-trials/2024-11-13T23:08:12+08:00https://flcube.com/bristol-myers-squibbs-krazati-meets-primary-endpoint-in-late-stage-lung-cancer-study/2024-11-13T23:08:12+08:00https://flcube.com/fda-approves-broadened-use-of-bms-next-gen-tki-augtyro-for-advanced-solid-tumors/2024-11-13T23:08:11+08:00https://flcube.com/abbvie-warns-shareholders-against-tutanotas-unsolicited-mini-tender-offer/2024-11-13T23:08:11+08:00https://flcube.com/legend-biotech-corporation-appoints-alan-bash-as-president-of-carvykti/2024-11-13T23:08:10+08:00https://flcube.com/bms-expands-opdivo-indication-with-fda-approval-for-nsclc-combo-therapy/2024-11-13T23:08:10+08:00https://flcube.com/bmss-opdivo-secures-nmpa-approval-for-urothelial-carcinoma-treatment/2024-11-13T23:08:09+08:00https://flcube.com/lanova-medicines-regains-rights-to-claudin-18-2-targeting-adc-lm-302-from-bms/2024-11-13T23:07:11+08:00https://flcube.com/bms-launches-cardiac-myosin-inhibitor-camzyos-in-china-for-obstructive-hypertrophic-cardiomyopathy/2024-11-13T23:06:43+08:00https://flcube.com/bmss-dual-immunotherapy-achieves-global-first-approval-for-msi-h-dmmr-crc-in-china/2024-11-13T23:06:15+08:00https://flcube.com/2seventy-bio-and-bms-discontinue-phase-iii-trial-for-multiple-myeloma-therapy-abecma/2024-11-13T23:04:00+08:00https://flcube.com/qilu-pharmaceutical-gains-approval-for-generic-dasatinib-expanding-cml-treatment-options-in-china/2024-11-13T23:02:11+08:00https://flcube.com/bristol-myers-squibb-terminates-partnership-with-agenus-on-tigit-cd96-bispecific-antibody/2024-11-13T23:01:43+08:00https://flcube.com/bristol-myers-squibb-q2-2024-sales-boosted-by-growth-portfolio-offset-by-rd-impairment/2024-11-13T23:01:15+08:00https://flcube.com/bristol-myers-squibb-ends-collaboration-with-eisai-on-farletuzumab-eteribulin/2024-11-13T23:00:47+08:00https://flcube.com/bmss-opdivo-yervoy-combo-misses-pfs-endpoint-in-unresectable-stage-iii-nsclc-trial/2024-11-13T23:00:19+08:00https://flcube.com/novartis-q3-earnings-reflect-strong-growth-post-sandoz-spinoff/2024-11-13T22:51:31+08:00https://flcube.com/fosun-pharma-gains-nmpa-approval-for-phase-i-trial-of-xs-03-in-advanced-solid-tumors/2024-11-13T22:39:20+08:00https://flcube.com/cutia-therapeutics-cu-20401-completes-phase-i-study-for-obesity-treatment/2024-11-13T22:36:39+08:00https://flcube.com/peking-university-unveils-national-standardized-pain-treatment-center-in-china/2024-11-13T22:30:32+08:00https://flcube.com/leadinno-medical-valley-secures-series-a-funding-for-neuroregulation-device-rd/2024-11-13T22:27:41+08:00https://flcube.com/china-grand-pharma-initiates-phase-iii-trial-for-gpn00833-in-cataract-surgery-recovery/2024-11-13T22:22:19+08:00https://flcube.com/bms-regains-full-rights-to-mavacamten-in-china-and-asia-from-lianbio/2024-11-13T20:35:10+08:00https://flcube.com/sihuan-pharmaceutical-gains-nmpa-approval-for-innovative-type-2-diabetes-treatment/2024-11-13T19:49:41+08:00https://flcube.com/jiangsu-aideas-hiv-1-drug-acc017-accepted-for-nmpa-review-in-china/2024-11-13T19:45:21+08:00https://flcube.com/fibrogen-inc-reports-15-yoy-revenue-growth-in-q3-2024-led-by-evrenzo/2024-11-13T18:30:16+08:00https://flcube.com/astrazeneca-inc-reports-21-yoy-revenue-growth-in-q3-2024-financials/2024-11-13T18:18:08+08:00https://flcube.com/beigenes-q3-2024-results-show-28-yoy-revenue-growth-driven-by-brukinsa-and-tevimbra/2024-11-13T18:00:10+08:00https://flcube.com/bayer-ag-posts-modest-q3-growth-with-strong-performance-from-new-pharmaceuticals/2024-11-13T17:43:17+08:00https://flcube.com/sunshine-lake-pharma-inks-licensing-deal-with-apollo-therapeutics-for-apl-18881/2024-11-13T17:03:26+08:00https://flcube.com/boehringer-ingelheim-joins-mtm-vision-consortium-to-advance-diabetes-retinopathy-research/2024-11-13T16:17:11+08:00https://flcube.com/jj-medtech-receives-fda-ide-for-ottava-robotic-surgical-system-trials/2024-11-13T16:00:04+08:00https://flcube.com/zai-lab-ltd-reports-46-yoy-revenue-growth-in-q3-2024-driven-by-vygart-zejula-and-nuzyra/2024-11-13T15:50:01+08:00https://flcube.com/legend-biotechs-q3-revenue-soars-67-yoy-driven-by-carvykti-sales/2024-11-13T15:38:37+08:00https://flcube.com/canhelp-genomics-partners-with-mirxes-to-expand-tumor-origin-testing-in-southeast-asia/2024-11-13T15:24:31+08:00https://flcube.com/vesalius-therapeutics-partners-with-gsk-for-novel-parkinsons-disease-treatments/2024-11-13T15:11:01+08:00https://flcube.com/flare-therapeutics-and-roche-enter-strategic-collaboration-for-oncology-drug-discovery/2024-11-13T14:53:36+08:00https://flcube.com/schrodinger-and-novartis-ink-deal-to-accelerate-drug-discovery-candidates/2024-11-13T14:43:49+08:00https://flcube.com/cspc-pharmaceutical-gains-nmpa-approval-for-clinical-trial-of-mrna-vaccine-sys6026/2024-11-13T14:29:40+08:00https://flcube.com/biogens-biib080-shows-promise-in-phase-ib-trial-for-mild-alzheimers-disease/2024-11-13T14:21:34+08:00https://flcube.com/sinotau-pharmaceutical-group-secures-rights-to-blue-earth-diagnostics-flotufolastat-in-china/2024-11-13T14:08:28+08:00https://flcube.com/shanghai-pharmaceuticals-partners-with-asymchem-for-advanced-drug-development-and-production/2024-11-13T13:56:25+08:00https://flcube.com/sonosemi-medical-secures-over-usd-27-3-million-in-series-b-funding-for-vascular-intervention-devices/2024-11-13T13:37:57+08:00https://flcube.com/huadong-medicines-elahere-accepted-for-nmpa-review-in-china-for-ovarian-cancer-treatment/2024-11-13T13:31:02+08:00https://flcube.com/novartis-pluvicto-demonstrates-positive-phase-iii-results-in-mcrpc-treatment/2024-11-13T13:16:23+08:00https://flcube.com/life-molecular-imaging-and-sinotau-pharmaceutical-secure-nmpa-approval-for-neuraceq-in-china/2024-11-13T13:12:23+08:00https://flcube.com/innovent-biologics-gfh925-on-track-for-priority-review-status-for-nsclc-treatment/2024-11-13T12:54:31+08:00https://flcube.com/cde-releases-75th-batch-of-generic-reference-preparations-with-updated-specifications/2024-11-13T12:48:21+08:00https://flcube.com/hejiang-jianfeng-receives-fda-approval-for-jfan-1001-clinical-trial-in-nsclc/2024-11-13T12:44:36+08:00https://flcube.com/microport-cardioflow-medtech-completes-clinical-implantations-of-second-generation-tavi-device/2024-11-13T12:36:25+08:00https://flcube.com/cspc-pharmaceutical-gains-nmpa-approval-for-clinical-study-of-bispecific-antibody-nbl-028/2024-11-13T12:26:15+08:00https://flcube.com/shanghai-henlius-initiates-global-phase-iii-study-for-hansizhuang-in-ls-sclc/2024-11-13T12:14:10+08:00https://flcube.com/qilu-pharmaceutical-unveils-promising-data-for-ql1706-in-cervical-cancer-treatment-at-esmo-2023/2024-11-13T11:55:47+08:00https://flcube.com/microport-medbots-toumai-robot-gains-nmpa-approval-for-endoscopic-surgery/2024-11-13T09:48:27+08:00https://flcube.com/danaher-corporation-reports-q3-2023-earnings-with-10-5-global-revenue-decline/2024-11-13T09:39:25+08:00https://flcube.com/strategic-alliance-formed-by-ubrigene-fraserna-and-virogin-for-cell-and-gene-therapy-services/2024-11-13T00:33:08+08:00https://flcube.com/ubrigene-partners-with-xjtlu-to-develop-car-nk-cell-therapies-for-solid-tumors/2024-11-13T00:20:49+08:00https://flcube.com/fujian-cosunter-gains-ethical-approval-for-phase-iia-study-of-gst-hg131-in-hepatitis-b/2024-11-13T00:16:54+08:00https://flcube.com/abbisko-therapeutics-gets-nmpa-approval-for-phase-i-study-of-absk112-in-nsclc/2024-11-13T00:10:14+08:00https://flcube.com/nmpa-unveils-73rd-batch-of-reference-drugs-for-generic-quality-consistency/2024-11-13T00:05:48+08:00https://flcube.com/gsks-viiv-healthcare-secures-nmpa-approval-for-vocabria-in-hiv-1-treatment/2024-11-13T00:03:09+08:00https://flcube.com/abbvies-rinvoq-gains-two-new-indications-in-china-axspa-and-ankylosing-spondylitis/2024-11-12T23:58:47+08:00https://flcube.com/takedas-global-revenues-grow-strong-performance-in-plasma-therapies-and-gastroenterology/2024-11-12T23:55:48+08:00https://flcube.com/eli-lillys-omvoh-receives-fda-approval-for-ulcerative-colitis-treatment/2024-11-12T23:44:54+08:00https://flcube.com/novartis-seeks-access-to-takedas-business-records-over-confidentiality-concerns/2024-11-12T23:39:50+08:00https://flcube.com/roches-vabysmo-receives-fda-approval-for-macular-edema-treatment-following-rvo/2024-11-12T23:34:00+08:00https://flcube.com/abbvies-q3-2023-report-shows-6-0-yoy-decline-in-net-revenues/2024-11-12T23:29:22+08:00https://flcube.com/dr-reddys-laboratories-reports-9-yoy-revenue-growth-in-q2-2024-fiscal-year/2024-11-12T23:04:05+08:00https://flcube.com/jenscare-scientifics-ken-valve-enters-nmpa-priority-review-for-aortic-valve-system/2024-11-12T22:57:25+08:00https://flcube.com/alphamab-oncology-and-3d-medicines-gain-fda-approval-for-envafolimab-phase-iii-trial/2024-11-12T22:51:32+08:00https://flcube.com/china-grand-pharmas-lava-liquid-embolic-agent-officially-commercialized-in-the-us/2024-11-12T22:40:04+08:00https://flcube.com/mindray-bio-medical-electronics-posts-strong-q1-q3-2023-financial-results/2024-11-12T22:32:20+08:00https://flcube.com/fosun-pharma-gains-nmpa-approval-for-clinical-trials-of-hlx42-and-hlx43-adcs/2024-11-12T22:19:31+08:00https://flcube.com/innovent-biologics-mazdutide-shows-promising-weight-loss-results-in-phase-ii-trial/2024-11-12T22:08:28+08:00https://flcube.com/sanofi-sa-reports-q3-2023-financials-with-focus-on-rd-and-dupixent-growth/2024-11-12T22:01:37+08:00https://flcube.com/junshi-biosciences-pd-1-inhibitor-loqtorzi-approved-by-fda-for-nasopharyngeal-carcinoma/2024-11-12T21:54:52+08:00https://flcube.com/tg-immunopharmas-bispecific-antibody-tgi-6-approved-for-phase-i-clinical-study-by-nmpa/2024-11-12T21:43:41+08:00https://flcube.com/everest-medicines-nefecon-receives-first-regional-nda-approval-in-macau-for-igan-treatment/2024-11-12T21:37:42+08:00https://flcube.com/wyze-biotechs-rjmty19-injection-accepted-for-cde-review-for-r-r-b-cell-nhl/2024-11-12T21:25:57+08:00https://flcube.com/shanghai-pharmaceuticals-posts-13-11-yoy-revenue-growth-in-q3-2023-financials/2024-11-12T21:19:55+08:00https://flcube.com/shanghai-henlius-biotech-and-intas-pharmaceuticals-ink-new-licensing-deal-for-pd-1-mab/2024-11-12T21:15:50+08:00https://flcube.com/nhsa-and-mof-announce-medical-insurance-fund-prepayment-initiative-to-aid-healthcare-institutions/2024-11-12T16:16:43+08:00https://flcube.com/innocare-pharma-reports-29-8-revenue-increase-in-q3-2024-financials/2024-11-12T16:09:06+08:00https://flcube.com/triton-partners-mulls-acquisition-of-germanys-evotec-se-shares-soar-22/2024-11-12T15:57:35+08:00https://flcube.com/genscript-biotech-expands-in-australia-with-new-sydney-operations-and-logistics-center/2024-11-12T15:43:14+08:00https://flcube.com/biocytogens-first-in-class-b7h3-ptk7-bispecific-adc-option-exercised-by-ideaya-biosciences/2024-11-12T15:14:03+08:00https://flcube.com/gan-lees-gzr18-shows-significant-weight-loss-in-phase-iib-study-at-obesityweek-2024/2024-11-12T14:51:39+08:00https://flcube.com/jjs-nipocalimab-receives-fda-breakthrough-therapy-designation-for-sjogrens-disease/2024-11-12T14:38:26+08:00https://flcube.com/zai-lab-and-argenx-receive-nmpa-approval-for-vygart-hytrulo-in-chronic-inflammatory-demyelinating-polyneuropathy/2024-11-12T14:18:34+08:00https://flcube.com/cutia-therapeutics-cu-10201-receives-nmpa-approval-for-acne-vulgaris-treatment/2024-11-12T13:58:04+08:00https://flcube.com/beyondspring-presents-positive-phase-ii-data-for-plinabulin-combination-therapy-in-nsclc-at-sitc/2024-11-12T13:48:26+08:00https://flcube.com/abbisko-therapeutics-pimicotinib-meets-primary-endpoint-in-phase-iii-maneuver-study-for-tgct/2024-11-12T13:06:06+08:00https://flcube.com/etern-therapeutics-ets-006-receives-fda-orphan-drug-designation-for-pleural-mesothelioma/2024-11-12T12:54:42+08:00https://flcube.com/frontera-therapeutics-receives-fda-approval-for-phase-ii-study-of-ft-003-in-namd/2024-11-12T12:21:25+08:00https://flcube.com/coheruss-loqtorzi-gains-fda-approval-for-nasopharyngeal-carcinoma-treatment/2024-11-12T11:56:48+08:00https://flcube.com/staidson-receives-nmpa-approval-for-clinical-trial-of-stsa-1301-in-primary-immune-thrombocytopenia/2024-11-12T11:45:10+08:00https://flcube.com/allist-pharmaceuticals-furmonertinib-receives-fda-breakthrough-therapy-designation-for-nsclc/2024-11-12T11:36:14+08:00https://flcube.com/yirui-pharmaceuticals-yr001-completes-successful-phase-i-clinical-study-in-the-us/2024-11-12T11:23:32+08:00https://flcube.com/danyang-huichuang-secures-over-usd-13-7-million-in-series-b-funding-for-fnirs-development/2024-11-12T11:02:24+08:00https://flcube.com/cde-grants-priority-review-to-lanovas-lm-302-roches-alectinib-and-alphamabs-kn026/2024-11-12T10:55:59+08:00https://flcube.com/boan-biotech-enrolls-first-patient-in-phase-iii-study-for-opdivo-biosimilar-ba1104-in-china/2024-11-12T10:51:29+08:00https://flcube.com/boan-biotech-secures-fda-orphan-drug-designations-for-pancreatic-cancer-treatments/2024-11-12T10:48:03+08:00https://flcube.com/chinas-health-authorities-release-third-list-of-41-drugs-for-recommended-generic-development/2024-11-12T10:42:59+08:00https://flcube.com/cspc-pharmaceutical-group-gains-nmpa-approval-for-bivalent-covid-19-mrna-vaccine-study/2024-11-12T10:40:04+08:00https://flcube.com/genfleet-therapeutics-sls009-receives-fda-fast-track-status-for-ptcl-treatment/2024-11-12T10:33:24+08:00https://flcube.com/cstone-pharmaceuticals-receives-nmpa-approval-for-sugemalimab-in-r-r-enktl/2024-11-12T10:22:38+08:00https://flcube.com/simcere-pharmaceutical-group-secures-full-approval-for-cosela-in-china/2024-11-12T10:14:46+08:00https://flcube.com/novartis-announces-positive-interim-results-for-atrasentan-in-iga-nephropathy-phase-iii-study/2024-11-12T10:06:53+08:00https://flcube.com/novartis-cosentyx-gains-fda-approval-for-hidradenitis-suppurativa-treatment/2024-11-12T00:39:18+08:00https://flcube.com/anheart-therapeutics-signs-exclusive-license-deal-with-nippon-kayaku-for-taletrectinib/2024-11-12T00:35:29+08:00https://flcube.com/roches-gene-therapy-elevidys-misses-primary-endpoint-in-dmd-trial/2024-11-12T00:27:43+08:00https://flcube.com/biolinerx-licenses-multiple-myeloma-drug-motixafortide-to-guangzhou-gloria-biosciences/2024-11-12T00:23:39+08:00https://flcube.com/gloria-bios-motixafortide-approved-as-urgently-needed-import-drug-by-hainan-medical-products-administration/2024-11-12T00:22:29+08:00https://flcube.com/amgen-reports-q3-2023-financials-5-growth-driven-by-volume-expansion/2024-11-12T00:18:26+08:00https://flcube.com/guangxi-hsa-expands-coverage-for-assisted-reproductive-medical-services-under-bmi/2024-11-12T00:15:13+08:00https://flcube.com/siyi-intelligence-secures-approval-for-innovative-rehabilitation-robots-in-china/2024-11-12T00:12:53+08:00https://flcube.com/triastek-partners-with-basf-to-advance-3d-printing-materials-for-pharmaceuticals/2024-11-12T00:07:44+08:00https://flcube.com/hainan-poly-pharm-receives-fda-approval-for-pl002-in-primary-liver-cancer-surgery/2024-11-12T00:01:19+08:00https://flcube.com/changchun-bcht-biotechnology-receives-nmpa-approval-for-anti-tetanus-monoclonal-antibody-injection/2024-11-11T23:57:47+08:00https://flcube.com/shenzhen-chipscreen-biosciences-gets-nmpa-approval-for-phase-i-study-of-cs32582-in-psoriasis/2024-11-11T23:51:53+08:00https://flcube.com/shanghais-argo-biopharma-raises-usd-41-million-in-series-a-financing-round/2024-11-11T23:48:33+08:00https://flcube.com/immuxell-biotech-secures-over-rmb-100-million-in-series-a-funding-for-cell-therapy-development/2024-11-11T23:42:44+08:00https://flcube.com/shanghai-henlius-biotechs-hansizhuang-shows-positive-results-in-phase-iii-astrum-002-study/2024-11-11T23:33:47+08:00https://flcube.com/luye-pharma-groups-rivastigmine-patch-ly03013-approved-by-chinas-nmpa-for-alzheimers-treatment/2024-11-11T23:29:25+08:00https://flcube.com/bio-techne-corporation-reports-2-yoy-revenue-growth-in-q1-2024-fiscal-report/2024-11-11T23:21:52+08:00https://flcube.com/pfizer-inc-reports-q3-2023-revenue-contraction-and-launches-cost-realignment-program/2024-11-11T23:15:06+08:00https://flcube.com/astrazeneca-partners-with-cellectis-for-next-generation-cell-and-gene-therapies/2024-11-11T23:07:05+08:00https://flcube.com/daiichi-sankyo-reports-19-5-yoy-revenue-growth-in-first-half-of-fiscal-2023/2024-11-11T23:00:47+08:00https://flcube.com/epimah-biotherapeutics-to-present-first-in-human-results-for-emb-06-at-sitc-annual-meeting/2024-11-11T22:46:22+08:00https://flcube.com/gsk-reports-modest-2-yoy-growth-in-q3-2023-finances-vaccines-unit-soars-24/2024-11-11T22:39:07+08:00https://flcube.com/chongqing-precision-biotechnologys-pcar-19b-receives-cde-nod-for-breakthrough-therapy-designation/2024-11-11T22:09:17+08:00https://flcube.com/astellas-pharma-inc-reports-moderate-revenue-growth-in-h1-fiscal-2023-financials/2024-11-11T22:02:29+08:00https://flcube.com/sichuan-kelun-biotechs-skb264-receives-priority-review-status-for-tnbc-treatment-in-china/2024-11-11T21:53:50+08:00https://flcube.com/sichuan-kelun-biotech-secures-nmpa-nod-for-generic-lynparza-equivalent/2024-11-11T21:49:04+08:00https://flcube.com/kelun-biotechs-a400-receives-fast-track-status-from-fda-for-ret-fusion-positive-nsclc/2024-11-11T21:47:46+08:00https://flcube.com/kelun-biotechs-ret-inhibitor-a400-advances-to-phase-ii-trial-with-fda-approval/2024-11-11T21:47:03+08:00https://flcube.com/sichuan-kelun-biotech-receives-nmpa-clearance-for-skb518-clinical-trial-in-solid-tumors/2024-11-11T21:45:44+08:00https://flcube.com/sichuan-kelun-biotechs-sacituzumab-tirumotecan-files-for-new-indication-with-chinas-nmpa/2024-11-11T21:44:26+08:00https://flcube.com/hinova-pharmaceuticals-hp518-receives-nmpa-approval-for-mcrpc-clinical-trial/2024-11-11T21:41:08+08:00https://flcube.com/sino-biopharmaceuticals-tqg3902-injection-receives-nmpa-approval-for-septic-shock-clinical-trial/2024-11-11T21:33:53+08:00https://flcube.com/sirnaomics-stp705-demonstrates-positive-results-in-phase-i-focal-fat-reduction-study/2024-11-11T21:30:19+08:00https://flcube.com/3sbio-inc-and-cstone-pharmaceuticals-enter-strategic-partnership-for-nofazinlimab/2024-11-11T21:25:08+08:00https://flcube.com/resolian-expands-global-reach-with-acquisition-of-china-based-denali-medpharma/2024-11-11T21:17:33+08:00https://flcube.com/viatris-reports-q3-2024-global-sales-of-usd-3-8-billion-with-a-5-yoy-decline/2024-11-11T16:03:47+08:00https://flcube.com/gilead-sciences-reports-7-yoy-increase-in-q3-2024-product-sales-driven-by-hiv-therapies/2024-11-11T15:54:27+08:00https://flcube.com/gsk-leaves-bio-joining-other-major-companies-in-withdrawing-membership/2024-11-11T15:43:18+08:00https://flcube.com/atlatl-and-takeda-enter-mou-to-collaborate-on-early-stage-drug-development-and-innovation/2024-11-11T15:33:08+08:00https://flcube.com/alteogen-secures-exclusive-licensing-deal-with-daiichi-sankyo-for-subcutaneous-enhertu/2024-11-11T15:22:26+08:00https://flcube.com/baheal-pharmaceutical-group-leads-usd-78-million-investment-in-zap-surgical-systems/2024-11-11T15:15:29+08:00https://flcube.com/pfizer-partners-with-beijing-mabworks-and-kyinno-biotechnology-on-multiple-myeloma-treatments-in-china/2024-11-11T15:03:23+08:00https://flcube.com/astrazenecas-tezspire-meets-phase-iii-co-primary-endpoints-in-crswnp-study/2024-11-11T14:46:20+08:00https://flcube.com/sino-medical-sciences-technology-secures-marketing-approval-in-peru-for-ht-supreme-stent-system/2024-11-11T14:36:41+08:00https://flcube.com/jiangsu-kanion-pharmaceutical-gets-fda-approval-to-test-kys202004a-for-psoriasis/2024-11-11T14:29:03+08:00https://flcube.com/johnson-johnson-submits-regulatory-filings-for-darzalex-faspro-and-subcutaneous-daratumumab/2024-11-11T14:22:25+08:00https://flcube.com/alphamab-oncology-presents-jskn033-phase-i-ii-study-results-at-sitc-2024/2024-11-11T13:54:33+08:00https://flcube.com/gaush-meditech-ltd-receives-nmpa-approval-for-rigid-corneal-contact-lens/2024-11-11T13:25:51+08:00https://flcube.com/sino-biopharmaceutical-ltd-receives-nmpa-approval-for-kras-g12c-inhibitor-garsorasib/2024-11-11T13:21:37+08:00https://flcube.com/bayer-extends-collaboration-with-broad-institute-to-2028-for-oncology-drug-targets-and-therapies/2024-11-11T13:06:15+08:00https://flcube.com/abbvie-secures-option-agreement-with-aldeyra-therapeutics-for-rasp-modulator-reproxalap/2024-11-11T13:03:26+08:00https://flcube.com/novo-nordisk-reports-33-yoy-growth-in-q3-2023-with-diabetes-and-obesity-care-driving-sales/2024-11-11T12:54:41+08:00https://flcube.com/cutia-therapeutics-achieves-primary-endpoint-in-phase-i-study-of-cu-40101-for-androgenic-alopecia/2024-11-11T12:22:37+08:00https://flcube.com/sanofi-regains-exclusive-rights-to-rezurock-in-china-terminating-agreement-with-bionova-and-bk-pharmaceuticals/2024-11-11T12:17:30+08:00https://flcube.com/innovent-biologics-reports-q3-2023-sales-exceeding-rmb-1-6-billion-with-45-yoy-growth/2024-11-11T12:09:05+08:00https://flcube.com/wuhan-hiteck-biological-pharma-receives-nmpa-approval-for-aponermin-in-multiple-myeloma-treatment/2024-11-11T11:28:17+08:00https://flcube.com/abbisko-therapeutics-to-present-csf-1r-inhibitor-absk021-data-at-ctos-annual-meeting/2024-11-11T11:22:42+08:00https://flcube.com/ascentage-pharmas-olverembatinib-showcases-promising-results-at-ash-annual-meeting/2024-11-11T11:19:45+08:00https://flcube.com/sino-medical-sciences-technology-secures-tfda-approval-for-ht-supreme-drug-eluting-stent-system/2024-11-11T11:15:24+08:00https://flcube.com/shanghai-pharmaceuticals-gets-nmpa-approval-for-phase-i-clinical-study-of-b019-car-t-cell-injection/2024-11-11T11:12:45+08:00https://flcube.com/i-mab-and-hi-bios-felzartamab-earns-breakthrough-therapy-designation-from-us-fda/2024-11-11T11:09:44+08:00https://flcube.com/eli-lilly-co-reports-36-yoy-sales-growth-in-q3-2023-with-key-drug-performances/2024-11-11T11:05:07+08:00https://flcube.com/organon-reports-q3-2023-financials-with-mixed-results-notable-decline-in-womens-health-sales/2024-11-11T10:28:34+08:00https://flcube.com/micurx-pharmaceuticals-secures-clinical-trial-approvals-for-mrx-4-and-contezolid-in-multiple-countries/2024-11-10T23:53:29+08:00https://flcube.com/baheal-pharmaceutical-partners-with-astrazeneca-for-exclusive-distribution-of-losec-in-china/2024-11-10T23:48:58+08:00https://flcube.com/bayer-unveils-real-world-insights-on-kerendia-for-ckd-and-t2d-management/2024-11-10T23:33:47+08:00https://flcube.com/astrazeneca-announces-positive-phase-iib-results-for-ckd-treatment-combination/2024-11-10T23:26:35+08:00https://flcube.com/hku-and-siidb-collaborate-on-drug-development-for-infectious-diseases/2024-11-10T23:23:54+08:00https://flcube.com/dizal-pharmaceutical-presents-updates-on-dzd8586-and-golidocitinib-at-ash-annual-meeting/2024-11-10T23:20:59+08:00https://flcube.com/zhejiang-huahai-pharmaceuticals-hb0052-receives-us-fda-ind-approval-for-solid-tumors/2024-11-10T23:04:23+08:00https://flcube.com/innovent-biologics-presents-positive-clinical-results-for-efdamrofusp-alfa-and-ibi324-at-aao/2024-11-10T22:54:06+08:00https://flcube.com/qingdaos-raise-care-secures-over-rmb-100-million-in-series-b-financing-led-by-citic-capital/2024-11-10T22:51:08+08:00https://flcube.com/cspc-pharmaceutical-group-gets-nmpa-approval-for-sys6011-biologic-drug-clinical-study/2024-11-10T22:43:58+08:00https://flcube.com/chengdu-kanghong-pharmaceuticals-kh629-receives-fda-approval-for-nash-clinical-trial/2024-11-10T22:40:05+08:00https://flcube.com/fibrogen-inc-reports-155-yoy-sales-increase-in-q3-2023-financial-results/2024-11-10T22:35:56+08:00https://flcube.com/gsk-acquires-global-rights-to-janssens-hepatitis-b-antiviral-jnj-3989-in-1-billion-deal/2024-11-10T22:30:06+08:00https://flcube.com/gilead-sciences-and-arcus-biosciences-announce-positive-phase-ii-data-for-domvanalimab-combination-therapy/2024-11-10T22:12:17+08:00https://flcube.com/clover-biopharmaceuticals-submits-market-filing-for-seasonal-influenza-vaccine-in-brazil/2024-11-10T22:04:13+08:00https://flcube.com/wuxi-xdc-aims-for-hkex-listing-with-ipo-of-178-4-million-shares/2024-11-10T21:56:46+08:00https://flcube.com/boehringer-ingelheims-aldosterone-synthase-inhibitor-bi-690517-shows-promise-in-ckd-phase-ii-trial/2024-11-10T21:45:07+08:00https://flcube.com/sun-yat-sen-memorial-hospital-partners-with-siemens-healthineers-on-metaverse-visualization-surgery/2024-11-10T21:43:01+08:00https://flcube.com/danone-enters-chinas-adult-fsmp-market-with-local-production-of-fortimel/2024-11-10T21:39:28+08:00https://flcube.com/sciclone-pharmaceuticals-secures-exclusive-rights-to-menarini-groups-orserdu-in-china/2024-11-10T00:54:33+08:00https://flcube.com/sciclones-partner-menarini-files-for-elacestrant-approval-in-macau-for-advanced-breast-cancer/2024-11-10T00:53:21+08:00https://flcube.com/sciclone-pharmaceuticals-teams-up-with-sph-health-and-hi-dr-to-launch-internet-hospital-in-china/2024-11-10T00:52:57+08:00https://flcube.com/sciclone-and-menarini-file-for-import-license-of-antibacterial-drug-vaborem-in-macau/2024-11-10T00:52:26+08:00https://flcube.com/gl-capital-and-sciclone-pharmaceuticals-agree-to-privatization-and-delisting/2024-11-10T00:51:22+08:00https://flcube.com/sciclone-pharmaceuticals-gets-nmpa-approval-for-phase-iii-study-of-first-in-class-serd-orserdu/2024-11-10T00:50:30+08:00https://flcube.com/rinuagene-receives-us-fda-ind-approval-for-hpv-associated-tumor-mrna-vaccine-rg002/2024-11-10T00:44:43+08:00https://flcube.com/enhertu-receives-priority-review-status-for-her2-positive-gastric-cancer-treatment-in-china/2024-11-10T00:39:24+08:00https://flcube.com/teva-partners-with-cr-guangdong-to-launch-fremanezumab-for-migraines-in-chinas-gba/2024-11-10T00:34:35+08:00https://flcube.com/takeda-partners-with-new-horizon-health-technology-to-manage-helicobacter-pylori-in-china/2024-11-10T00:31:13+08:00https://flcube.com/intuitive-surgical-fosun-medical-launches-da-vinci-xi-surgical-robot-at-ciie/2024-11-10T00:22:45+08:00https://flcube.com/biontech-secures-exclusive-rights-to-biotheus-inc-s-bsab-pm8002-in-landmark-deal/2024-11-10T00:16:10+08:00https://flcube.com/fosun-pharmaceutical-and-insightec-collaborate-on-non-invasive-brain-treatment-technology/2024-11-10T00:09:02+08:00https://flcube.com/9th-national-volume-based-procurement-round-results-in-70-price-reduction-for-41-drugs/2024-11-09T23:53:50+08:00https://flcube.com/worg-pharmaceuticals-expands-into-spain-with-acquisition-of-diater-for-eur-150-million/2024-11-09T22:24:40+08:00https://flcube.com/janssens-nipocalimab-shows-promising-results-in-phase-ii-rheumatoid-arthritis-trial/2024-11-09T22:18:13+08:00https://flcube.com/gilead-reports-q3-2023-financials-with-1-yoy-revenue-increase-and-updates-2023-outlook/2024-11-09T22:13:34+08:00https://flcube.com/astrazeneca-expands-china-presence-with-over-30-agreements-at-ciie/2024-11-09T22:05:54+08:00https://flcube.com/moderna-initiates-construction-of-first-china-based-pharmaceutical-plant-in-shanghai/2024-11-09T21:59:57+08:00https://flcube.com/senti-biosciences-and-celest-therapeutics-partner-on-car-nk-cell-therapy-clinical-trial-in-china/2024-11-09T21:47:26+08:00https://flcube.com/eisai-partners-with-shanghai-pharmaceuticals-for-alzheimers-drug-leqembi-in-china/2024-11-09T21:36:09+08:00https://flcube.com/bayer-and-shanghai-pharmaceuticals-launch-co-lab-to-incubate-life-sciences-innovation-in-china/2024-11-09T21:31:25+08:00https://flcube.com/abbisko-therapeutics-receives-fda-approval-for-phase-i-study-of-fgfr4-inhibitor-absk012/2024-11-09T21:26:04+08:00https://flcube.com/daiichi-sankyo-and-alteogen-sign-300-million-deal-to-develop-subcutaneous-enhertu/2024-11-09T15:04:11+08:00https://flcube.com/dizal-pharmaceutical-submits-nda-to-fda-for-sunvozertinib-as-nsclc-therapy/2024-11-09T00:15:25+08:00https://flcube.com/sichuan-biokin-pharmaceutical-gets-fda-approval-for-phase-i-study-of-bl-m17d1-in-solid-tumors/2024-11-08T16:15:57+08:00https://flcube.com/mgi-tech-co-ltd-partners-with-human-cell-atlas-consortium-to-advance-cell-mapping/2024-11-08T16:14:48+08:00https://flcube.com/astrazeneca-confirms-executive-vice-president-leon-wangs-detention-in-china/2024-11-08T16:09:01+08:00https://flcube.com/jiangsu-kanion-pharmaceutical-to-acquire-xintrum-pharmaceuticals-for-rmb-270-million/2024-11-08T16:05:37+08:00https://flcube.com/ascletis-pharmas-asc47-showcases-promising-weight-loss-results-in-phase-i-clinical-trial/2024-11-08T15:59:54+08:00https://flcube.com/shanghai-henlius-biotech-partners-with-svax-to-boost-menat-regions-access-to-biological-drugs/2024-11-08T15:48:28+08:00https://flcube.com/johnson-johnson-medtechs-varipulse-platform-receives-fda-approval-for-atrial-fibrillation-treatment/2024-11-08T15:43:24+08:00https://flcube.com/bayer-ag-receives-fda-510k-clearance-for-medrad-centargo-ct-injection-system/2024-11-08T15:33:01+08:00https://flcube.com/sichuan-huiyu-pharmaceuticals-hyp-6589-receives-nmpa-approval-for-solid-tumor-clinical-trial/2024-11-08T15:27:43+08:00https://flcube.com/ascentage-pharmas-lisaftoclax-and-acelink-therapeutics-al01211-receive-fda-designations/2024-11-08T15:14:51+08:00https://flcube.com/askbios-ab-1003-receives-rare-pediatric-disease-and-orphan-drug-designations-from-fda/2024-11-08T15:03:38+08:00https://flcube.com/teva-pharmaceutical-expands-partnerships-in-chinas-one-health-sector-with-new-agreements/2024-11-08T14:53:40+08:00https://flcube.com/bayers-leap-forward-implementing-salesforce-on-alibaba-cloud-for-customer-engagement/2024-11-08T14:44:51+08:00https://flcube.com/cde-releases-technical-guidelines-for-pilot-registration-and-phased-manufacturing-of-adcs/2024-11-08T13:39:28+08:00https://flcube.com/shanghai-pharmaceuticals-meditrust-health-partners-with-eisai-for-comprehensive-patient-services/2024-11-08T13:26:32+08:00https://flcube.com/boehringer-ingelheim-partners-with-wuhan-union-hospital-to-enhance-clinical-research-and-development/2024-11-08T13:12:01+08:00https://flcube.com/nhsa-and-mca-boost-medical-assistance-with-enhanced-information-sharing-measures/2024-11-08T12:55:12+08:00https://flcube.com/hainan-haiyao-enters-jv-with-haikou-and-xenios-ag-to-advance-ecmo-technology/2024-11-08T12:49:07+08:00https://flcube.com/roches-lymphoma-therapy-columvi-receives-nmpa-approval-for-adult-patients-with-relapsed-dlbcl/2024-11-07T23:33:29+08:00https://flcube.com/eccogene-inc-secures-60-million-milestone-payment-from-astrazeneca-for-ecc5004-azd5004/2024-11-07T23:29:22+08:00https://flcube.com/eccogene-secures-exclusive-licensing-deal-with-astrazeneca-for-glp-1-agonist-ecc5004/2024-11-07T23:25:14+08:00https://flcube.com/sandoz-enters-euro-debt-market-with-2-1-billion-eurobond-issuance/2024-11-07T23:16:50+08:00https://flcube.com/janssen-presents-real-world-data-on-tremfyas-efficacy-in-treatment-resistant-psoriatic-arthritis/2024-11-07T23:13:51+08:00https://flcube.com/zhejiang-boner-medical-secures-over-rmb-800-million-in-pre-ipo-financing-for-strategic-expansion/2024-11-07T23:07:38+08:00https://flcube.com/immuneonco-biopharmaceuticals-timdarpacept-imm01-earns-orphan-drug-designation-for-cmml/2024-11-07T23:00:37+08:00https://flcube.com/lifetech-scientific-corporation-receives-nmpa-approval-for-peripheral-thrombus-suction-catheter/2024-11-07T22:55:01+08:00https://flcube.com/bayers-q3-2023-financial-report-a-mixed-bag-with-consumer-health-driving-growth/2024-11-07T22:50:14+08:00https://flcube.com/viatris-inc-reports-q3-2023-global-net-sales-growth-of-1-and-highlights-from-earnings-call/2024-11-07T22:43:48+08:00https://flcube.com/abbisko-therapeutics-cd73-inhibitor-absk051-clears-for-phase-i-clinical-trial-in-china/2024-11-07T22:38:11+08:00https://flcube.com/us-fda-approves-hutchmed-and-takedas-fruzaqla-for-metastatic-colorectal-cancer-treatment/2024-11-07T22:32:21+08:00https://flcube.com/suzhou-porton-biologics-partners-with-biomap-to-enhance-aav-vector-design-in-gene-therapy/2024-11-07T22:27:20+08:00https://flcube.com/belief-biomeds-bbm-d101-receives-fda-orphan-drug-and-pediatric-rare-disease-designations-for-dmd/2024-11-07T18:59:19+08:00https://flcube.com/sanofi-and-cathay-capital-forge-partnership-to-boost-sino-french-pharmaceutical-cooperation/2024-11-07T18:44:21+08:00https://flcube.com/eisai-and-ge-healthcare-sign-mou-at-ciie-to-collaborate-on-alzheimers-disease-solutions/2024-11-07T18:38:03+08:00https://flcube.com/lohmann-rauscher-partners-with-allmed-medical-products-at-ciie-for-medical-dressings/2024-11-07T18:31:50+08:00https://flcube.com/i-mab-appoints-sean-xi-yong-fu-as-permanent-ceo-effective-november-1-2024/2024-11-07T18:21:11+08:00https://flcube.com/novo-nordisk-reports-q3-2024-financials-with-24-yoy-revenue-growth/2024-11-07T18:09:36+08:00https://flcube.com/siemens-healthineers-ag-reports-fiscal-2024-results-with-targeted-revenue-growth/2024-11-07T17:43:20+08:00https://flcube.com/hutchmed-to-present-updated-data-from-solvleplenib-eslim-01-phase-iii-trial-at-ash-and-esmo-congress-2024/2024-11-07T17:23:23+08:00https://flcube.com/bayer-healthcare-partners-with-china-population-welfare-foundation-at-ciie-for-public-health-initiatives/2024-11-07T17:10:29+08:00https://flcube.com/medtronic-partners-with-china-resources-guangdong-pharmaceutical-at-ciie-for-medical-equipment-development/2024-11-07T17:03:56+08:00https://flcube.com/china-resources-guangdong-pharmaceutical-partners-with-bd-to-enhance-drug-and-device-distribution-in-gba/2024-11-07T16:58:00+08:00https://flcube.com/pfizers-talzenna-talazoparib-approved-by-chinas-nmpa-for-mcrpc-treatment/2024-11-07T16:42:44+08:00https://flcube.com/shouyao-holdings-adjusts-development-strategy-for-sy-1530-halts-monotherapy-clinical-trials/2024-11-07T16:36:11+08:00https://flcube.com/nanjing-leads-biolabs-secures-fda-orphan-drug-designation-for-lbl-034-in-multiple-myeloma-treatment/2024-11-07T16:23:53+08:00https://flcube.com/sanofis-dupixent-gains-ema-approval-for-eosinophilic-esophagitis-in-children/2024-11-07T16:11:03+08:00https://flcube.com/novartis-forges-partnerships-at-ciie-to-strengthen-radioligand-therapy-ecosystem-in-china/2024-11-07T15:44:28+08:00https://flcube.com/amgens-tavneos-receives-nmpa-approval-for-anca-associated-vasculitis-treatment-in-china/2024-11-07T15:27:37+08:00https://flcube.com/chinas-nhc-announces-initiative-to-boost-gerontology-medical-services/2024-11-07T15:23:41+08:00https://flcube.com/vantive-secures-collaborations-with-kertone-and-qiantang-longyue-at-ciie-for-dialysis-solutions/2024-11-07T15:16:51+08:00https://flcube.com/boston-scientific-launches-vercisie-genius-dbs-system-in-china-for-parkinsons-disease-treatment/2024-11-07T14:38:08+08:00https://flcube.com/merck-reports-q3-2023-financial-results-with-mixed-performance-across-segments/2024-11-07T12:52:45+08:00https://flcube.com/chinas-nmpa-grants-conditional-approval-for-juventas-car-t-therapy-inaticabtagene-autoleucel/2024-11-07T12:41:09+08:00https://flcube.com/chinas-nmpa-officially-seeks-membership-in-the-pharmaceutical-inspection-co-operation-scheme-pic-s/2024-11-07T12:34:39+08:00https://flcube.com/eli-lillys-zepbound-approved-by-fda-for-chronic-weight-management-in-adults/2024-11-07T12:25:46+08:00https://flcube.com/danaher-corporation-partners-with-chea-to-boost-oncology-centers-in-chinese-counties/2024-11-07T12:17:13+08:00https://flcube.com/yantai-dongcheng-pharmaceutical-gets-singapore-hsa-nod-for-phase-i-study-of-177lu-lnc1003/2024-11-07T12:05:34+08:00https://flcube.com/sanegenebio-partners-with-huadong-medicine-to-develop-rnai-therapeutics-for-metabolic-diseases/2024-11-07T12:01:10+08:00https://flcube.com/chongqing-lummy-pharmaceuticals-generic-ramosetron-passes-gqce-in-china/2024-11-07T11:48:34+08:00https://flcube.com/shanghai-qingyun-pharmaceutical-teams-up-with-organon-at-ciie-for-remeron-marketing/2024-11-07T11:43:13+08:00https://flcube.com/sino-medical-sciences-technology-secures-eu-mdr-approval-for-ht-supreme-drug-eluting-stent-system/2024-11-07T11:31:37+08:00https://flcube.com/biosmelt-pharma-partners-with-shenzhen-eureka-biotechnology-for-cell-and-gene-therapy-advancements/2024-11-07T11:22:42+08:00https://flcube.com/bayer-secures-multiple-procurement-deals-at-the-6th-ciie/2024-11-07T11:10:16+08:00https://flcube.com/ayer-partners-with-changzhou-qianhong-bio-pharma-to-advance-digestive-health-solutions/2024-11-07T11:03:48+08:00https://flcube.com/sirius-therapeutics-pursues-first-in-human-trial-for-srsd107-in-australia/2024-11-07T10:56:28+08:00https://flcube.com/establishment-labs-receives-nmpa-approval-for-motiva-silicone-gel-filled-breast-implants/2024-11-07T10:32:13+08:00https://flcube.com/astrazeneca-reports-q3-2023-revenue-growth-and-oncology-milestones/2024-11-07T10:25:07+08:00https://flcube.com/novartis-remibrutinib-meets-milestones-in-late-stage-chronic-spontaneous-urticaria-studies/2024-11-07T10:20:04+08:00https://flcube.com/cstone-pharmaceuticals-enters-licensing-agreement-with-allist-pharmaceuticals-for-gavreto-in-china/2024-11-07T10:16:34+08:00https://flcube.com/lundbeck-a-s-reports-7-yoy-revenue-increase-in-q3-2023-and-9-growth-for-the-first-three-quarters/2024-11-07T00:24:41+08:00https://flcube.com/lundbeck-secures-rights-to-bexicaserin-with-acquisition-of-longboard-pharmaceuticals/2024-11-07T00:09:26+08:00https://flcube.com/lundbecks-vyepti-migraine-treatment-available-at-sun-yat-sen-memorial-hospital-through-greater-bay-area-policy/2024-11-07T00:09:04+08:00https://flcube.com/sandoz-invests-in-new-biosimilars-and-penicillin-api-production-sites-in-europe/2024-11-07T00:05:52+08:00https://flcube.com/hansoh-pharmaceuticals-hs-10511-tablets-for-hypertrophic-cardiomyopathy-cleared-for-clinical-trials/2024-11-07T00:01:18+08:00https://flcube.com/chiesi-farmaceutici-and-shanghai-pharmaceutical-partner-on-distribution-at-ciie/2024-11-06T23:55:50+08:00https://flcube.com/alvotech-scores-fda-nod-for-interchangeable-high-concentration-biosimilar-to-humira/2024-11-06T23:53:10+08:00https://flcube.com/bayer-shifts-focus-of-recursion-pharmaceuticals-collaboration-to-precision-oncology/2024-11-06T23:41:12+08:00https://flcube.com/lizhu-pharmaceutical-cancels-chinext-ipo-opts-for-neeq-listing-for-subsidiary-lizhu-reagent/2024-11-06T23:37:45+08:00https://flcube.com/novo-nordisk-commits-over-dkk-42-billion-to-expand-chronic-disease-production-in-denmark/2024-11-06T23:32:15+08:00https://flcube.com/eli-lilly-chinas-president-benjamin-l-basil-to-depart-for-personal-reasons/2024-11-06T23:28:37+08:00https://flcube.com/clinical-research-on-raav-gene-drug-zs805-for-fabry-disease-launched-by-zhishan-weixin/2024-11-06T23:25:18+08:00https://flcube.com/beijing-aosaikangs-combo-therapy-for-nsclc-accepted-for-clinical-trial-by-nmpa/2024-11-06T23:14:20+08:00https://flcube.com/carsgen-therapeutics-presents-latest-car-t-data-at-ash-annual-meeting/2024-11-06T19:12:50+08:00https://flcube.com/huadong-medicine-co-ltd-receives-nmpa-approval-for-stelara-biosimilar-sailexin/2024-11-06T18:35:48+08:00https://flcube.com/northeast-pharmaceutical-to-acquire-majority-stake-in-dingcheng-peptide-source-for-rmb-186-8-million/2024-11-06T18:22:31+08:00https://flcube.com/ascentage-pharma-to-present-olverembatinib-and-lisaftoclax-clinical-data-at-ash-annual-meeting/2024-11-06T17:46:36+08:00https://flcube.com/cstone-pharmaceuticals-presents-cs5001-clinical-data-at-the-ash-annual-meeting/2024-11-06T17:36:53+08:00https://flcube.com/roche-to-showcase-40-abstracts-on-blood-disorders-at-ash-annual-meeting/2024-11-06T17:32:14+08:00https://flcube.com/china-medical-systems-opzelura-approved-in-hong-kong-for-non-segmental-vitiligo-treatment/2024-11-06T17:26:51+08:00https://flcube.com/legend-biotech-to-showcase-cartitude-4-trial-data-on-carvykti-at-ash-annual-meeting/2024-11-06T17:18:01+08:00https://flcube.com/shanghai-duoning-biotechnology-partners-with-branca-bunus-for-transfection-reagents-innovation/2024-11-06T16:03:24+08:00https://flcube.com/nmpa-draft-proposal-aims-to-strengthen-supervision-of-drug-entrusted-manufacturing/2024-11-06T15:40:07+08:00https://flcube.com/asieris-pharmaceuticals-receives-nmpa-approval-for-hexvix-apl-1706-in-bladder-cancer-diagnosis/2024-11-06T15:36:08+08:00https://flcube.com/frontier-biotechnologies-inc-gets-nmpa-approval-for-phase-ii-study-of-albuvirtide-as-hiv-therapy/2024-11-06T15:26:28+08:00https://flcube.com/fresenius-medical-care-reports-2-yoy-revenue-decrease-in-2024-q3-financial-results/2024-11-06T15:16:32+08:00https://flcube.com/novartis-pharma-ag-partners-with-legend-biotech-corp-for-car-t-therapies-in-1-1-billion-deal/2024-11-06T13:52:15+08:00https://flcube.com/nona-biosciences-partners-with-genequantum-healthcare-to-advance-drug-conjugate-discovery/2024-11-06T13:46:56+08:00https://flcube.com/autobio-diagnostics-expands-strategic-partnership-with-guorun-medical-supply-chain-services/2024-11-06T11:56:03+08:00https://flcube.com/bayer-withdraws-aliqopa-fda-filing-following-missed-phase-iii-endpoint/2024-11-06T11:45:41+08:00https://flcube.com/boehringer-ingelheim-and-scottish-enterprise-co-lead-gbp-4-3m-seed-funding-for-glox-therapeutics/2024-11-06T11:39:33+08:00https://flcube.com/anchordx-medical-partners-with-diacarta-for-global-molecular-diagnostics-development/2024-11-06T11:33:08+08:00https://flcube.com/sisram-medical-ltd-expands-asia-pacific-presence-with-new-direct-sales-office-in-japan/2024-11-06T11:27:19+08:00https://flcube.com/beijing-based-immupeutics-medicine-secures-tens-of-millions-in-pre-series-a-financing/2024-11-06T11:13:26+08:00https://flcube.com/serviers-tibsovo-receives-fda-approval-for-idh1-mutated-r-r-mds-expanding-indications/2024-11-06T11:09:01+08:00https://flcube.com/huadong-medicines-arcalyst-rilonacept-filing-for-capss-accepted-by-chinas-nmpa/2024-11-06T10:59:10+08:00https://flcube.com/astrazenecas-imfinzi-gains-nmpa-approval-for-first-line-cholangiocarcinoma-treatment/2024-11-06T10:48:38+08:00https://flcube.com/chinas-nmpa-accepts-eoc-pharma-groups-filing-for-vascepa-icosapent-ethyl-for-review/2024-11-06T10:44:34+08:00https://flcube.com/eli-lilly-clears-final-regulatory-hurdle-with-nrc-approval-for-point-biopharma-acquisition/2024-11-06T10:29:44+08:00https://flcube.com/merck-kgaa-outlines-expansion-plans-for-us-healthcare-market-with-anticipated-2025-drug-launches/2024-11-06T10:26:01+08:00https://flcube.com/hubei-topgene-biotechnology-and-shanghai-genechem-partner-on-drug-toxicological-safety-and-clinical-research/2024-11-06T10:21:14+08:00https://flcube.com/precedo-secures-over-rmb-100-million-in-financing-to-build-living-primary-cancer-cell-bank/2024-11-06T10:03:52+08:00https://flcube.com/yantai-dongcheng-pharmaceutical-and-eckert-ziegler-form-joint-venture-for-medical-isotopes/2024-11-06T10:01:57+08:00https://flcube.com/chinas-national-allied-procurement-office-announces-vbp-tender-for-medical-consumables-and-3d-printing-products/2024-11-06T09:56:27+08:00https://flcube.com/sansure-biotech-secures-ce-ivdr-certifications-for-chemiluminescence-analyzers-in-the-eu/2024-11-06T09:54:36+08:00https://flcube.com/huadong-medicine-co-ltd-secures-partnership-and-commercial-rights-for-yuyans-botulinum-toxin/2024-11-06T09:52:03+08:00https://flcube.com/zeiss-group-and-chinas-healthcare-cloud-collaborate-on-ophthalmic-services-in-china/2024-11-06T09:41:53+08:00https://flcube.com/eli-lillys-donanemab-on-track-for-priority-review-in-china-for-early-stage-alzheimers/2024-11-06T09:39:11+08:00https://flcube.com/casi-pharmaceuticals-reports-q3-2023-results-with-mixed-fortunes-and-positive-developments/2024-11-06T09:33:25+08:00https://flcube.com/astellas-pharma-acquires-propella-therapeutics-for-175-million-to-boost-prostate-cancer-treatment/2024-11-06T00:05:20+08:00https://flcube.com/novartis-acquires-hdac6-inhibitor-ckd-510-from-ckd-pharmaceutical-in-a-1-31-billion-deal/2024-11-06T00:02:18+08:00https://flcube.com/sinomab-biosciences-suciraslimab-ind-accepted-for-review-by-chinas-nmpa/2024-11-05T23:57:32+08:00https://flcube.com/shanghai-henlius-biotech-reports-84-0-yoy-revenue-growth-in-q3-2023-financials/2024-11-05T23:55:13+08:00https://flcube.com/sino-medical-sciences-technologys-ht-supreme-stent-gains-brazilian-market-approval/2024-11-05T23:51:05+08:00https://flcube.com/gileads-kite-expands-partnership-with-arcellx-for-innovative-cell-therapies/2024-11-05T23:46:27+08:00https://flcube.com/fujian-cosunters-covid-19-therapy-gst-hg171-ritonavir-nda-accepted-by-nmpa/2024-11-05T23:39:44+08:00https://flcube.com/alphamab-oncologys-jskn003-adc-promising-preliminary-data-in-advanced-solid-tumors/2024-11-05T23:15:31+08:00https://flcube.com/final-results-of-chinas-round-9-volume-based-procurement-tender-announced/2024-11-05T23:12:04+08:00https://flcube.com/cde-releases-76th-batch-of-chemical-generic-reference-preparations/2024-11-05T23:03:47+08:00https://flcube.com/yipinhong-pharmacys-ar882-shows-promise-in-gout-treatment-in-phase-ii-study/2024-11-05T23:01:33+08:00https://flcube.com/easton-pharmaceutical-receives-fda-approval-for-generic-nalmefene/2024-11-05T22:57:58+08:00https://flcube.com/university-of-hong-kong-to-host-infectious-disease-labs-by-uns-vaccine-institute-and-cambridge-university/2024-11-05T22:54:28+08:00https://flcube.com/visen-pharmaceuticals-reports-positive-phase-ii-results-for-transcon-cnp-in-achondroplasia/2024-11-05T22:41:06+08:00https://flcube.com/jiangxi-rimag-group-eyes-hong-kong-ipo-to-expand-medical-imaging-services/2024-11-05T22:37:43+08:00https://flcube.com/vertex-pharmaceuticals-and-crispr-therapeutics-receive-conditional-approval-for-crispr-gene-editing-therapy/2024-11-05T22:34:54+08:00https://flcube.com/q32-bio-reclaims-development-rights-to-anti-il-7r%ce%b1-biologic-from-amgen/2024-11-05T22:29:50+08:00https://flcube.com/beijing-mabworks-biotechs-ipo-application-accepted-by-beijing-stock-exchange/2024-11-05T16:26:13+08:00https://flcube.com/insilico-medicines-ai-generated-drug-candidate-ism001-055-shows-positive-phase-ii-results-in-ipf-study/2024-11-05T16:14:25+08:00https://flcube.com/takeda-reports-5-yoy-revenue-growth-and-upgrades-forecasts-for-fiscal-2024/2024-11-05T15:37:51+08:00https://flcube.com/windtree-therapeutics-secures-hong-kong-patent-for-istaroxime-heart-failure-treatment/2024-11-05T15:27:05+08:00https://flcube.com/boston-scientific-corporation-announces-acquisition-of-cortex-inc/2024-11-05T15:07:25+08:00https://flcube.com/chinas-nmpa-issues-guidelines-for-domestic-manufacturing-of-imported-medical-devices/2024-11-05T14:50:27+08:00https://flcube.com/novo-nordisk-secures-global-licensing-agreement-with-ascendis-pharma-for-transcon-technology/2024-11-05T14:28:34+08:00https://flcube.com/mirxes-holding-company-updates-ipo-prospectus-with-2024-financials/2024-11-05T14:21:19+08:00https://flcube.com/insilico-medicine-secures-revolving-loan-facility-with-hsbc-to-boost-drug-discovery-pipeline/2024-11-05T14:13:11+08:00https://flcube.com/shanghai-heartcare-medical-technology-receives-nmpa-approval-for-embolization-stent/2024-11-05T14:04:58+08:00https://flcube.com/boehringer-ingelheim-partners-with-broad-institute-for-mental-health-treatments/2024-11-05T13:36:47+08:00https://flcube.com/nmpa-grants-marketing-license-to-abonisi-medical-technologys-knee-joint-prosthesis-system/2024-11-05T13:18:56+08:00https://flcube.com/isap-biotech-secures-fda-ind-approval-for-isap-0909-for-bladder-cancer-imaging/2024-11-05T13:11:11+08:00https://flcube.com/china-grand-pharmaceutical-completes-phase-iii-clinical-study-for-post-cataract-surgery-treatment/2024-11-05T12:53:01+08:00https://flcube.com/111-inc-appoints-yang-luke-chen-to-board-of-directors-following-resignation-of-dr-lian-yong-chen/2024-11-05T12:44:50+08:00https://flcube.com/jiangsu-aidea-pharmaceutical-partners-with-fidson-healthcare-for-hiv-aids-treatments-in-nigeria/2024-11-05T11:54:06+08:00https://flcube.com/ge-healthcares-shanghai-innovation-hub-onboards-initial-start-ups/2024-11-05T11:49:58+08:00https://flcube.com/wuxi-biologics-subsidiary-wuxi-xdc-lists-on-hong-kong-stock-exchange/2024-11-05T11:38:17+08:00https://flcube.com/winning-health-partners-with-shanghai-seventh-peoples-hospital-on-medical-ai-services/2024-11-05T11:33:44+08:00https://flcube.com/thermo-fisher-scientific-expands-partnership-with-sangon-biotech-to-include-gc-ms/2024-11-05T11:31:10+08:00https://flcube.com/usynova-pharmaceuticals-inks-licensing-deal-with-astrazeneca-for-krasg12d-inhibitor-ua022/2024-11-05T11:28:38+08:00https://flcube.com/ascentage-pharma-secures-additional-indication-approval-for-olverembatinib-from-nmpa/2024-11-05T11:23:44+08:00https://flcube.com/cspc-pharmaceutical-group-receives-nmpa-approval-for-phase-ii-clinical-study-of-almb-0168/2024-11-05T11:15:38+08:00https://flcube.com/fosun-pharmaceutical-secures-clinical-trial-approvals-for-vt-101-in-china-and-the-us/2024-11-05T11:08:24+08:00https://flcube.com/national-reimbursement-drug-list-negotiations-and-bidding-process-conclude/2024-11-05T11:05:32+08:00https://flcube.com/amgen-partners-with-postera-for-small-molecule-drug-discovery-initiative/2024-11-05T10:59:53+08:00https://flcube.com/baheal-pharmaceutical-group-enters-commercialization-partnership-with-guangdong-ruidio-technology/2024-11-05T10:57:13+08:00https://flcube.com/pfizer-and-astellas-pharma-secure-fda-approval-for-xtandi-in-high-risk-non-metastatic-prostate-cancer/2024-11-05T10:53:59+08:00https://flcube.com/yifan-pharmaceuticals-subsidiary-receives-fda-approval-for-ryzneuta-f-627/2024-11-05T10:50:45+08:00https://flcube.com/astrazeneca-receives-fda-approval-for-truqap-in-hr-positive-her2-negative-breast-cancer/2024-11-05T10:43:47+08:00https://flcube.com/bayer-initiates-us-recall-of-trk-inhibitor-vitrakvi-due-to-mold-contamination/2024-11-04T22:54:34+08:00https://flcube.com/belgium-bans-ozempic-for-weight-loss-as-global-shortage-persists/2024-11-04T22:51:17+08:00https://flcube.com/asia-regenerative-medicine-secures-pre-series-a-financing-for-bioartificial-organ-development/2024-11-04T22:32:53+08:00https://flcube.com/cspc-pharmaceuticals-glumetinib-earns-breakthrough-therapy-designation-in-china/2024-11-04T22:30:33+08:00https://flcube.com/astrazeneca-launches-evinova-to-enhance-global-clinical-development-with-digital-health-solutions/2024-11-04T22:21:05+08:00https://flcube.com/emas-chmp-endorses-bristol-myers-squibbs-car-t-therapy-abecma-for-multiple-myeloma/2024-11-04T22:08:31+08:00https://flcube.com/suzhou-porton-biologics-partners-with-asclepius-technology-for-nk-cell-project/2024-11-04T22:00:05+08:00https://flcube.com/shanghai-pharmaceuticals-chairman-zhou-jun-resigns-amid-investigation/2024-11-04T21:55:17+08:00https://flcube.com/viva-biotech-holdings-secures-nearly-usd-210-million-in-financing-round/2024-11-04T21:51:21+08:00https://flcube.com/jiangsu-aidea-pharmaceuticals-ainuovirine-receives-priority-review-status-from-cde/2024-11-04T21:48:51+08:00https://flcube.com/medilink-therapeutics-yl201-earns-orphan-drug-designation-for-esophageal-cancer/2024-11-04T21:44:37+08:00https://flcube.com/chiesi-farmaceutici-acquires-global-rights-to-haisco-pharmaceuticals-hsk31858-for-respiratory-diseases/2024-11-04T21:42:16+08:00https://flcube.com/fosun-pharmaceuticals-us-subsidiary-partners-with-treehill-partners-for-clinical-stage-investments/2024-11-04T21:35:58+08:00https://flcube.com/hunan-warrant-pharmaceuticals-zg-001-approved-for-clinical-trial-by-nmpa/2024-11-04T21:30:10+08:00https://flcube.com/vivavision-biotech-inc-receives-fda-approval-for-vvn461-phase-ii-clinical-trial/2024-11-04T21:27:23+08:00https://flcube.com/anheart-therapeutics-and-innovent-biologics-file-taletrectinib-for-marketing-approval-in-china/2024-11-04T21:25:05+08:00https://flcube.com/genentech-and-nvidia-collaborate-to-advance-drug-discovery-with-ai/2024-11-04T21:21:52+08:00https://flcube.com/oneness-biotech-and-microbio-partner-with-cr-double-crane-for-fespixon-commercialization-in-china/2024-11-04T21:10:57+08:00https://flcube.com/janssen-submits-indication-extension-application-to-fda-for-rybrevant-in-nsclc-treatment/2024-11-04T18:48:22+08:00https://flcube.com/dizal-pharmaceutical-and-wuxi-gaofa-investment-to-establish-joint-venture-for-auto-immune-disease-treatments/2024-11-04T18:39:30+08:00https://flcube.com/fosun-pharmaceuticals-fcn-437c-filing-accepted-for-review-by-chinas-nmpa/2024-11-04T18:30:19+08:00https://flcube.com/merck-kgaa-completes-second-phase-of-biologics-testing-center-expansion-in-china/2024-11-04T18:24:14+08:00https://flcube.com/shanghai-rmx-biopharma-and-pharmaengine-ink-distribution-deal-for-liporaxel-in-taiwan/2024-11-04T16:52:13+08:00https://flcube.com/chinas-national-allied-procurement-office-launches-10th-vbp-tender-round-information-filing/2024-11-04T16:01:11+08:00https://flcube.com/nmpa-releases-84th-batch-of-reference-drugs-for-gqce-and-first-batch-stripped-of-status/2024-11-04T15:52:22+08:00https://flcube.com/jj-medtech-completes-pilot-enrollment-for-omny-af-study-on-atrial-fibrillation-treatment/2024-11-04T15:44:15+08:00https://flcube.com/innorna-co-ltd-receives-fda-rare-pediatric-disease-designation-for-mrna-drug-in015/2024-11-04T14:58:55+08:00https://flcube.com/teva-pharmaceutical-reports-positive-phase-iii-results-for-tev-749-in-schizophrenia-trial/2024-11-04T14:41:19+08:00https://flcube.com/neurodawn-pharmaceutical-secures-hundreds-of-millions-in-series-c-financing/2024-11-04T14:19:38+08:00https://flcube.com/suzhou-basecare-medicals-bka210-receives-marketing-approval-in-jiangsu-province/2024-11-04T14:08:30+08:00https://flcube.com/reprogenix-secures-over-rmb100-million-in-series-a-financing-led-by-china-venture-capital/2024-11-04T13:55:39+08:00https://flcube.com/novo-nordisks-semaglutide-meets-primary-endpoints-in-essence-phase-iii-study-for-mash/2024-11-04T13:44:56+08:00https://flcube.com/jiuzhitang-co-ltd-announces-clinical-clearance-for-volagidemab-in-type-1-diabetes/2024-11-04T13:05:03+08:00https://flcube.com/shenzhen-chipscreen-biosciences-receives-nmpa-approval-for-chiauranib-clinical-study/2024-11-04T12:51:13+08:00https://flcube.com/innovent-biologics-halts-subscription-agreement-with-lostrancos-ventures/2024-11-04T12:32:21+08:00https://flcube.com/chinas-cde-releases-88th-batch-of-reference-preparations-for-generic-drug-evaluation/2024-11-04T12:15:33+08:00https://flcube.com/scg-cell-therapys-scg101-receives-tacit-approval-for-cholangiocarcinoma-clinical-trial-in-china/2024-11-04T12:03:23+08:00https://flcube.com/akeso-biopharmas-cadonilimab-meets-primary-endpoint-in-phase-iii-cervical-cancer-study/2024-11-04T11:59:56+08:00https://flcube.com/remegens-telitacicept-receives-full-approval-for-systemic-lupus-erythematosus-in-china/2024-11-04T11:49:58+08:00https://flcube.com/boehringer-ingelheim-acquires-t3-pharmaceuticals-to-boost-immuno-oncology-portfolio/2024-11-04T11:46:46+08:00https://flcube.com/bayer-halts-late-stage-trial-for-asundexian-after-underperformance/2024-11-04T11:43:42+08:00https://flcube.com/brii-biosciences-brii-179-vaccine-on-track-for-breakthrough-therapy-designation-in-china/2024-11-04T11:39:29+08:00https://flcube.com/venus-medtech-partners-with-valgen-holding-on-dragonfly-valve-system/2024-11-04T11:33:33+08:00https://flcube.com/oculotronics-secures-pre-series-a-funding-for-ophthalmic-surgical-robotics/2024-11-04T11:27:33+08:00https://flcube.com/sumitomo-pharma-receives-chinese-approval-for-xenleta-to-treat-pneumonia/2024-11-04T11:24:43+08:00https://flcube.com/gilead-announces-low-carbon-bronchodilator-study-for-h1-2024/2024-11-04T11:18:38+08:00https://flcube.com/simcere-pharmaceutical-secures-rights-to-develop-rademikibart-in-china/2024-11-04T01:10:43+08:00https://flcube.com/bayer-invests-usd-130-million-in-parenteral-drugs-manufacturing-site-in-germany/2024-11-04T01:07:28+08:00https://flcube.com/novo-nordisk-invests-dkk-16-billion-to-expand-french-production-facility/2024-11-04T01:04:56+08:00https://flcube.com/european-commission-proposes-overhaul-of-pharmaceutical-legislation/2024-11-04T00:59:02+08:00https://flcube.com/pyrotech-biotechnologys-ptt-936-gets-us-fda-clinical-trial-approval/2024-11-04T00:56:49+08:00https://flcube.com/boehringer-ingelheim-and-eli-lillys-jardiance-receives-nmpa-approval-for-ckd-treatment/2024-11-04T00:51:37+08:00https://flcube.com/zhejiang-huanqing-medical-technology-secures-series-a-financing-for-heart-failure-innovations/2024-11-04T00:32:57+08:00https://flcube.com/boehringer-ingelheim-and-eli-lilly-secure-nmpa-approval-for-jardiance-in-chronic-kidney-disease/2024-11-04T00:30:22+08:00https://flcube.com/true-health-secures-over-rmb-100-million-in-series-b-financing-for-surgical-robot-development/2024-11-04T00:24:48+08:00https://flcube.com/micurx-pharmaceuticals-secures-nmpa-approval-for-mrx-4-and-contezolid-combination-therapy/2024-11-04T00:22:43+08:00https://flcube.com/c2-pharma-secures-c-dmf-approval-for-pilocarpine-nitrate-api/2024-11-04T00:16:24+08:00https://flcube.com/chinas-nhsa-issues-guidelines-to-strengthen-medical-pricing-and-procurement-credit-ratings/2024-11-03T22:55:55+08:00https://flcube.com/dxvx-secures-license-for-ovm-200-anti-cancer-vaccine-from-oxford-vacmedix/2024-11-03T22:54:00+08:00https://flcube.com/kingwise-partners-with-truking-technology-for-gynecological-tumor-gene-therapy-facilities/2024-11-03T22:52:18+08:00https://flcube.com/takedas-takecab-receives-nmpa-approval-for-helicobacter-pylori-eradication-in-china/2024-11-03T22:49:41+08:00https://flcube.com/fujian-cosunters-oral-covid-19-therapy-receives-conditional-approval-in-china/2024-11-03T22:47:13+08:00https://flcube.com/sichuan-kelun-pharmaceuticals-ret-inhibitor-a400-earns-fda-orphan-drug-designation/2024-11-03T22:43:37+08:00https://flcube.com/yantai-dongcheng-pharmaceutical-gets-green-light-for-prostate-cancer-diagnostic-drug-trial/2024-11-03T22:37:33+08:00https://flcube.com/orbusneich-medical-group-to-acquire-majority-stake-in-indonesian-distributor-pt-revass-utama-medika/2024-11-03T22:34:43+08:00https://flcube.com/kintor-pharmaceuticals-kx-826-shows-promising-results-in-phase-iii-aga-clinical-trial/2024-11-03T22:32:23+08:00https://flcube.com/eirgenixs-trastuzumab-biosimilar-receives-european-commission-marketing-approval/2024-11-03T22:29:27+08:00https://flcube.com/broncus-medical-and-hangzhou-norchant-terminate-licensing-agreement-with-cancellation-fee/2024-11-03T22:26:42+08:00https://flcube.com/fda-raises-concerns-over-research-conditions-at-roches-genentech-trial-site/2024-11-03T22:22:52+08:00https://flcube.com/jiangxi-jemincare-group-secures-nmpa-approval-for-generic-ibrance-capsules/2024-11-03T22:19:46+08:00https://flcube.com/jiangxi-jemincare-group-secures-clinical-trial-approvals-for-six-drugs-in-china-and-the-us/2024-11-03T22:15:37+08:00https://flcube.com/chinas-cde-releases-draft-guidelines-for-decentralized-trials-in-rare-disease-drug-development/2024-11-03T22:13:11+08:00https://flcube.com/abbvie-sues-to-protect-rinvoq-from-generic-competition-in-the-us-market/2024-11-03T22:10:48+08:00https://flcube.com/novo-nordisk-sets-february-2024-launch-for-wegovy-in-japan-expanding-into-asia/2024-11-03T22:06:13+08:00https://flcube.com/jenscare-scientifics-lux-valve-plus-shows-positive-one-year-results-in-travel-ii-study/2024-11-03T21:25:16+08:00https://flcube.com/national-reimbursement-drug-list-nrdl-negotiations-conclude-with-lower-generic-drug-approval-rate/2024-11-03T21:23:40+08:00https://flcube.com/astrazeneca-china-president-leon-wang-involved-in-chinese-investigation-amid-industry-probes/2024-11-03T21:18:17+08:00https://flcube.com/shenzhen-chipscreen-biosciences-tivozanib-secures-nmpa-approval-for-es-sclc-phase-iii-trial/2024-11-03T21:06:25+08:00https://flcube.com/novartis-trispecific-antibody-pit565-secures-nmpa-approval-for-clinical-trial/2024-11-03T20:53:32+08:00https://flcube.com/dupixent-by-sanofi-and-regeneron-approved-by-fda-for-eosinophilic-esophagitis-in-younger-pediatric-patients/2024-11-03T17:36:38+08:00https://flcube.com/regenerons-linvoseltamab-faces-fda-complete-response-letter-awaiting-reinspection-of-manufacturer/2024-11-03T17:36:24+08:00https://flcube.com/regeneron-secures-eu-approval-for-ordspono-its-first-bispecific-antibody/2024-11-03T17:36:09+08:00https://flcube.com/dupixent-secures-back-to-back-copd-approvals-from-us-fda-and-china-nmpa/2024-11-03T17:35:54+08:00https://flcube.com/dupixent-trial-success-reinforces-potential-in-moderate-to-severe-copd-treatment/2024-11-03T17:35:43+08:00https://flcube.com/regeneron-pharmaceuticals-reports-11-yoy-revenue-growth-in-q3-2024/2024-11-03T17:34:46+08:00https://flcube.com/abbvies-epcoritamab-earns-ema-review-and-fda-breakthrough-designation-for-follicular-lymphoma/2024-11-03T17:31:15+08:00https://flcube.com/astrazeneca-to-open-rd-center-in-hong-kong-focusing-on-cell-and-gene-therapies/2024-11-03T17:28:29+08:00https://flcube.com/bayer-faces-backlash-after-bond-sale-preceding-late-stage-pipeline-failure/2024-11-03T17:25:50+08:00https://flcube.com/everest-medicines-nefecon-for-igan-receives-nmpa-approval-in-china/2024-11-03T17:23:32+08:00https://flcube.com/beijing-ql-biopharmaceutical-boosts-pipeline-with-rmb-200-million-series-b-round/2024-11-03T17:21:13+08:00https://flcube.com/henlius-biotech-gets-fda-clearance-for-clinical-study-of-pd-l1-targeting-adc-hlx43/2024-11-03T17:19:12+08:00https://flcube.com/cspc-pharmaceutical-gets-nmpa-green-light-for-syh2038-solid-tumor-study/2024-11-03T17:16:36+08:00https://flcube.com/abbisko-therapeutics-launches-phase-ii-trial-for-pimocitinib-in-advanced-pancreatic-cancer/2024-11-03T17:14:25+08:00https://flcube.com/xiamen-inno-medical-partners-with-olympus-to-advance-ai-in-digestive-endoscopy/2024-11-03T17:11:55+08:00https://flcube.com/jenscare-reports-positive-one-year-outcomes-for-lux-valve-in-tricuspid-valve-replacement-study/2024-11-03T17:10:07+08:00https://flcube.com/coherus-biosciences-sets-price-for-pd-1-inhibitor-loqtorzi-at-8892-03-offering-20-discount-compared-to-keytruda/2024-11-03T17:05:25+08:00https://flcube.com/pfizer-enters-strategic-alliance-with-guangdong-government-to-boost-biomedicine-rd/2024-11-03T15:48:50+08:00https://flcube.com/bayer-partners-with-hurdle-to-launch-saliva-based-age-tests-in-global-e-commerce/2024-11-03T15:46:46+08:00https://flcube.com/chinas-pharma-distribution-market-grows-steadily-in-2022-driven-by-retail-sales-surge/2024-11-03T14:22:38+08:00https://flcube.com/blue-sail-medical-and-china-national-medical-device-forge-strategic-partnership-for-growth/2024-11-03T13:12:02+08:00https://flcube.com/alibaba-health-reports-12-7-revenue-growth-in-h1-2023-driven-by-pharmaceutical-and-digital-services/2024-11-03T13:09:09+08:00https://flcube.com/jw-therapeutics-secures-priority-review-for-carteyva-in-relapsed-refractory-mantle-cell-lymphoma/2024-11-03T13:07:11+08:00https://flcube.com/lees-pharmaceutical-secures-nmpa-approval-for-adasuve-pioneering-loxapine-inhaler-for-agitation/2024-11-03T13:03:17+08:00https://flcube.com/ak-medical-holdings-receives-nmpa-approval-for-hip-surgery-navigation-system-ibot/2024-11-03T13:00:34+08:00https://flcube.com/gracell-biotechnologies-gets-fda-green-light-for-fastcar-t-therapy-in-systemic-lupus-erythematosus/2024-11-03T12:57:30+08:00https://flcube.com/mabwell-bioscience-enters-thai-market-with-licensing-deal-with-innobic/2024-11-03T12:50:57+08:00https://flcube.com/taihe-weiye-biotechnology-secures-rmb-300-million-in-series-a-financing-to-expand-production/2024-11-03T12:49:03+08:00https://flcube.com/takeda-reinforces-takeda-spark-incubator-program-with-expanded-partnerships-in-china/2024-11-03T12:47:09+08:00https://flcube.com/novocure-restructures-and-prioritizes-pipeline-amid-anticipated-nsclc-approval/2024-11-03T12:13:28+08:00https://flcube.com/abbvies-telisotuzumab-vedotin-shows-promising-results-in-nsclc-phase-2-trial/2024-11-03T12:10:26+08:00https://flcube.com/boehringer-ingelheim-partners-with-phenomic-ai-to-target-stroma-rich-cancers/2024-11-03T12:08:15+08:00https://flcube.com/asieris-pharmaceuticals-hexvix-for-bladder-cancer-accepted-for-review-by-chinas-nmpa/2024-11-03T12:03:47+08:00https://flcube.com/jiangxi-jemincares-kras-inhibitor-earns-breakthrough-designation-from-chinas-cde-for-nsclc/2024-11-03T12:01:39+08:00https://flcube.com/eli-lilly-partners-with-prism-biolab-to-discover-peptide-mimicking-small-molecule-inhibitors/2024-11-03T11:59:08+08:00https://flcube.com/roches-mosunetuzumab-and-anhearts-taletrectinib-poised-for-priority-review-in-china/2024-11-03T11:56:19+08:00https://flcube.com/chinas-cde-expands-market-approval-services-with-two-new-regional-windows/2024-11-03T11:54:00+08:00https://flcube.com/sinocelltechs-pd-1-inhibitor-sct-i10a-for-hnscc-accepted-for-nmpa-review/2024-11-03T11:52:27+08:00https://flcube.com/bosscome-science-technology-secures-series-a-funding-for-precision-medical-navigation-systems/2024-11-03T11:49:21+08:00https://flcube.com/nmpa-approves-tingsn-technologys-disposable-intracardiac-ultrasound-diagnostic-catheter/2024-11-03T11:46:47+08:00https://flcube.com/everest-medicines-nefecon-nda-for-igan-accepted-for-review-in-south-korea/2024-11-03T11:44:21+08:00https://flcube.com/cloudr-partners-with-yangtze-river-pharmaceutical-to-digitize-chronic-disease-marketing/2024-11-03T11:41:55+08:00https://flcube.com/car-t-cell-therapy-stocks-plunge-as-fda-investigates-cancer-reports-linked-to-treatments/2024-11-03T11:37:22+08:00https://flcube.com/concentra-biosciences-targets-china-based-biotech-lianbio-in-unsolicited-takeover-bid/2024-11-03T11:33:29+08:00https://flcube.com/chinas-state-council-unveils-comprehensive-plan-to-boost-beijings-healthcare-sector/2024-11-03T02:00:07+08:00https://flcube.com/bayer-partners-with-crossbay-medical-to-enhance-hormonal-ius-delivery-system/2024-11-03T01:58:13+08:00https://flcube.com/johnson-johnson-acquires-laminar-for-400-million-to-enhance-heart-rhythm-solutions/2024-11-03T01:55:54+08:00https://flcube.com/yingli-pharma-enrolls-first-patient-in-phase-i-study-for-kras-inhibitor-yl-17231-at-md-anderson/2024-11-03T01:53:57+08:00https://flcube.com/akesos-ak111-achieves-key-efficacy-milestones-in-phase-iii-trial-for-plaque-psoriasis/2024-11-03T01:49:02+08:00https://flcube.com/sichuan-kelun-biotech-to-present-promising-phase-ii-results-for-skb264-in-mtnbc-at-sabcs-2023/2024-11-03T01:46:55+08:00https://flcube.com/tg-immunopharma-secures-u-s-fda-ind-approval-for-promising-mab-tgi-5-targeting-multiple-cancers/2024-11-03T01:44:03+08:00https://flcube.com/insilico-medicine-launches-clinical-study-for-first-in-class-phd-inhibitor-ism5411-in-ibd/2024-11-03T01:42:16+08:00https://flcube.com/simcere-secures-nmpa-approval-for-edaravone-sublingual-tablets-targeting-post-stroke-cognitive-impairment/2024-11-03T01:26:43+08:00https://flcube.com/everest-medicines-reports-positive-phase-iii-results-for-velsipity-in-ulcerative-colitis/2024-11-03T01:24:50+08:00https://flcube.com/acotec-secures-fda-ide-approval-for-acoart-litos-paclitaxel-coated-balloon-catheter/2024-11-03T01:22:50+08:00https://flcube.com/perpetual-medicines-launches-with-8-million-seed-round-led-by-chengwei-capital/2024-11-03T01:20:14+08:00https://flcube.com/valgen-secures-nmpa-approval-for-chinas-first-transcatheter-mitral-valve-clamp-system/2024-11-03T01:15:55+08:00https://flcube.com/ambio-gains-fda-approval-for-generic-forteo-challenging-eli-lillys-osteoporosis-market/2024-11-03T01:13:42+08:00https://flcube.com/pfizers-danuglipron-phase-iib-trial-achieves-weight-loss-goals-amid-tolerability-concerns/2024-11-03T01:04:12+08:00https://flcube.com/everest-medicines-secures-ind-review-for-zetomipzomib-in-china/2024-11-03T01:02:06+08:00https://flcube.com/sunshine-guojians-ssgj-608-meets-phase-iii-efficacy-endpoints-in-psoriasis-trial/2024-11-03T00:59:35+08:00https://flcube.com/novartis-invests-usd-86-4-million-in-new-radiotherapy-facility-in-china/2024-11-03T00:57:29+08:00https://flcube.com/abbvie-to-acquire-immunogen-for-usd-10-1-billion-expanding-oncology-portfolio/2024-11-03T00:55:38+08:00https://flcube.com/sanegenebio-secures-over-usd-80-million-in-series-a-funding-to-advance-rnai-therapeutics/2024-11-03T00:49:42+08:00https://flcube.com/shanghai-junshis-loqtorzi-enters-australian-market-approval-process-for-nasopharyngeal-carcinoma/2024-11-03T00:47:17+08:00https://flcube.com/carsgen-therapeutics-secures-u-s-fda-approval-for-ct071-clinical-trials-in-multiple-myeloma/2024-11-03T00:44:48+08:00https://flcube.com/nona-biosciences-partners-with-lycia-therapeutics-to-advance-lytac-platform-for-novel-therapies/2024-11-03T00:41:01+08:00https://flcube.com/fda-investigates-safety-of-china-made-plastic-syringes-due-to-quality-concerns/2024-11-03T00:35:25+08:00https://flcube.com/boehringer-ingelheim-partners-with-shanghai-handu-pharma-to-enhance-oral-medication-delivery/2024-11-03T00:33:10+08:00https://flcube.com/gedeon-richter-acquires-rights-to-mithras-contraceptive-and-menopause-treatments-for-chinese-market/2024-11-03T00:30:31+08:00https://flcube.com/aspen-pharmacare-holdings-to-boost-china-presence-with-full-acquisition-of-sandozs-subsidiary/2024-11-03T00:28:02+08:00https://flcube.com/astrazeneca-halts-late-stage-trials-for-lokelma-in-hyperkalemia-due-to-timing-and-event-rate-issues/2024-11-03T00:24:18+08:00https://flcube.com/worg-pharmaceuticals-gets-fda-approval-for-phase-ii-graves-disease-study/2024-11-03T00:14:53+08:00https://flcube.com/nanchang-baiji-pharmaceuticals-budesonide-nasal-spray-approved-by-chinas-nmpa/2024-11-03T00:13:04+08:00https://flcube.com/eli-lillys-jaypirca-receives-fda-accelerated-approval-for-chronic-lymphocytic-leukemia/2024-11-03T00:06:28+08:00https://flcube.com/autobio-diagnostics-and-china-national-medical-device-form-strategic-partnership/2024-11-03T00:04:11+08:00https://flcube.com/luye-pharmas-lurbinectedin-for-metastatic-sclc-wins-macau-regulatory-nod/2024-11-03T00:00:24+08:00https://flcube.com/yantai-dongcheng-pharmaceutical-gets-nmpa-green-light-for-fap-targeting-radiotherapeutic-drug/2024-11-02T23:58:14+08:00https://flcube.com/tonghua-dongbao-pharmaceuticals-secures-nmpa-approval-for-biosimilar-liraglutide/2024-11-02T23:55:11+08:00https://flcube.com/simcere-pharmaceuticals-sim0501-receives-fda-approval-for-advanced-solid-tumor-clinical-trial/2024-11-02T23:45:50+08:00https://flcube.com/wuxi-biologics-shares-plunge-22-on-slower-cdmo-industry-growth-and-revenue-shortfall/2024-11-02T23:43:05+08:00https://flcube.com/abbisko-therapeutics-strikes-licensing-deal-with-merck-kgaa-for-csf-1r-inhibitor-pimicotinib/2024-11-02T23:41:05+08:00https://flcube.com/pfizer-allegedly-disbands-prevenar-13-team-in-china-amid-industry-competition/2024-11-02T23:38:20+08:00https://flcube.com/novartis-fabhalta-wins-fda-nod-as-first-in-class-treatment-for-paroxysmal-nocturnal-hemoglobinuria/2024-11-02T23:35:37+08:00https://flcube.com/abbvie-partners-with-bighat-biosciences-to-develop-next-gen-antibodies-for-oncology-and-neuroscience/2024-11-02T23:32:46+08:00https://flcube.com/jj-forecasts-5-7-cagr-through-2030-driven-by-innovative-medicine-and-device-growth/2024-11-02T22:34:38+08:00https://flcube.com/china-medical-systems-methotrexate-injection-receives-nmpa-review-for-rheumatoid-arthritis-indication/2024-11-02T22:32:12+08:00https://flcube.com/sinocare-incs-blood-glucose-monitoring-system-earns-us-fda-approval/2024-11-02T22:30:09+08:00https://flcube.com/huadong-medicine-gets-nmpa-green-light-for-sirolimus-real-world-study-in-pediatric-epilepsy/2024-11-02T22:27:48+08:00https://flcube.com/sino-biopharmaceutical-initiates-phase-i-trial-for-hepatitis-b-sirna-drug-tqa3038/2024-11-02T22:25:11+08:00https://flcube.com/jingxin-pharmaceuticals-didaxini-gains-nmpa-approval-as-category-1-drug/2024-11-02T22:22:44+08:00https://flcube.com/biocytogen-pharmaceuticals-secures-us-patent-for-fully-human-antibody-mice-platform-renmab/2024-11-02T21:56:36+08:00https://flcube.com/chinas-betta-pharmaceuticals-advances-cft8919-for-egfr-mutated-nsclc-after-nmpa-approval/2024-11-02T21:53:37+08:00https://flcube.com/ascletis-pharmas-denifanstat-advances-to-phase-iii-for-severe-acne-vulgaris-treatment/2024-11-02T21:50:26+08:00https://flcube.com/sino-medical-secures-market-approval-in-taiwan-for-nc-rockstar-coronary-catheter/2024-11-02T21:47:03+08:00https://flcube.com/novartis-reports-kisqali-success-in-reducing-recurrence-risk-in-early-breast-cancer/2024-11-02T00:57:03+08:00https://flcube.com/hutchmeds-sovleplenib-set-for-priority-review-in-china-for-chronic-immune-thrombocytopenia/2024-11-02T00:56:16+08:00https://flcube.com/trinomabs-tnm002-antitetanus-monoclonal-antibody-filing-accepted-for-review-in-china/2024-11-02T00:53:37+08:00https://flcube.com/eli-lilly-seeks-approval-for-pirtobrutinib-in-china-for-relapsed-mantle-cell-lymphoma/2024-11-02T00:49:16+08:00https://flcube.com/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion-strengthening-neuroscience-portfolio/2024-11-02T00:47:00+08:00https://flcube.com/shenzhen-targetrxs-tgrx-678-set-to-receive-breakthrough-therapy-designation-for-cml-ap/2024-11-02T00:44:46+08:00https://flcube.com/quinovare-partners-with-aim-vaccine-to-enhance-vaccine-accessibility-in-china/2024-11-02T00:42:31+08:00https://flcube.com/hisilicon-medical-technology-secures-nearly-rmb-100-million-in-series-a-funding/2024-11-02T00:40:17+08:00https://flcube.com/changchun-bcht-secures-nmpa-approval-for-freeze-dried-human-rabies-vaccine-trials/2024-11-02T00:38:24+08:00https://flcube.com/shanghai-pharmaceuticals-gains-nmpa-approval-for-wst04-clinical-trials-in-oncology/2024-11-02T00:36:13+08:00https://flcube.com/boehringer-ingelheim-partners-with-ten63-therapeutics-to-discover-novel-drug-molecules/2024-11-02T00:31:46+08:00https://flcube.com/antengene-secures-nda-approval-for-xpovio-in-macau-for-advanced-multiple-myeloma/2024-11-02T00:29:57+08:00https://flcube.com/innovent-biologics-expands-partnership-with-synaffix-for-new-adc-development/2024-11-02T00:27:15+08:00https://flcube.com/taiwan-bio-and-tract-therapeutics-forge-partnership-to-combat-organ-rejection/2024-11-02T00:23:22+08:00https://flcube.com/abelzeta-and-astrazeneca-team-up-for-co-development-of-gpc3-targeted-car-t-therapy/2024-11-02T00:21:04+08:00https://flcube.com/shanghai-henlius-partners-with-china-resource-medicine-to-enhance-product-accessibility/2024-11-02T00:17:15+08:00https://flcube.com/medtronic-exits-738-million-deal-to-acquire-eoflow-amid-regulatory-and-legal-challenges/2024-11-02T00:15:04+08:00https://flcube.com/ak-medical-secures-nmpa-approval-for-advanced-3d-printed-hip-prosthesis-component/2024-11-02T00:12:54+08:00https://flcube.com/mabwell-secures-nmpa-approval-for-phase-iii-study-of-adc-9mw2821-in-urothelial-carcinoma/2024-11-02T00:04:20+08:00https://flcube.com/keymed-biosciences-stapokibart-filing-accepted-for-priority-review-in-china-for-atopic-dermatitis/2024-11-02T00:02:01+08:00https://flcube.com/zelgen-biopharmaceuticals-partners-with-grand-life-sciences-for-exclusive-marketing-of-recombinant-human-thrombin/2024-11-01T23:59:39+08:00https://flcube.com/pfizer-and-cstone-secure-nmpa-approval-for-sugemalimab-first-pd-l1-inhibitor-for-escc/2024-11-01T23:57:01+08:00https://flcube.com/sanofi-eyes-blockbuster-potential-with-12-pipeline-assets-projects-eur-10-billion-in-annual-sales-by-2030/2024-11-01T23:54:12+08:00https://flcube.com/cde-requests-feedback-on-77th-batch-of-chemical-generic-reference-preparations-by-december-20/2024-11-01T23:51:00+08:00https://flcube.com/kelun-biotechs-skb264-nda-accepted-by-nmpa-for-mtnbc-poised-to-be-chinas-first-trop2-targeted-adc/2024-11-01T23:49:18+08:00https://flcube.com/nona-biosciences-partners-with-evive-biotech-to-discover-h2l2-antibodies-using-harbour-mice-platform/2024-11-01T23:45:12+08:00https://flcube.com/chinese-biotech-precision-biotechnology-gets-nmpa-green-light-for-advanced-cancer-therapies/2024-11-01T23:42:18+08:00https://flcube.com/bayer-partners-with-salus-optima-to-advance-precision-health-solutions-for-healthy-aging/2024-11-01T23:39:25+08:00https://flcube.com/fosun-pharma-to-establish-greater-bay-area-hq-in-shenzhens-pingshan-district/2024-11-01T23:32:04+08:00https://flcube.com/sanofi-abandons-mze001-licensing-deal-following-ftc-intervention-over-pompe-disease-monopoly-concerns/2024-11-01T23:25:01+08:00https://flcube.com/sanofi-partners-with-minapharm-for-local-production-of-anticoagulant-clexane-in-egypt/2024-11-01T23:19:54+08:00https://flcube.com/sisram-medicals-profhilo-accepted-for-review-by-chinas-nmpa/2024-11-01T23:17:05+08:00https://flcube.com/staidson-pharmaceutical-initiates-clinical-study-for-ards-treatment-stsa-1002/2024-11-01T23:12:26+08:00https://flcube.com/staidson-pharmaceutical-halts-clinical-trial-for-hepatitis-b-drug-due-to-efficacy-concerns/2024-11-01T23:07:18+08:00https://flcube.com/zylox-tonbridge-medical-technologys-zenflow-t18-receives-nmpa-marketing-approval/2024-11-01T23:05:17+08:00https://flcube.com/skyline-therapeutics-gene-therapy-skg0201-for-sma-gets-green-light-from-chinas-nmpa/2024-11-01T23:03:17+08:00https://flcube.com/haplox-and-illumina-mark-milestone-with-production-of-nextseq-2000dx-cn-hap-sequencing-system-in-china/2024-11-01T22:44:44+08:00https://flcube.com/abbvie-partners-with-evolveimmune-to-develop-immunotherapies-for-cancer/2024-11-01T16:33:38+08:00https://flcube.com/carsgen-therapeutics-suspended-car-t-therapies-get-fda-green-light-to-resume/2024-11-01T16:16:37+08:00https://flcube.com/aim-vaccine-submits-market-filing-for-13-valent-pneumococcal-conjugate-vaccine-in-china/2024-11-01T16:08:44+08:00https://flcube.com/eisai-and-biogen-complete-bla-submission-for-alzheimers-drug-leqembi-to-fda/2024-11-01T15:43:48+08:00https://flcube.com/biogen-reports-q3-2024-sales-dip-raises-full-year-guidance/2024-11-01T15:16:55+08:00https://flcube.com/tasly-pharmaceuticals-gets-fda-approval-for-acute-ischemic-stroke-cell-therapy-clinical-study/2024-11-01T14:50:09+08:00https://flcube.com/hutchmed-to-receive-20-million-milestone-payment-from-takeda-for-fruzaqla-sales/2024-11-01T14:43:05+08:00https://flcube.com/zhejiang-huahai-pharmaceutical-gets-new-zealand-approval-for-asthma-bispecific-antibody-trial/2024-11-01T14:33:16+08:00https://flcube.com/youcare-pharmaceutical-group-gets-nmpa-approval-for-ykyy015-phase-i-study/2024-11-01T14:26:12+08:00https://flcube.com/innovent-biologics-reports-q3-2024-sales-exceeding-rmb-2-3-billion-up-40-yoy/2024-11-01T13:56:35+08:00https://flcube.com/chinas-2023-nrdl-expands-coverage-with-126-new-drugs-aims-for-savings-and-accessibility/2024-11-01T11:59:14+08:00https://flcube.com/astrazeneca-acquires-icosavax-to-boost-infectious-disease-pipeline-with-vlp-vaccine-technology/2024-11-01T11:55:47+08:00https://flcube.com/hong-kong-aims-for-first-level-approvals-with-new-drug-regulatory-institution/2024-11-01T11:47:10+08:00https://flcube.com/sino-medical-sciences-secures-market-approvals-in-hong-kong-china-and-malaysia-for-medical-devices/2024-11-01T11:44:36+08:00https://flcube.com/jjs-carvykti-demonstrates-extended-time-to-symptom-worsening-in-multiple-myeloma-patients/2024-11-01T11:41:31+08:00https://flcube.com/dizal-pharmaceutical-presents-positive-trial-data-for-golidocitinib-at-ash-annual-meeting/2024-11-01T11:36:09+08:00https://flcube.com/china-medical-system-gets-nmpa-green-light-for-phase-iii-vitiligo-study-with-ruxolitinib-cream/2024-11-01T11:31:59+08:00https://flcube.com/carsgen-therapeutics-halts-clinical-studies-for-three-car-t-therapies-in-the-us-following-fda-request/2024-11-01T11:29:11+08:00https://flcube.com/shanghai-henlius-biotech-submits-another-application-for-serplulimab-in-china/2024-11-01T11:25:39+08:00https://flcube.com/clover-biopharmaceuticals-commences-phase-i-trial-for-rsv-vaccine-in-australia/2024-11-01T11:20:28+08:00https://flcube.com/hutchmeds-elunate-tyvyt-combination-study-for-renal-cell-carcinoma-completes-enrollment/2024-11-01T11:15:32+08:00https://flcube.com/luye-pharmas-lurbinectedin-receives-market-approval-in-hong-kong-for-sclc-treatment/2024-11-01T11:11:59+08:00https://flcube.com/suzhou-osai-biopharmas-l-crispatus-capsule-meets-phase-iii-endpoints-in-bacterial-vaginosis-study/2024-11-01T11:07:25+08:00https://flcube.com/abbvie-and-genmabs-epcoritamab-shows-promising-results-in-follicular-lymphoma-study/2024-10-31T22:23:17+08:00https://flcube.com/amgens-tarlatamab-receives-fda-priority-review-for-advanced-small-cell-lung-cancer-treatment/2024-10-31T22:18:59+08:00https://flcube.com/pfizers-43-billion-seagen-acquisition-closes-amid-lackluster-2024-forecast/2024-10-31T22:16:15+08:00https://flcube.com/fosun-pharmaceutical-and-insightec-form-jv-to-bring-mrgfus-brain-therapy-to-china/2024-10-31T22:13:16+08:00https://flcube.com/jiangsu-initiates-sunshine-procurement-round-for-medical-consumables-with-46-products/2024-10-31T22:11:01+08:00https://flcube.com/hightide-therapeutics-inc-raises-usd-25-million-in-hong-kong-ipo/2024-10-31T22:09:21+08:00https://flcube.com/microport-medbots-r-one-vascular-intervention-robot-approved-by-chinas-nmpa/2024-10-31T22:05:54+08:00https://flcube.com/eisai-and-bioarctic-set-december-launch-for-alzheimers-drug-leqembi-in-japan/2024-10-31T22:03:27+08:00https://flcube.com/abbisko-therapeutics-pimicotinib-earns-fda-fast-track-status-for-tgct-treatment/2024-10-31T22:00:34+08:00https://flcube.com/bayer-partners-with-clearnote-health-to-explore-prostate-cancer-treatment-response/2024-10-31T21:36:43+08:00https://flcube.com/3d-medicines-initiates-phase-iii-trial-for-envafolimab-in-nsclc-patient/2024-10-31T21:33:24+08:00https://flcube.com/seagen-inc-acquires-global-rights-to-hbm9033-adc-in-deal-with-nona-biosciences-and-medilink-therapeutics/2024-10-31T21:29:44+08:00https://flcube.com/vectorbuilder-partners-with-sino-biological-to-boost-global-biological-reagents-market/2024-10-31T21:19:19+08:00https://flcube.com/catug-biotechnology-partners-with-carcell-biopharma-to-advance-nucleic-acid-drug-development/2024-10-31T21:16:35+08:00https://flcube.com/sino-biopharmaceutical-submits-market-approval-application-for-recombinant-coagulation-factor-viia/2024-10-31T21:14:08+08:00https://flcube.com/abelzeta-pharma-expands-janssen-partnership-to-include-commercial-rights-in-china/2024-10-31T21:09:29+08:00https://flcube.com/fosun-pharmaceutical-secures-ghit-fund-investment-for-malaria-drug-trial/2024-10-31T21:06:14+08:00https://flcube.com/china-releases-emergency-use-rules-for-medical-devices-amid-public-health-emergencies/2024-10-31T21:00:06+08:00https://flcube.com/novo-nordisk-acquires-alkermes-irish-production-site-for-92-5-million-to-boost-glp-1-output/2024-10-31T20:57:49+08:00https://flcube.com/reetoo-biotechnology-boosts-ai-in-medical-diagnostics-with-14-million-funding-round/2024-10-31T20:55:07+08:00https://flcube.com/bio-thera-solutions-gets-nmpa-green-light-for-pd-1-inhibitor-bat1308-in-endometrial-cancer/2024-10-31T20:50:59+08:00https://flcube.com/mingyi-zhizao-secures-14-million-to-scale-gene-sequencing-platform-and-production/2024-10-31T20:47:50+08:00https://flcube.com/shanghai-pharmaceuticals-hit-with-anti-monopoly-fine-by-shanghai-market-supervision-bureau/2024-10-31T20:44:48+08:00https://flcube.com/sanofis-rezurock-secures-marketing-approval-in-china-for-chronic-graft-vs-host-disease/2024-10-31T20:34:45+08:00https://flcube.com/innocares-tyk2-inhibitor-icp-332-shows-positive-results-in-atopic-dermatitis-phase-ii-study/2024-10-31T20:30:06+08:00https://flcube.com/cstone-pharmaceuticals-sugemalimab-wins-uk-approval-for-nsclc-treatment/2024-10-31T16:42:15+08:00https://flcube.com/dizal-pharmaceuticals-q3-2024-revenues-soar-236-yoy-on-strong-product-sales/2024-10-31T16:34:50+08:00https://flcube.com/amgen-reports-q3-2024-revenues-of-usd-8-5-billion-marking-a-23-yoy-increase/2024-10-31T16:30:38+08:00https://flcube.com/hob-biotech-group-and-sino-biopharmaceutical-ltd-form-strategic-partnership-in-allergy-treatments/2024-10-31T16:23:55+08:00https://flcube.com/sandoz-q3-2024-sales-boosted-by-biosimilars-and-generics-up-12-yoy/2024-10-31T16:18:10+08:00https://flcube.com/junshi-biosciences-reports-q3-2024-financials-with-revenue-growth-and-narrowed-losses/2024-10-31T15:57:20+08:00https://flcube.com/chipsscreen-biosciences-and-zhejiang-hisun-pharmaceutical-end-strategic-partnership-for-chiglitazar-launch/2024-10-31T15:49:38+08:00https://flcube.com/eli-lilly-reports-20-yoy-revenue-growth-in-q3-2024-driven-by-mounjaro-and-zepbound/2024-10-31T15:41:39+08:00https://flcube.com/abbvies-allergan-aesthetics-launches-juvederm-volux-in-china/2024-10-31T15:08:06+08:00https://flcube.com/gsk-reports-mixed-q3-2024-results-with-2-yoy-revenue-growth/2024-10-31T14:50:26+08:00https://flcube.com/allmed-medical-products-to-establish-wholly-owned-subsidiary-in-indonesia/2024-10-31T14:42:43+08:00https://flcube.com/akeso-biopharma-initiates-phase-iii-clinical-trial-for-pd-1-vegf-bispecific-antibody-combination/2024-10-31T14:27:02+08:00https://flcube.com/abbvie-reports-q3-2024-revenue-growth-strength-in-immunology-and-neuroscience/2024-10-31T14:20:12+08:00https://flcube.com/shanghai-henlius-and-organon-submit-biosimilar-application-for-denosumab-to-fda/2024-10-31T14:13:38+08:00https://flcube.com/china-grand-pharmaceuticals-secures-distribution-of-sirtexs-sir-spheres-for-liver-cancer/2024-10-31T13:13:33+08:00https://flcube.com/organon-in-licenses-eli-lillys-emgality-and-rayvow-for-european-migraine-market/2024-10-31T13:10:11+08:00https://flcube.com/huidagene-secures-rare-pediatric-disease-designation-for-crispr-therapy-hg302-targeting-dmd/2024-10-31T13:02:00+08:00https://flcube.com/blue-sail-medical-partners-with-weifang-government-on-healthcare-initiative/2024-10-31T12:58:10+08:00https://flcube.com/highfield-biopharmaceutical-doses-first-patient-in-hfk1-clinical-trial-targeting-solid-tumors/2024-10-31T12:54:33+08:00https://flcube.com/emas-chmp-gives-green-light-to-sanofis-fexinidazole-for-acute-sleeping-sickness-treatment/2024-10-31T12:49:02+08:00https://flcube.com/bgi-genomics-receives-nmpa-approval-for-innovative-colorectal-cancer-detection-kit/2024-10-31T12:46:03+08:00https://flcube.com/inventisbios-kras-g12c-inhibitor-d-1553-advances-toward-priority-review-in-china/2024-10-31T12:43:37+08:00https://flcube.com/gsks-cco-calls-china-a-hotbed-for-innovative-molecules-and-licensing-deals/2024-10-31T12:40:19+08:00https://flcube.com/biocytogen-and-ona-therapeutics-forge-antibody-evaluation-and-licensing-agreement/2024-10-31T12:30:13+08:00https://flcube.com/wuxi-biologics-partners-with-visen-pharmaceuticals-for-lonapegsomatropin-manufacturing/2024-10-31T12:25:52+08:00https://flcube.com/sirnaomics-ltd-granted-fda-approval-for-phase-i-rsv-mrna-vaccine-study/2024-10-31T12:19:42+08:00https://flcube.com/roche-receives-nmpa-approval-for-ophthalmology-bsab-vabysmo-farcimab-for-diabetic-macular-edema/2024-10-31T12:16:43+08:00https://flcube.com/huadong-medicine-gets-nmpa-green-light-for-clinical-study-of-ryzodeg-biosimilar/2024-10-31T12:12:48+08:00https://flcube.com/lianbio-board-turns-down-concentra-biosciences-buyout-offer/2024-10-31T12:09:16+08:00https://flcube.com/gilead-acquires-pre-clinical-il-18bp-targeting-antibody-candidate-from-compugen-in-848-million-deal/2024-10-31T12:05:01+08:00https://flcube.com/jiangsu-synthgene-and-starna-therapeutics-join-forces-in-mrna-technology-advancement/2024-10-31T12:00:57+08:00https://flcube.com/shanghai-escugen-partners-with-inxmed-for-global-development-rights-to-ezwi-fit-platform/2024-10-31T11:56:14+08:00https://flcube.com/remegen-ltd-receives-fda-clearance-for-msln-targeting-adc-rc88-in-gynecological-tumors/2024-10-31T11:44:04+08:00https://flcube.com/china-announces-new-hospital-inspection-measures-to-standardize-healthcare-system/2024-10-31T11:40:47+08:00https://flcube.com/huadong-medicine-strikes-exclusive-promotion-deal-with-impact-therapeutics-for-senaparib-in-china/2024-10-31T11:23:50+08:00https://flcube.com/staidson-pharmaceuticals-bdb-001-earns-breakthrough-therapy-designation-in-china-for-aav-treatment/2024-10-31T11:16:06+08:00https://flcube.com/staidson-pharmaceuticals-bemiltenase-alfa-earns-orphan-drug-designation-from-us-fda-for-hemophilia-treatment/2024-10-31T11:14:59+08:00https://flcube.com/staidson-pharmaceutical-gets-nmpa-green-light-for-neurotrophic-keratitis-eye-drop-clinical-trial/2024-10-31T11:14:40+08:00https://flcube.com/staidson-launches-phase-ia-trial-for-stsp-0902-injection-in-oligoasthenozoospermia/2024-10-31T11:14:22+08:00https://flcube.com/3sbio-subsidiary-gets-green-light-for-ssgj-608-ankylosing-spondylitis-study/2024-10-31T11:11:26+08:00https://flcube.com/lynk-pharmaceuticals-initiates-phase-iii-clinical-trial-for-rheumatoid-arthritis-drug-in-china/2024-10-31T11:08:55+08:00https://flcube.com/tower-cold-chain-expands-into-china-with-partnership-with-tower-winner-solutions/2024-10-31T11:06:14+08:00https://flcube.com/gsk-secures-exclusive-rights-to-hansohs-adc-candidate-hs-20093-in-new-licensing-deal/2024-10-31T00:18:57+08:00https://flcube.com/3sbio-partners-with-hq-pharma-to-develop-and-commercialize-eltrombopag-olamine-dry-suspension/2024-10-31T00:15:50+08:00https://flcube.com/zylox-tonbridge-completes-patient-enrollment-for-zenflex-study-in-germany/2024-10-31T00:12:52+08:00https://flcube.com/zylox-tonbridge-receives-uae-approval-for-five-medical-devices-expands-middle-east-presence/2024-10-31T00:11:55+08:00https://flcube.com/remegens-telitacicept-secures-fda-approval-for-global-phase-iii-study-in-primary-sjogrens-syndrome/2024-10-31T00:04:27+08:00https://flcube.com/novo-nordisk-foundation-launches-260-million-initiative-to-develop-respiratory-disease-vaccines/2024-10-31T00:02:29+08:00https://flcube.com/astrazeneca-advances-to-phase-iii-with-pd-1xtigit-bsab-for-biliary-tract-cancer/2024-10-31T00:00:19+08:00https://flcube.com/zhiyi-biotechnology-and-henlius-biotech-partner-to-develop-novel-drug-products-and-platforms/2024-10-30T23:48:34+08:00https://flcube.com/shanghai-novopathway-and-pony-biomedicine-join-forces-for-pre-clinical-drug-development-platform/2024-10-30T23:43:46+08:00https://flcube.com/jiangsu-nhwa-pharmaceutical-gets-nmpa-green-light-for-schizophrenia-drug-trial/2024-10-30T23:40:56+08:00https://flcube.com/legend-biotechs-carvykti-therapy-to-include-myeloid-neoplasms-warning-in-label-update/2024-10-30T23:38:52+08:00https://flcube.com/takedas-livtencity-receives-nmpa-approval-a-first-in-china-for-cmv-infection-treatment/2024-10-30T23:34:41+08:00https://flcube.com/china-grand-pharmaceutical-to-acquire-majority-stake-in-mitsubishi-tanabes-tianjin-subsidiary/2024-10-30T23:32:17+08:00https://flcube.com/beijing-strong-biotechnologies-strikes-distribution-deal-with-elitechgroup-for-immunohistochemical-staining-systems/2024-10-30T23:24:33+08:00https://flcube.com/sanofi-broadens-collaboration-with-exscientia-licensing-new-precision-drug-program/2024-10-30T23:21:19+08:00https://flcube.com/cstone-pharmaceuticals-regains-exclusive-rights-to-tibsovo-in-greater-china-and-singapore/2024-10-30T23:17:25+08:00https://flcube.com/yifan-pharmaceuticals-f-652-shows-promise-in-phase-ii-clinical-trial-for-aclf/2024-10-30T23:14:04+08:00https://flcube.com/takeda-ends-gene-therapy-collaboration-with-jcr-pharmaceuticals-returns-ip/2024-10-30T22:58:45+08:00https://flcube.com/sanofi-halts-development-of-tusamitamab-ravtansine-after-missed-trial-endpoints/2024-10-30T22:55:32+08:00https://flcube.com/cnipa-releases-updated-patent-law-rules-with-pharma-industry-in-focus/2024-10-30T22:53:39+08:00https://flcube.com/chinas-cde-issues-draft-guidelines-for-overseas-drug-market-approval-filings/2024-10-30T22:29:32+08:00https://flcube.com/cstone-pharmaceuticals-disbands-sales-team-for-gavreto-after-nrdl-setback/2024-10-30T22:22:25+08:00https://flcube.com/roche-diagnostics-and-beijing-strong-biotechnologies-deepen-ties-to-innovate-in-hemostasis-diagnostics/2024-10-30T22:20:04+08:00https://flcube.com/asieris-pharmaceuticals-gets-australian-greenlight-for-acinetobacter-infection-drug-trial/2024-10-30T22:15:21+08:00https://flcube.com/kossel-medtech-secures-over-14-million-in-series-b-financing-to-boost-international-expansion/2024-10-30T22:12:31+08:00https://flcube.com/sino-biopharmaceutical-completes-enrollment-for-phase-iii-trial-of-anlotinib-in-soft-tissue-sarcoma/2024-10-30T22:10:05+08:00https://flcube.com/pfizer-reports-strong-q3-results-boosts-2024-guidance-to-61-64-billion/2024-10-30T16:42:40+08:00https://flcube.com/aim-vaccine-secures-nmpa-approval-for-mrna-vaccine-targeting-rsv/2024-10-30T16:34:36+08:00https://flcube.com/acotec-secures-nmpa-approval-for-acotrace-disposable-catheter-sheath/2024-10-30T16:29:00+08:00https://flcube.com/innovents-fortvita-stake-sale-sparks-controversy-shares-plummet-nearly-13/2024-10-30T16:23:18+08:00https://flcube.com/sino-medical-reports-five-year-pioneer-study-results-for-ht-supreme-stent-system/2024-10-30T16:16:48+08:00https://flcube.com/novartis-secures-fda-accelerated-approval-for-scemblix-in-newly-diagnosed-cml-patients/2024-10-30T16:12:28+08:00https://flcube.com/mgi-tech-partners-with-oncodna-to-enhance-precision-oncology-solutions/2024-10-30T16:07:34+08:00https://flcube.com/mindray-reports-q3-2024-financials-international-revenues-surge-over-18-amid-domestic-challenges/2024-10-30T15:56:46+08:00https://flcube.com/biogen-partners-with-neomorph-to-develop-molecular-glue-degraders-for-alzheimers-and-rare-diseases/2024-10-30T15:39:35+08:00https://flcube.com/yantai-dongcheng-pharma-secures-fda-fast-track-designation-for-177lu-lnc1004-in-thyroid-cancer/2024-10-30T15:33:00+08:00https://flcube.com/sunshine-guojian-pharmaceutical-secures-nmpa-approval-for-clinical-trials-of-ssgj-626-in-lupus-indications/2024-10-30T15:25:27+08:00https://flcube.com/zai-lab-reports-positive-phase-iii-results-for-karxt-showcasing-efficacy-in-psychiatric-conditions/2024-10-30T15:18:44+08:00https://flcube.com/gsk-secures-global-rights-to-chimagen-biosciences-t-cell-engager-in-850-million-deal/2024-10-30T14:33:48+08:00https://flcube.com/fosun-pharmaceutical-reports-q3-2024-revenue-growth-and-rd-progress/2024-10-30T14:24:01+08:00https://flcube.com/shanghai-pharmaceuticals-reports-q3-2024-revenue-growth-strengthens-drug-pipeline/2024-10-30T14:14:35+08:00https://flcube.com/astrazeneca-to-acquire-chinas-gracell-biotechnologies-in-1-2-billion-deal/2024-10-30T14:00:37+08:00https://flcube.com/chinas-nhc-releases-third-list-of-recommended-generic-drugs-for-development/2024-10-30T13:57:25+08:00https://flcube.com/abbvie-and-alpine-immune-sciences-halt-early-enrollment-in-lupus-trial/2024-10-30T13:52:19+08:00https://flcube.com/jiangsu-province-announces-dual-channel-management-and-separate-payment-drug-list/2024-10-30T13:41:17+08:00https://flcube.com/jjs-rybrevant-lazertinib-combo-accepted-for-fda-review-in-nsclc/2024-10-30T13:39:29+08:00https://flcube.com/hunan-province-releases-dual-channel-drug-payment-list-with-226-products/2024-10-30T13:36:25+08:00https://flcube.com/shanghai-fosun-to-exclusively-commercialize-generic-entresto-in-china/2024-10-30T13:34:18+08:00https://flcube.com/shouyao-holdings-receives-ethical-approval-for-phase-iii-study-of-alk-inhibitor-sy-3505/2024-10-30T13:30:28+08:00https://flcube.com/baidu-health-and-chongqings-fifth-peoples-hospital-collaborate-on-integrated-medical-services/2024-10-30T13:19:20+08:00https://flcube.com/suzhou-ribo-life-science-strikes-deal-with-qilu-pharmaceutical-for-pcsk9-sirna-drug/2024-10-30T13:16:55+08:00https://flcube.com/panlin-capital-raises-second-fund-focused-on-biopharmaceutical-innovation/2024-10-30T12:32:58+08:00https://flcube.com/xrgenesis-raises-14-million-in-series-a-to-advance-ophthalmic-surgical-technology/2024-10-30T12:17:33+08:00https://flcube.com/taiwan-fda-reviews-nefecon-new-drug-application-from-everest-medicines/2024-10-30T12:14:34+08:00https://flcube.com/jjs-janssen-secures-exclusive-global-rights-to-develop-lcb84-adc-from-legochem-biosciences/2024-10-30T12:11:28+08:00https://flcube.com/amgens-lumakras-faces-full-approval-delay-as-fda-requests-new-study/2024-10-30T12:01:40+08:00https://flcube.com/chinas-nmpa-proposes-enhanced-it-and-visualization-requirements-for-blood-product-gmp/2024-10-30T10:42:51+08:00https://flcube.com/fresenius-medical-care-expands-dialysis-solutions-in-china-with-6008-caresystem-launch/2024-10-30T10:40:48+08:00https://flcube.com/china-charts-course-for-advanced-disease-prevention-and-control-system-by-2030/2024-10-30T10:38:15+08:00https://flcube.com/innovent-biologics-partners-with-sanegene-bio-usa-to-develop-hypertension-drug/2024-10-30T10:34:37+08:00https://flcube.com/guangdong-zhongsheng-pharmaceuticals-zsp1273-for-influenza-a-accepted-for-review-by-nmpa/2024-10-30T10:31:07+08:00https://flcube.com/jianzhijia-health-chain-to-purchase-local-drug-retailer-for-23-5-million/2024-10-30T10:22:39+08:00https://flcube.com/aidea-pharmaceutical-co-terminates-acc006-technology-transfer-deal-with-lixin-bio/2024-10-30T10:11:47+08:00https://flcube.com/janssen-acquires-rights-to-gene-therapy-botaretigene-sparoparvovec-from-meiragtx-for-xlrp-treatment/2024-10-30T00:08:28+08:00https://flcube.com/astrazeneca-secures-fda-approval-for-self-administered-hattr-pn-therapy-wainua/2024-10-30T00:05:14+08:00https://flcube.com/elpiscience-partners-with-astellas-for-bi-specific-macrophage-engager-research/2024-10-30T00:02:25+08:00https://flcube.com/eli-lilly-completes-acquisition-of-point-biopharma-expanding-radiopharmaceutical-portfolio/2024-10-29T23:59:52+08:00https://flcube.com/fosuns-hlx42-receives-fast-track-designation-from-fda-for-nsclc-treatment/2024-10-29T23:56:52+08:00https://flcube.com/catug-biotechnology-partners-with-persongen-to-advance-global-car-t-cell-therapies/2024-10-29T23:53:30+08:00https://flcube.com/simcere-secures-approval-for-local-manufacturing-of-cosela-boosting-patient-access/2024-10-29T23:48:11+08:00https://flcube.com/chengda-pharmaceuticals-halts-shanghai-research-project-amid-market-challenges/2024-10-29T23:45:54+08:00https://flcube.com/tyk-medicines-secures-nearly-rmb-200-million-in-series-d-financing-led-by-sichuan-huiyu-pharmaceutical/2024-10-29T23:43:52+08:00https://flcube.com/nmpa-approves-pulnovo-medicals-novel-catheter-for-treating-pulmonary-arterial-hypertension/2024-10-29T23:40:51+08:00https://flcube.com/innovent-biologics-partners-with-xuanzhu-biopharma-for-clinical-trial-of-sintilimab-and-km-501-in-advanced-tumors/2024-10-29T23:38:46+08:00https://flcube.com/sanofi-gains-nmpa-approval-for-innovative-rosuvastatin-and-ezetimibe-combination-therapy/2024-10-29T23:36:32+08:00https://flcube.com/eli-lilly-teams-up-with-fauna-bio-to-uncover-new-anti-obesity-drug-targets/2024-10-29T23:28:05+08:00https://flcube.com/gileads-kite-receives-fda-nod-to-add-overall-survival-data-to-yescarta-for-large-b-cell-lymphoma/2024-10-29T23:26:15+08:00https://flcube.com/fda-prioritizes-roches-xolair-for-food-allergy-indication-extension-ahead-of-q1-decision/2024-10-29T23:22:51+08:00https://flcube.com/sino-medical-secures-approvals-for-key-coronary-devices-in-taiwan-india-and-uzbekistan/2024-10-29T23:18:11+08:00https://flcube.com/shanghai-henlius-secures-indonesian-approval-for-hansizhuang-in-small-cell-lung-cancer/2024-10-29T23:15:50+08:00https://flcube.com/ivd-medical-ends-strategic-partnership-with-japans-sysmex-in-coagulation-products/2024-10-29T23:12:57+08:00https://flcube.com/clover-biopharmas-scb-219m-shows-promising-phase-i-results-for-chemotherapy-induced-thrombocytopenia/2024-10-29T23:10:57+08:00https://flcube.com/innovent-biologics-picankibart-shows-64-6-skin-clearance-in-phase-ii-psoriasis-study/2024-10-29T17:48:59+08:00https://flcube.com/livzon-pharmaceuticals-leuprorelin-acetate-microspheres-passes-chinas-gqce/2024-10-29T17:38:40+08:00https://flcube.com/xian-xintong-pharmas-pradefavir-wins-nmpa-nod-for-chronic-hepatitis-b-treatment/2024-10-29T17:22:30+08:00https://flcube.com/eli-lillys-mounjaro-approved-in-hong-kong-for-obesity-and-type-2-diabetes-treatment/2024-10-29T17:10:18+08:00https://flcube.com/clover-biopharmaceuticals-reports-strong-phase-i-results-for-rsv-vaccine-scb-1019/2024-10-29T17:05:04+08:00https://flcube.com/wuxi-apptec-reports-q3-2024-revenues-of-rmb-10-46-billion-amid-biosecure-act-challenges/2024-10-29T15:25:21+08:00https://flcube.com/monte-rosa-therapeutics-strikes-licensing-deal-with-novartis-for-vav1-degraders/2024-10-29T15:15:49+08:00https://flcube.com/astrazenecas-fasenra-approved-by-eu-for-eosinophilic-granulomatosis-treatment/2024-10-29T14:44:49+08:00https://flcube.com/abbvie-inks-1-4-billion-deal-to-acquire-alzheimers-drug-developer-aliada-therapeutics/2024-10-29T14:34:24+08:00https://flcube.com/servier-faces-475-million-penalty-over-banned-antidiabetic-drug-mediator-in-france/2024-10-29T12:51:24+08:00https://flcube.com/serviers-voranigo-receives-fda-nod-for-idh-inhibitor-as-brain-tumor-treatment/2024-10-29T12:49:33+08:00https://flcube.com/servier-and-hust-forge-partnership-to-cultivate-innovative-therapies-through-shinedocs-program/2024-10-29T12:48:56+08:00https://flcube.com/jj-shareholders-cleared-to-sue-over-hidden-asbestos-risks-in-talc-products/2024-10-29T12:45:17+08:00https://flcube.com/chinas-cde-releases-guidelines-for-cgt-clinical-trials-communication/2024-10-29T12:42:10+08:00https://flcube.com/chinas-nhc-unveils-plan-to-conserve-drug-resources-and-reduce-waste/2024-10-29T12:39:29+08:00https://flcube.com/chinas-nhc-unveils-guidelines-to-fortify-county-level-medical-communities/2024-10-29T12:37:19+08:00https://flcube.com/roche-to-expand-diagnostics-portfolio-with-acquisition-of-lumiradx-technology/2024-10-29T12:33:58+08:00https://flcube.com/roche-secures-diagnostics-deal-with-lumiradx-for-295m/2024-10-29T12:20:46+08:00https://flcube.com/huadong-medicine-cancels-collaboration-with-vtv-therapeutics-on-ttp273-for-type-2-diabetes-drug/2024-10-29T12:17:10+08:00https://flcube.com/jiangsu-recbios-rec610-shingles-vaccine-shows-positive-results-in-first-in-human-study/2024-10-29T12:14:16+08:00https://flcube.com/innovent-biologics-initiates-phase-iii-trial-for-mazdutide-in-obesity-treatment/2024-10-29T12:10:53+08:00https://flcube.com/hainan-poly-pharms-novel-nanomedicine-plat001-gets-us-fda-approval-for-clinical-trials/2024-10-29T12:07:07+08:00https://flcube.com/careray-digital-medical-technology-to-acquire-30-stake-in-uks-isdi-for-usd-15-2-million/2024-10-29T12:04:40+08:00https://flcube.com/grifols-sells-20-stake-in-shanghai-raas-to-haier-group-for-usd-1-8-billion/2024-10-29T11:59:37+08:00https://flcube.com/microport-cardioflow-medtech-to-acquire-controlling-stake-in-la-ronda-for-usd-20-million/2024-10-29T11:55:29+08:00https://flcube.com/p-cure-initiates-construction-of-affordable-proton-therapy-center-in-chinas-shandong-province/2024-10-29T11:52:32+08:00https://flcube.com/medilink-therapeutics-secures-multi-billion-dollar-deal-with-roche-for-c-met-targeting-adc/2024-10-29T11:50:28+08:00https://flcube.com/jw-therapeutics-and-2seventy-bio-ink-exclusive-deal-for-car-t-cell-therapy-in-greater-china/2024-10-29T11:43:12+08:00https://flcube.com/inventisbios-kras-g12c-inhibitor-garsorasib-nda-accepted-for-review-by-chinas-nmpa/2024-10-29T11:40:14+08:00https://flcube.com/frontage-laboratories-expands-european-footprint-with-acquisition-of-acceleras-dmpk-businesses/2024-10-29T11:36:14+08:00https://flcube.com/astrazeneca-and-sanofis-rsv-prevention-drug-beyfortus-approved-by-chinas-nmpa/2024-10-29T11:33:18+08:00https://flcube.com/china-medical-system-expands-into-southeast-asia-with-singapore-manufacturing-plant-lease/2024-10-29T11:28:58+08:00https://flcube.com/ascletis-pharmas-asc41-shows-promising-results-in-phase-ii-nash-study/2024-10-29T11:26:36+08:00https://flcube.com/shanghai-junshi-biosciences-toripalimab-gains-nmpa-approval-for-nsclc-perioperative-treatment/2024-10-29T11:23:46+08:00https://flcube.com/roches-phesgo-and-faricimab-receive-nmpa-approvals-for-breast-cancer-and-nam/2024-10-29T10:59:49+08:00https://flcube.com/wuxi-xdc-and-intocell-enter-mou-to-advance-toxin-linker-technology-and-crdmo-services/2024-10-29T10:55:21+08:00https://flcube.com/allorion-therapeutics-strikes-deal-with-astrazeneca-for-egfr-l858r-inhibitor-development-and-commercialization/2024-10-29T10:43:32+08:00https://flcube.com/orient-gene-biotech-to-acquire-hangzhou-laihe-biotech-expanding-poct-and-ai-in-healthcare/2024-10-29T10:40:18+08:00https://flcube.com/shanghai-teogen-life-technology-and-china-national-medical-device-form-strategic-partnership/2024-10-29T10:37:42+08:00https://flcube.com/shanghai-pharmaceuticals-and-sanofi-broaden-collaboration-to-include-nationwide-disease-management/2024-10-29T10:35:18+08:00https://flcube.com/chinas-national-peoples-congress-approves-stricter-punishments-for-sector-specific-bribery/2024-10-29T10:29:42+08:00https://flcube.com/daiichi-sankyo-and-esperion-therapeutics-amend-collaboration-on-antilipidemic-drugs/2024-10-29T10:26:18+08:00https://flcube.com/shanghai-bdgene-technologys-thalassemia-gene-therapy-bd211-clears-nmpa-for-clinical-trials/2024-10-29T10:22:51+08:00https://flcube.com/belief-biomed-group-initiates-clinical-study-for-hemophilia-a-gene-therapy-bbm-h803-in-china/2024-10-29T10:18:40+08:00https://flcube.com/full-life-technologies-secures-usd-63-3-million-in-financing-to-boost-radiotherapeutics-pipeline-and-manufacturing/2024-10-29T10:11:17+08:00https://flcube.com/immunotech-biopharm-commences-patient-enrollment-in-phase-ii-study-for-car-t-19-injection/2024-10-29T10:04:47+08:00